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Abstract 
The International Diabetes Federation reports 642 million adults globally will be living with diabetes 
by 2040. Approximately one third will go on to develop some extent of diabetic retinopathy (DR), 
with ca. 93 million current sufferers.  
Current therapeutic options for DR target the late stages of the disease when vision is already 
significantly degraded. These treatments aim to prevent haemorrhaging using laser therapy or 
intraocular injections of corticosteroids and therapeutic anti-vascular endothelial growth factor 
(VEGF) antibodies. However, efficacy is low or variable with frequent injections required and 
associated with serious ocular side-effects. Moreover, all result in some degree of tissue destruction. 
New therapies to prevent the onset or arrest the progression of the disease before overt 
microvascular pathologies are therefore essential.  
Somatostatin (SST) has been reported to have neuroprotective, antiangiogenic effects in addition to 
the regulation of water and ion transport in the retina. It is postulated that SST could attenuate key 
pathological changes in DR. However, studies with SST analogues such as octreotide demonstrated 
that systemic administration resulted in the drug reaching the retina only when there is a 
breakdown of the blood retinal barrier.  
SST is produced by the retina and there is downregulation of SST levels in the retina of diabetic 
patients, correlated to retinal neurodegeneration. SST eye drops show some promise 
(EUROCONDOR). The purpose of this thesis was to develop a modified-release formulation of SST 
enhancing the treatment of diabetic retinopathy. 
The physicochemical characterization of SST self-assembled hydrogels was performed to investigate 
the rheological and morphological properties of the self-assembled hydrogels and their influence on 
the mechanism and rate of SST release in vitro. This study demonstrated that the SST hydrogels were 
shear-thinning, did not exhibit thermogelation and exhibited a higher degree of structure with 
higher somatostatin concentration and in the presence of electrolytes. Transmission electron 
micrographs demonstrated the presence of nanofibrils that were narrower and denser in 
appearance in the presence of electrolytes. This corresponds to the higher G’ (storage modulus) of 
the SST hydrogels in electrolytes and at a higher SST concentration. In the presence of electrolytes 
SST hydrogels released a lower cumulative percentage of SST monomers at 48 hours compared to 
those in water. The release kinetics of the SST monomers demonstrated concurrent first-order and 
zero-order mechanisms. However the limited release at 48 hours in vitro precludes these self-
assembled hydrogels as depots for SST delivery. 
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Two formulation candidates of SST were produced and characterized. The first candidate was SST 
2.5% w/w microparticles encapsulated in a triblock polymer of polycaprolactone-polyethylene 
glycol-polycaprolactone (PCL-PEG-PCL) prepared by the double emulsion method. Encapsulation 
efficiency of SST ranged from 19% to 43% of which 1.4% -4% was released over 16-24 days. Scanning 
electron microscopy of the microparticles showed spherical aggregates which averaged 32 µm in 
size. The release kinetics of somatostatin from the microparticles demonstrated first-order decay to 
a plateau with good mean R2 value of 0.979. 
The second formulation candidate consisted of somatostatin 5% w/w entrapped in hydroxypropyl 
methylcellulose (HPMC) 3% w/w or 6% w/w hydrogel. The SST in HPMC hydrogels were subjected to 
rheological studies and FTIR characterization, transmission electron microscopy and release studies. 
Rheological tests demonstrated that inclusion of SST at a concentration of 5% w/w did not alter the 
characteristic properties of HPMC matrices. FTIR data showed transition of SST structure from 
random conformations to structured organisations upon exposure to simulated lachrymal fluid (SLF). 
These transitions were hindered in the HPMC hydrogels compared to SST 5% w/w in water, 
consistent with the hypothesis that the entanglement network of HPMC acts a barrier to the 
interaction of the electrolytes in SLF with SST. This was supported by the TEM images. Release 
studies demonstrated an extended release of SST monomers from the SST/HPMC hydrogels 
compared to SST 5% w/w in water. The SST 5% w/w solution reached a 100% release at 6 hours. The 
SST 5% w/w in HPMC 3% w/w gels released a total of 45.6% incorporated SST at 96 hours whereas 
the SST 5% w/w in HPMC 6% w/w gels continued to release a total of 37.6% at 10 days. The release 
kinetics of SST 5% w/w in HPMC 3% w/w and HPMC 6% w/w hydrogels were fitted to a hybrid model 
of release with R2 values of 0.998 and 0.997 respectively. Mass spectrometry confirmed the 
structural integrity of the SST released from hydrogels. SST 5% w/w in HPMC 6% w/w hydrogels are 
the most promising candidate in terms of SST delivery, with delayed SST nanofibril formation and 
extended duration of release in comparison to SST 5% w/w aqueous dispersions. 
The safety and efficacy of SST solutions at different concentrations and that from hydrogel 
formulations were tested on immortalized human retinal pigment epithelium cells (ARPE-19). MTT 
cell viability assay was conducted to assess the effect of the release samples from SST/HPMC 
hydrogels and SST 10-7 M and 10-6 M on the viability of the ARPE-19 cells. The results of the MTT 
assay demonstrated a significant decrease in cell viability only by the Release Day 1 samples 
compared to control. It is postulated that the combination of the viscosity of the Release Day 1 
sample with the higher concentration of SST present at 24 hours may have additive effects on the 
viability of the cells. The markers for assessment for efficacy were expression of vascular endothelial 
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growth factor receptor-2 (VEGF-R2) and secretion of VEGF by the ARPE-19 cells. 
Immunofluorescence was used to assess the effect of SST concentrations (10-8 M to 10-5 M) on the 
expression of VEGF-R2 levels. The results of the first study showed that SST 10-7 M produced 
significant downregulation of VEGF-R2 expression in high glucose (25 mM) conditions compared to 
normal glucose (5 mM) conditions. The quantitative analysis of VEGF secretion in the same 
conditions performed by ELISA did not show any significant effect by the treatments applied in the 
same conditions.  
In conclusion, two formulations of somatostatin for ocular delivery were developed and 
characterised. The microparticle formulation showed reasonable encapsulation and duration of 
release, however, the more promising candidate consisted of somatostatin entrapped in a HPMC 
network and demonstrated modified release of somatostatin over 10 days. This work has introduced 
HPMC as a suitable candidate for modifying the release rate of peptides. The current work also 
evidenced the downregulation of the VEGF receptor 2 (VEGF-R2) by somatostatin at a concentration 
of 10-7 M in high glucose (25 mM) conditions. Although further studies are warranted on other 
retinal cell lines and animal models with additional markers, the identification of a new polymeric 
carrier for the delivery of somatostatin adds to the current body of work in the search for a non-
invasive treatment for diabetic retinopathy. 
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CHAPTER 1: INTRODUCTION  
1.1 Anatomy of the Human Eye 
The human eye (Figure 1.1) is a complex organ that focuses and converts light rays to electrical 
signals which can be converted to an image in the visual cortex of the brain. The eye can be clinically 
divided to anterior and posterior chambers. It can also be divided into three main layers: fibrous, 
vascular and neural. 
 
 
The anterior chamber of the eye is located between the cornea and the iris. The posterior chamber 
is between the lens and the iris encompassing the vitreous humor which is almost completely 
surrounded by the retina. The aqueous humor fills the anterior chamber and is responsible for 
maintaining the shape of the eyeball, moisturizing and providing nutrients to avascular tissues like 
the cornea. The aqueous humor is produced by the ciliary body at a constant rate and removed at a 
constant amount at the base of the cornea through the Canal of Schlemm. This maintains the 
intraocular pressure at a constant level. The vitreous humor is a transparent, jelly-like fluid 
Figure 1.1: Cross-section of the human eye (Reprinted with 
permission from T Thrimawithana)(Thrimawithana, 2011) 
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composed of 99% water. This too maintains the shape of the eyeball, holding the lens and retina in 
place, maintaining the intraocular pressure and serving as a refractive medium for light entering the 
eye (Tate, 2009). The outer fibrous layer of the eye consists of the sclera and cornea. The middle 
vascular layer contains the choroid, ciliary body and iris. The inner neural layer contains the retina 
(Tate, 2009)(Figure 1.2). 
 
Figure 1.2: Hematoxylin and eosin (H & E) stain image of posterior segment sections (15µm) of a 
human eye, depicting the sclera, choroid and retinal architecture. (Reprinted with permission from T 
Thrimawithana.) 
1.1.1 The Fibrous Layers of the Eye 
 1.1.1.1 The Sclera  
The sclera, the “white of the eye”, is the posterior five-sixths of the outer eye ball. It is composed of 
dense collagenous connective tissue with elastic fibers, which makes it firm and opaque. It provides 
three main functions: it gives the eyeball its shape, protects the internal structures of the eye, and 
provides a surface for attachment of the ocular muscles. The sclera is a good target for drug delivery 
as it has an appreciable surface area of 16.3 cm2 (Olsen, Aaberg, Geroski, & Edelhauser, 1998). 
Studies have shown that the sclera is highly permeable to hydrophilic drugs with a strong 
dependence on molecular radius. Lower molecular weight hydrophilic compounds can permeate 
through the sclera’s pores and intracellular spaces at a greater extent (Lawrence & Miller, 2004). In 
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vivo, proteins as large as 145 kDa were shown to penetrate though the sclera and were detected in 
the choroid in rabbits (Demetriades, et al., 2008; Nomoto, et al., 2009). In ex vivo human sclera, up 
to 150 kDa dextran and 149 kDa bevacizumab were able to penetrate across the sclera (Wen, Hao, & 
Li, 2013). 
1.1.1.2 The Cornea  
The cornea is the remaining one-sixth of the outer fibrous layer of the eye. The cornea is transparent 
and makes up the anterior section of the eyeball. There are five layers that make up the cornea, 
namely, the epithelial membrane, Bowman’s membrane, stroma, Descemet’s membrane and 
endothelium. The outer epithelium in the human cornea ranges in thickness between 50 to 100 µm 
and has 5 sub-layers. The epithelium’s lipophilicity confers 90% of the eye’s barrier to hydrophilic 
drugs and 10% of its barrier to the entry of hydrophobic drugs. The Bowman’s membrane averages 
8–14 µm in thickness. This layer is not regenerative and is not considered to present a barrier for the 
entry of drugs across the cornea. The hydrophilic stroma and constitutes ~90% of the cornea’s 
volume. Approximately 80% of the stroma is water with the remaining weight made up of collagen, 
other proteins and mucopolysaccharides. The stroma is considered the main barrier to lipophilic 
drugs absorption across the cornea. The next layer, Descemet’s membrane, is a thin regenerative 6 
µm membrane, and has no appreciable impact on ocular drug absorption. Lastly, the endothelium is 
a single layer of cells that covers the entire posterior surface of the cornea. Gap junctions between 
its cells make this layer 200-fold more permeable than the epithelium. The endothelium is critical to 
maintaining the tonicity of the stroma through the bicarbonate dependent Na+/K+-ATPase pump, 
which functions to control the passive movement of fluids into the stroma and the active removal 
out of the stroma. This pump therefore controls the transparency of the cornea and corneal 
thickness (Tate, 2009).   
1.1.1.3 The Conjunctiva 
This is a thin stratified epithelial consisting of three main regions: the bulbar epithelium, fornix 
epithelium and the palpebral epithelium. Although these cells are bound together by tight junctions 
like the cornea, the conjunctiva is more permeable to hydrophilic compounds due to more and 
larger paracellular epithelial pores (Lawrence & Miller, 2004).  
1.1.2 The Vascular Layer of the Eye  
The eye is vascularized by the short ciliary arteries that circle the optic nerve and by branches from 
the ophthalmic artery. The majority of the eye’s blood vessels are located in the vascular layer 
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comprising the choroid, the ciliary body and iris. The melanin pigments contained in many of the 
cells in this layer contribute to the inherent black color. 
The posterior section of the vascular layer (the choroid) lines the inner surface of the sclera (Tate, 
2009). This layer forms the blood-ocular barrier, which tightly regulates the entry of substances into 
the eye from the blood.  The blood-retinal barrier (BRB) is composed of the retinal vascular 
endothelium and the retinal pigment epithelium (RPE). The tight junctions of the BRB make up a 
formidable barrier to the entry of several substances from the choroidal capillaries to the retina. 
Efflux pumps, such as P-glycoprotein and multi-drug resistance (MDR) pumps (MRP) have been 
found on the RPE (Aukunuru, Sunkara, Bandi, Thoreson, & Kompella, 2001; Brian G. Kennedy & 
Nancy J. Mangini, 2002). These pumps limit the permeation of various xenobiotics and endogeneous 
compounds from the choroid into the retina and vitreous (Duvvuri, Majumdar, & Mitra, 2003). 
1.1.3 The Neural Layer of the Eye  
The innermost layer of the posterior section of the eyeball is the retina. The retina has an outer layer 
of pigmented cuboidal cells and an inner light-sensitive neural layer. This neural layer has 120 million 
photoreceptors rod cells and 6–7 million photoreceptor cone cells and other relay neurons. Rods are 
responsible for vision at low light levels while the cones are active at higher light levels and are 
capable of colour vision (Gresh, Goletz, Crouch, & Rohrer, 2003). Light is focused on two adjoining 
areas of the retina, the fovea and macula. The greatest visual acuity is obtained by focusing light in 
the fovea since it has the greatest concentration of photoreceptors of the retina. The fovea is rod-
free and has a very high density of cones. The retinal artery and vein enter and exit the retina at the 
optical disc, also called the “blind spot” since it does not have any photoreceptor cells (Tate, 2009). 
The intravitreal segment or neural layer are the most challenging area in terms of ocular drug 
delivery for the treatment of disorders affecting the retina, also due to the possibility of drug 
metabolism and excretion. 
1.2 Ocular drug delivery 
1.2.1 Routes of ocular drug delivery 
1.2.1.1 Topical Administration 
The topical route remains the most suitable and effective route of ocular drug delivery to the 
anterior segment of the eye (Figure 1.3).  This usually involves the instillation of drops on the corneal 
surface but may also include ophthalmic gels or ointments instilled in the space between the lower 
eyelid and conjunctiva. These are generally easy to apply and have the advantage of being non-
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invasive. Drug entry into the eye by the topical route follows two local pathways: corneal and 
conjunctival (Maurice, 2002). The corneal pathway requires the drug to traverse the cornea followed 
by the iris, aqueous humor, lens and ciliary body. The conjunctival pathway involves drug 
permeability across the conjunctiva followed by the sclera, choroid, retinal pigment epithelium and 
retina. 
 The advantage of topical administration is that hepatic first-pass metabolism is avoided and 
selective targeting of the drug in the anterior chamber of the eye achieved. However there is poor 
ocular bioavailability and typically less than 1% of the topically applied dose reaches the aqueous 
humor (Duvvuri, et al., 2003) and ca. 0.001% is anticipated to reach the posterior segment 
(Sigurdsson, Konráðsdóttir, Loftsson, & Stefánsson, 2007). 
 
Figure 1.3: Ocular delivery routes (Reprinted with permission from Holz et al, 2014)(Holz, Schmitz-
Valckenberg, & Fleckenstein, 2014) 
 
1.2.1.2 Systemic Route 
Systemic administration of drugs as tablets, capsules or intravenous injections to target the eye 
depends on the ability of the drug to traverse the blood retinal barrier (BRB). Highly lipophilic 
molecules such as chloramphenicol and minocycline are able to penetrate the BRB and are suitable 
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for systemic administration whereas hydrophilic drugs like amikacin and cefazolin do not reach the 
vitreous in sufficient concentrations to be effective (Boddu & Nesamony, 2013). 
The disadvantages of systemic administration are that high doses and frequent administration are 
usually required for sufficient therapeutic concentrations to be reached at the target site. This can 
then result in systemic side effects (P. M. Hughes, Olejnik, Chang-Lin, & Wilson, 2005). 
1.2.1.3 Periocular Route 
This refers to the administration of drug using the retrobulbar, peribulbar, sub-Tenon, 
subconjunctival and posterior juxtascleral pathways (Figure 1.4). This route minimizes the risk of 
endophthalmitis and retinal damage and is less invasive than intravitreal injection. The drug may 
permeate from the periocular space into the vitreous humour via three pathways, namely; the 
anterior chamber, systemic circulation or direct penetration. In the anterior chamber pathway, the 
drug can diffuse into the aqueous humour either directly across the sclera and ciliary body or 
indirectly via the tear fluid and cornea, followed by diffusion into the posterior chamber. In the 
systemic circulation route, the drug is absorbed into the general circulation via conjunctival, 
episcleral or choroidal vessels and later returned into the eye with blood flow. The direct 
penetration pathway involves several membrane barriers, which contribute to the factors affecting 
transscleral drug delivery to posterior ocular tissue, including diffusion across these tissues, active 
transport in RPE, distribution and clearance via circulation (Ranta & Urtti, 2006). While permeability 
across the sclera is dependent on molecular radius rather than lipophilicity or size (Jayakrishna 
Ambati, et al., 2000), the RPE is the rate limiting membrane for drugs via the transscleral route (J. G. 
Cunha-Vaz, 1976; Duvvuri, et al., 2003). Although this route affords better bioavailability to the 
retina and vitreous humour (about 0.01-0.1%) than the topical route (H. Kim, et al., 2004; Urtti, 
Pipkin, Rork, & Repta, 1990), it is still lower than that of the intravitreal route (Nakatani, et al., 2011). 
Up to two orders of magnitude higher volumes of drug solution can be delivered via this route 
compared to the intravitreal route in humans (Kalsi, Silver, & Rootman, 1991).  Moreover, repeat 
injections under local anaesthesia can be performed without clouding of vision. Sustained drug 
delivery via this route is also possible to the anterior and posterior segments but risk rapid clearance 
through choroidal blood flow and possible systemic side effects (Ranta & Urtti, 2006). 
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Figure 1.4: Schematic representation of periocular routes of delivery (Reprinted with permission 
from T Thrimawithana)(Thrimawithana, 2011) 
1.2.1.4 Intravitreal route 
The intravitreal injection of drugs into the eye involves direct deposition of the formulation into the 
vitreous humor via the pars plana using a 30G needle (Sarao, Veritti, Boscia, & Lanzetta, 2014). Due 
to the proximity of the vitreous with retina, choroid and retinal pigment epithelium (RPE) cells, 
intravitrreal injections can achieve high drug loads and localization of the drug to the target tissue is 
enhanced. Drug release can also be sustained over a prolonged period of time using implant 
technology. However, molecules less than 500 Da tend to have a half-life of less than 3 days when 
applied intravitreally due to diffusion through the vitreous humour and subsequent elimination 
(Kaur & Kakkar, 2014). The disadvantages of intravitreal injections are the need for repeated 
injections which can result in retinal detachment, cataract, vitreous haemorrhage and 
endophthalmitis. The inner limiting membrane (ILM) comprising of a meshwork of pores ranging in 
size from 10 to 25 nm acts as a barrier to the movement of macromolecules from the vitreous to the 
retina. Kamei et al. (Kamei, Misono, & Lewis, 1999) have reported the failure of a 70-kDa tissue 
plasminogen activator to traverse the ILM on intravitreal injection. Patient acceptance is low 
because of the associated pain and invasiveness. Moreover, an ophthalmologist would be needed to 
perform such specialized injections, adding to the cost. 
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1.2.1.5 Suprachoroidal route  
More recently, a potential drug administration site to the posterior segment of the eye – the 
suprachoroidal space (SCS) – has been identified and studied (Einmahl, et al., 2002; Y. C. Kim, Park, & 
Prausnitz, 2012). This space lies internal to the sclera and external to the choroid. It is approximately 
30 µm in thickness and consists of tightly packed collagen fibres, elastic fibres, fibrocytes, 
melanocytes, ganglion cells and nerve plexi (Guyer, Schachat, & Green, 2006). The SCS of the eye 
provides a natural passageway for drugs injected across the sclera to flow quickly along the inner 
surface of the eye and subsequently into the posterior chamber; the flow is quick enough to warrant 
calling it the supra-choroidal (SC) highway. The delivery application, safety profile and 
pharmacokinetics of this route have been studied in rabbit and pig models for treatment of macular 
diseases where it has shown safety and tolerability profiles that justify further investigation in 
humans (Olsen, 2003). 
The SCS in a pig model has been reported to expand in a dose-dependent manner to accommodate 
different volumes (250– 1000 µL) of an aqueous solution containing a contrast agent. The injected 
material rapidly diffused into the entire posterior segment in less than 8 seconds(Seiler, et al., 2011). 
However, a maximum volume of 200 µL is recommended for injection to avoid further expansion of 
this loose layer and prevent choroidal edema and potential choroidal detachment. Interestingly, the 
drug injected to this SCS has limited access to the vitreous body; therefore, unwanted adverse 
effects such as vitreous haemorrhage and opacity to the visual axis are avoided. The effects of drug 
lipophilicity and molecular weight on SC delivery in rabbit ex vivo eye models were studied using 
eight beta-blockers of different lipophilic properties and fluorescein isothio-cyanate (FITC)-dextran 
of a molecular weight range of 4–40 kDa. Choroidal and retinal delivery of the studied beta-blockers 
were enhanced; this enhancement was directly related to the increase in drug lipophilicity, with 
tissue levels being the highest for the lipophilic beta-blocker propranolol and the least for the hydro-
philic beta-blocker atenolol. An opposite trend was seen with the delivery to the vitreous humour 
where drug lipophilicity showed an inverse relationship with vitreal concentration. For the effect of 
molecular weight (drug size), retinal and vitreal delivery were found to be significantly higher for 
4 kDa FITC-dextran than for the 40 kDa counterpart, whereas sclera and choroid-retinal pigment 
epithelium showed higher levels with 40 kDa FITC-dextran than that estimated for 4 kDa FITC-
dextran; this could be ascribed to the low diffusivity of the 40 kDa FITC-dextran (Kadam, Williams, 
Tyagi, Edelhauser, & Kompella, 2013). These results suggested that molecular size and lipophilicity of 
the drug have an impact on SC delivery and potential transit into the vitreous. 
 
 12 | P a g e  
 
1.2.2 Barriers to anterior segment delivery 
Most commercially-available eye drops dispense ca. 50 µL per drop; however, the eye is only able to 
hold 30 µL. Therefore, the rest of the applied eye drop overflows into the naso-lacrimal duct and is 
drained away, risking systemic absorption and resulting unintended effects (Koevary, 2003; Mishima, 
Gasset, Klyce, & Baum, 1966). The surface of the eye also has a rapid tear turnover of about 
1 µL/minute which results in dilution of the drug in the lacrimal fluid, affecting the concentration 
gradient required for diffusion of the drug across the cornea (Barar, Javadzadeh, & Omidi, 2008). 
Moreover, enzymes and proteins present in the lacrimal fluid result in metabolism, non-productive 
ab/adsorption and binding of the active ingredient. 
The cornea is made up of 3 layers: a lipophilic outer epithelium, a hydrophilic stroma and a lipophilic 
inner endothelium (Bourlais, et al., 1998) and is thus a barrier to the diffusion of both hydrophilic 
and lipophilic drugs. In addition, this potential target has a smaller surface area than the conjunctiva 
and sclera. The conjunctiva, though made up of tight junctions, is more permeable to hydrophilic 
compounds than the cornea due to a  greater number of and larger paracellular epithelial pores 
(Lawrence & Miller, 2004) . It also has a surface area 17 times greater than the cornea and therefore 
competes with corneal drug absorption in the anterior eye (Hamalainen, Kananen, Auriola, Kontturi, 
& Urtti, 1997; Kaur & Kanwar, 2002). 
The blood aqueous barrier (BAB), made up of the endothelium of the iris and ciliary blood vessels 
and non-pigmented ciliary epithelium, contains tight junctions that limit transport of solutes 
between the anterior and posterior segments (Raviola, 1977). Drugs that do reach the aqueous 
humor via fenestrated capillaries of the ciliary body tend to be readily eliminated due to the 
continuous outflow of aqueous humor through the Canal of Schlemm (J. Cunha-Vaz, 1979; Hornof, 
Toropainen, & Urtti, 2005; Janoria, Gunda, Boddu, & Mitra, 2007). 
1.2.3 Barriers to posterior Segment Drug Delivery 
There are a number of anatomical and physiological barriers that exist to protect the posterior eye 
against exogenous materials. The vitreous humour is acellular and comprises mostly water (98-99% 
w/w) with some collagen and glycosaminoglycans.  This hydrogel forms a diffusional barrier to drug 
delivery to the retina, particularly to high molecular weight compounds or suspended solids (Le Goff 
& Bishop, 2008; Mains & Wilson, 2012). 
The neural retina (separating the pigmented retinal layer from the vitreous humor) is a multilayered 
structure that binds to cations and limits their transport through the retina. It was demonstrated 
that the cationic charge was more of a limiting factor than molecular size when trying to traverse the 
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neural retina (Pitkänen, Ruponen, Nieminen, & Urtti, 2003). The inner limiting membrane of the 
neural retina has a meshwork of pores (10-25 nm) that act as a sieve keeping macromolecules from 
entering the retina from the vitreous (Kamei, Misono, & Lewis). 
The blood retinal barrier (BRB) (Figure 1.5) is composed of tight junctions and acts as a significant 
barrier to drug absorption into the retina and vitreous via the systemic route (Kiernan & Lim, 2010). 
The retinal pigment epithelium (RPE) is the main barrier to the penetration of hydrophilic molecules 
and macromolecules from the sclera (Pitkänen, Ranta, Moilanen, & Urtti, 2005). The lag time 
increases proportionally with the molecular size (as it determines the diffusion coefficient), while 
small, lipophilic molecules are able to permeate the RPE as efficiently as the sclera. These can bind 
to melanin in the RPE, compromising their passage (Edelhauser, et al., 2010). 
 
Figure 1.5: Blood-retinal barrier (Reprinted with permission from Che et al, 2014)(Che, Fan, & Wang, 
2014) 
The sclera allows drug molecules to permeate based on their hydrophilicity and molecular weight. 
Smaller, hydrophilic molecules are able to pass through the sclera more easily compared to their 
larger, more lipophilic counterparts (Berezovsky, Patel, McCarey, & Edelhauser, 2011; Prausnitz & 
Noonan, 1998; Thakur, Kadam, & Kompella, 2011). Lipophilic solutes and macromolecules are kept 
out by the pigmented nature of the choroid and especially by Bruch’s membrane (Cheruvu, Amrite, 
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& Kompella, 2008; Moore & Clover, 2001). The choroid being highly vascularized is responsible for 
retinal availability of drugs administered systemically but can also sweep drugs administered by 
other pathways into the systemic circulation. 
The human RPE contains efflux transporters such P-glycoprotein (P-gp) which act to limit the 
permeation of drugs from the choroid to the retina and vitreous humor (Boddu & Nesamony, 2013; 
P. M. Hughes, et al., 2005; B. G. Kennedy & N. J. Mangini, 2002).  Conjunctival and episcleral blood 
and lymphatic flow can easily clear small molecules that are administered subconjunctivally. In post-
mortem rabbits, blocking blood and lymphatic flow from the subconjunctival site improved drug 
delivery to the posterior segment significantly  
1.3 Diabetic Retinopathy 
The International Diabetes Federation (IDF) reports that 382 million people were diagnosed with 
diabetes in 2013, projected to rise to 642 million by 2040. This equates to one in ten adults 
developing diabetes. Diabetes provoked 5.1 million deaths and resulted in USD 548 billion dollars in 
global health spending in 2013. In 2017, IDF estimates the total healthcare expenditure on diabetes 
will reach USD 727 billion (20-79 years), which represents an 8% increase compared to the 2015 
estimate. The Western Pacific, including Australia, has a diabetes prevalence greater than any other 
region; Australia reporting 5.14% (associated with USD 7,931 diabetes-related healthcare 
expenditure per person) in 2014 (Source: IDF Diabetes Atlas, 2017) 
Approximately 30% of people with diabetes develop some degree of retinopathy (DR); currently the 
leading cause of vision loss in working age adults in the developed world. Of these, 10% have vision-
threatening states such as proliferative diabetic retinopathy (PDR) (Yau, et al., 2012) The social and 
financial impact of visual impairment is significant to those affected and their communities more 
broadly (Figure 1.6). 
 
 15 | P a g e  
 
  
Figure 1.6: Projections for Diabetic Retinopathy in 2030 and 2050 (in millions)”, National Eye 
Institute, National Institutes of Health 
Diabetic retinopathy can be divided in two stages. The first is non-proliferative diabetic retinopathy 
(NPDR) which is characterized by microaneurysms, intraretinal haemorrhaging and other 
microvascular aberrations.  
In NPDR, loss of pericytes leads to the breakdown of the blood-retinal barrier (BRB) and in the 
leakage of plasma. It also results in the outpouching of the capillary walls or microaneurysms, 
eventually thickening of these walls causes micro-occlusion of the lumen leading to areas of 
ischemia and promoting the abnormal growth of new, fragile vessels in the surrounding area (Wild, 
Roglic, Green, Sicree, & King, 2004). There is also evidence to show that neurodegenerative changes 
in the retina may precede detectable changes in the microvasculature. Electroretinogram 
abnormalities have been detected in both humans and rats with Type 1 diabetes without any 
evidence of microvascular abnormalities (Di Leo, et al., 1994; Di Leo, et al., 1990; Ewing, Deary, 
Strachan, & Frier, 1998; Shirao & Kawasaki, 1998). High glucose levels lead to oxidative stress in the 
retina with the production of advanced glycation end-products (AGEs). A downregulation of 
neuroprotective factors such as somatostatin and pigment epithetial derived factor also play an 
essential role. Glutamate (a major excitatory neurotransmitter in the retina) has been found to be 
elevated in experimental diabetic models as well as in the vitreous fluid of patients with proliferative 
Calendar year  
Number 
of 
people 
with DR 
in 
millions  
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diabetic retinopathy (J. Ambati, et al., 1997; Pulido, et al., 2007). Glutamate excess leads to 
excitotoxicity resulting in postsynaptic neuron death. The second stage is proliferative diabetic 
retinopathy (PDR) which is characterized by the onset of neovascularization and vitreous 
haemorrhage (Wilkinson, et al., 2003). 
1.3.1 Current therapies for the management of diabetic retinopathy 
Current therapeutic options target the late stages of diabetic retinopathy when vision is already 
significantly degraded. These established treatments aim to prevent haemorrhaging using laser 
therapy or intraocular injections of corticosteroids and therapeutic anti-vascular endothelial growth 
factor (VEGF) antibodies. However, efficacy is low or variable and frequent injections are required; 
serious ocular side-effects are possible and all result in some degree of tissue destruction. New 
therapies to prevent the onset or arrest the progression of the disease before overt microvascular 
pathologies are essential (Simo & Hernandez, 2015).  
Laser photocoagulation is the main treatment for established diabetic retinopathy generally 
indicated in proliferative diabetic retinopathy. While the exact mechanism for how laser 
photocoagulation achieves its therapeutic effect is an area of active investigation, the leading 
hypothesis as to mechanism of laser treatment is that it reduces neovascular disease by killing 
retinal cells in the poorly perfused portions of the retina, reducing relative ischemia, thus decreasing 
the production of angiogenic factors and increasing oxygenation of the vitreous. Since 
photoreceptors are the most metabolically active and numerous cells in the retina, laser 
photocoagulation for PDR involves the purposeful destruction of a fraction of the photoreceptors. 
This does not restore lost vision but can ameliorate deterioration if employed in the early stages of 
the disease. The technique risks serious complications including loss of peripheral vision, loss of 
visual acuity, impaired adaptation to changes in light levels or worsening macular edema (Simo & 
Hernandez, 2015). 
The role of intravitreal anti-vascular endothelial growth factor (VEGF) agents in proliferative diabetic 
retinopathy remains to be elucidated with several ongoing studies. The anti-VEGF agents are 
biologics that bind to the VEGF isoforms in the retina and are generally administered monthly for the 
first three months then every three months after. However, the optimal schedule of injections is still 
being investigated; currently, these are approved by the TGA but restricted to the treatment of 
diabetic macular edema, retinal vein occlusion and wet age-related macular degeneration. The use 
of these anti-VEGF agents in diabetic macular edema has been investigated in major randomized 
controlled clinical trials which provide robust evidence for their efficacy in preserving and improving 
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vision in patients with DME compared to laser therapy (Bandello, et al., 2012; N. Cheung, Wong, & 
Wong, 2014; Virgili, Parravano, Menchini, & Brunetti, 2012). Of the four anti-VEGF agents 
(ranibizumab, bevacizumab, pegaptanib and aflibercept), ranibizumab has the most evidence.  Local 
complications from these invasive injections including endophthalmitis and retinal detachment can 
result. Moreover, long term use of pan-VEGF injections may be implicated in circulatory disturbances 
of choriocapillaris or neurodegeneration of the remaining healthy retinal tissue (D'Amore, 2007). 
The risk of systemic absorption of these anti-VEGF drugs remains to be addressed by long-term 
studies and could result in hypertension, proteinuria, impaired wound healing and increased risk of 
cardiovascular events (R. Simó & Hernández, 2008; Rafael Simó, Sundstrom, & Antonetti, 2014). 
Intravitreal injections of corticosteroids are employed for their anti-inflammatory mechanisms and 
more recent studies identify neuroprotective potential (Zhang, Lai, Bao, Hambly, & Gillies, 2013). 
However, the incidence of complications following corticosteroid injection remains high, commonly 
resulting in elevated intraocular pressure and cataract formation. While there are different classes of 
intravitreal steroids available differing in potency and duration of action, there are two low-dose 
implants that can provide sustained-release delivery (the dexamethasone and flucinolone acetonide 
implants).  
The dexamethasone implant is marketed by Allergan as Ozurdex®. This is a biodegradable polymer 
implant that is placed into the vitreous humour via a 22-gauge needle and releases the drug for up 
to six months (Yasin, Svirskis, Seyfoddin, & Rupenthal, 2014). Iluvien® is the non-biodegradable 
implant containing fluocinolone acetonide and once inserted into the vitreous via a 25-gauge needle, 
releases the drug for up to 3 years (Yasin, et al., 2014). In a randomized phase II clinical trial, 
Ozurdex® resulted in similar rates of improvement in visual acuity compared to bevacizumab for 
DME. Ozurdex® achieved superior anatomic outcomes and fewer injections with similar 
improvements in visual quality-of-life scores. However, more eyes treated with  Ozurdex ® lost vision 
due to cataract (Gillies, et al., 2014). Iluvien® was found to have greater risk of inducing ocular 
hypertension and cataract (Ciulla, Harris, McIntyre, & Jonescu-Cuypers, 2014), although the longer 
duration of action could potentially decrease treatment burdens on the patient and families. 
Vitrectomy is the last treatment option; being both expensive and complicated this procedure is 
reserved for the ultimate blinding complications of diabetic retinopathy. However, the outcome 
after vitreo-retinal surgery remains unpredictable (Yorston, et al., 2008) and risks significant post-
operative complications, including vitreous cavity haemorrhage and retinal detachment (Newman, 
2010) resulting in blindness that the procedure is intended to prevent. Table 1.1 provides a summary 
of the discussion above. 
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Table 1.1- Summary of the current therapies for DR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure/ 
Formulation 
Dose/ 
Frequency 
Side-effects Brand & 
Manufacturer (if 
applicable) 
Reference 
Laser treatment  
Pan-retinal photo-
coagulation for 
proliferative diabetic 
retinopathy 
May be 
performed in 
2 or more 
sessions 
Moderate 
visual loss, 
some 
diminished 
visual field, 
reduced 
colour 
vision, and 
reduced 
contrast 
sensitivity 
N/A (Rafael 
Simó & 
Hernánd
ez, 2015) 
Anti-VEGF agents Monthly 
injections for 
the first five 
months 
followed by 
one injection 
every 2 
months 
thereafter 
(Eylea®) 
Monthly 
injections 
(Lucentis®) 
 
Conjunctival 
haemorr-
hage 
Endoph-
thalmitis 
Retinal 
detachment 
Aflibercept 2mg 
intravitreal 
injection- Eylea® 
(Regeneron 
Pharmaceuticals, 
Inc., NY, USA) 
Ranibizumab 
0.3mg and 
0.5mg 
intravitreal 
injection-
Lucentis® 
(Genentech, Inc., 
Roche Group, 
San Francisco, 
CA, USA) 
(R. Simó 
& 
Hernánd
ez, 2008) 
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Corticosteroid  Ozurdex-one 
implant every 
6 months 
Iluvien and 
Retisert- one 
implant for 3 
years 
 
Infection, 
glaucoma, 
and cataract 
formation 
Dexamethasone 
700mcg 
intravitreal 
implant- 
Ozurdex®, 
(Allergan, Irvine, 
CA, United 
States 
Fluocinolone 
acetonide 
0.19mg 
intravitreal 
insert-Iluvien® 
(Alimera 
Sciences, 
Alpharetta, GA, 
United States) 
Fluocinolone 
acetonide 
0.59mg 
intravitreal 
implant- 
Retisert (Bausch 
+ Lomb, NJ USA) 
(Arcinue, 
Cerón, & 
Foster, 
2013) 
Vitrectomy One-time 
procedure 
Expensive, 
complicated 
treatment 
that requires 
experienced 
vitreoretinal 
specialists  
N/A (Rafael 
Simó & 
Hernánd
ez, 2015) 
 20 | P a g e  
 
 
 
 
 
 
1.4 Somatostatin 
Somatostatin (SST) is an endogeneous cyclic tetradecapeptide hormone.  Primarily inhibitory in 
nature, this small peptide has anti-secretory and anti-proliferative effects and functions as a 
neurotransmitter. Originally isolated in the ovine hypothalamus and discovered as an inhibitor of 
growth hormone, somatostatin is now known to have widespread functions in the human body 
(Guillemin, 2008). The peptide is secreted throughout the central nervous system, in the 
gastrointestinal tract, retina, peripheral neurons and the pancreatic islets of Langerhans (Kumar & 
Grant, 2010). 
1.4.1 Overview of SST biological activity 
The anti-secretory activities of somatostatin are summarized in Table 1.2. As a neurotransmitter, 
somatostatin has effects on cognition, locomotor activity, sensory and autonomic functions 
mediated by the inhibition of release of dopamine, norepinephrine, thyroid-releasing hormone 
(TRH) and other lesser transmitters. In the gastrointestinal tract somatostatin inhibits exocrine 
secretion, gastric emptying and gall bladder contraction while inhibiting the secretion of insulin and 
glucagon from the pancreas.  
Table 1.2 –Summary of anti-secretory functions of SST (Adapted with permission from B. Boehm) 
Organ Function 
Pituitary Reduces secretion of GH and TSH 
Brain Inhibits release of norepinephrine, TRH and 
corticotrophin-releasing hormone and 
dopamine from the midbrain.  
Retinal 
detachment 
High 
intraocular 
pressure 
Cataract 
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Pancreas Reduces secretion of insulin, glucagon and 
pancreatic polypeptide as well as bicarbonate 
and enzyme secretion. 
Thyroid Reduces secretion of T3, T4 and calcitonin. 
Gastrointestinal tract Reduces secretion of gastrin, secretin, motilin, 
gastric acid, enteroglucagon, CCK, VIP, GIP, 
intrinsic factor, pepsin, neurotensin, bile 
secretion and colonic fluid secretion. 
Adrenals Inhibits angiotensin II stimulated- aldosterone 
secretion and acetylcholine stimulated 
medullary catecholamine secretion. 
Eye Inhibits VEGF production 
Abbreviations: CCK- Cholecystokinin, GH- growth hormone, GIP- gastric inhibitory polypeptide, TRH- 
thyroid-releasing hormone, TSH- thyroid- stimulating hormone, VIP- vasoactive intestinal peptide, 
VEGF- vascular endothelial growth factor 
1.4.2 Secretion pathway and somatostatin isoforms 
Initially secreted as a 116 amino acid precursor, preprosomatostatin is converted by endoproteolytic 
cleavage to prosomatostatin, which is then further processed into two active forms, somatostatin-28 
(SST-28) and somatostatin-14 (SST-14). SST-14 is the isoform that was originally characterized 
(Brazeau, et al., 1973). SST-28 was later discovered as an extended SST-14 sequence to the amino- 
terminus (N-terminus) (van der Hoek, Hofland, & Lamberts, 2005) (Figure 1.8). The distribution of 
the two active isoforms is similar, although one form generally predominates over the other in 
different parts of the body. In the enteric neurons and peripheral nerves, SST-14 is  prominent 
whereas SST-28 is the predominant form in the  retina and intestinal mucosal cells (Hernandez, et 
al., 2005).  
Somatostatin has an extremely short half-life of 1-3 minutes, being rapidly degraded by ubiquitously 
distributed  peptidases in plasma and the tissues (Benuck & Marks, 1976). Consequently circulating 
levels of somatostatin are low at 14-32.5 pgml-1 (Ensinck, et al., 1989; Gyr, et al., 1987; Peeters, 
Depraetere, & Vantrappen, 1981; Penman, et al., 1981; Shoelson, Polonsky, Nakabayashi, Jaspan, & 
Tager, 1986; Skamene & Patel, 1984; Tsuda, et al., 1981; Vasquez, Harris, & Unger, 1982).  The lack 
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of receptor specificity of native somatostatin, short half-life and the necessity of direct injection at 
the desired site of action has motivated the discovery and refinement of compounds with receptor 
selectivity and greater metabolic stability. Both peptide and non-peptide agonists have been 
synthesised (Section 2.4). 
 
1.4.3 Somatostatin receptors 
1.4.3.1 SSTR subtypes 
Somatostatin binds to five subtypes of G-protein coupled transmembrane receptors (SSTR1-5) (Y. C. 
Patel, 1999b). The receptors are 364-418 amino acids long and share 39-57% homology in sequence. 
All possess seven highly conserved α-helical transmembrane domains, with most divergence 
occurring in the extracellular N-terminus and intracellular carboxyl terminus (C-terminus) domains. 
SSTR1, 3, 4 and 5 have only single subtypes, whereas two spliced variants exist for SSTR2, termed 
SSTR2A and SSTR2B, which differ in the length of the C-terminus domain (Kumar & Grant, 2010). 
SSTRs 1 to 4 bind SST-14 and SST-28 with high (nanomolar) affinity, whereas SSTR5 exhibits a 5-10-
fold higher binding affinity for SST-28.  
1.4.3.2 SST receptor distribution 
SSTRs are widely distributed throughout the central nervous system (CNS) and periphery. Whilst all 
five subtypes are expressed in normal human tissues, the predominant subtypes in endocrine tissues 
are SSTR2 and SSTR5 (Barnett, 2003; Lamberts, van der Lely, & Hofland, 2002; Y. C. Patel, 1999b). 
Table 1.3 provides a summary of the distribution of the SSTRs and their signalling mechanisms.  
SSTR1 triggers antisecretory effects on growth hormone, prolactin and calcitonin. SSTR2 also inhibits 
secretion of growth hormone and that of adrenocorticotropin, glucagon, insulin, interferon-γ and 
gastric acid. SSTR5 has the same inhibitory effect on growth hormone, adrenocorticotropin, insulin 
and glucagon-like peptide-1 and inhibits the secretion of amylase. SSTR3 reduces cell proliferation 
and induces cell apoptosis, whereas the functions of SSTR4 remain largely unknown (Cejvan, Coy, & 
Efendic, 2003; Cervia, Petrucci, Bluet-Pajot, Epelbaum, & Bagnoli, 2002; Chisholm & Greenberg, 
2002; J. Gromada, Hoy, Buschard, Salehi, & Rorsman, 2001; Hannon, et al., 2002; Strowski, et al., 
2002; Strowski, et al., 2003; Weckbecker, et al., 2003; Zatelli, et al., 2002) 
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Table 1.3- Distribution and signalling mechanisms of Somatostatin receptors (SSTRs) (Adapted with 
permission from P. Dasgupta and B. Boehm) 
Subtype SSTR1 SSTR2 SSTR3 SSTR4 SSTR5  
Distribution      
Brain + + + + + 
Eye  +    
Kidneys +     
Pancreas + + +  + 
Pituitary     + 
Heart     + 
G-protein 
coupling via 
Gai1, Gai2, or 
Gai3 
 
+ + + + + 
Inhibition of 
GH, insulin, and 
glucagon Ca2+ 
channels  
 +   + 
Inward-
rectifyting K+ 
channel 
 + + + + 
Inhibition of 
Na+ /H 
exchanger 
activity 
+     
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Activation of 
protein tyrosine 
phosphatase 
 
+ + + +  
MAPK/ERK 
pathway 
+  + + + 
Activation of 
phospholipase 
A2 
 
   +  
Inhibition of 
Rho/Rac 
pathway 
 
+     
STAT3 
phosphorylation  
   +  
Inhibition of  
e-NOS pathway 
+ + +   
Inhibition of 
guanylate 
cyclase 
 
    + 
 
1.4.3.3 SST receptor signalling mechanisms 
All SSTRs are coupled to the pertussis toxin-sensitive Gi protein and inhibit adenylyl cyclase, thereby 
decreasing cyclic AMP levels (Y. C. Patel, Greenwood, Warszynska, Panetta, & Srikant, 1994). While 
there are similarities in signal transduction pathways, differences between the SSTRs result in 
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different actions effected by each receptor. Receptor endocytosis and trafficking further modulate 
SSTR signalling (Hofland & Lamberts, 2003). 
The antisecretory effect of SST results from inhibition of exocytosis. This is mediated not only by the 
aforementioned suppression of cyclic AMP levels, but also by activation of various types of K+ 
channels. This includes the delayed rectifying, inward rectifying and ATP sensitive K+ channels. This 
results in membrane hyperpolarization and inhibits depolarization-induced Ca2+ influx through 
voltage-sensitive Ca2+ channels. Thus there is reduced intracellular Ca2+ and inhibition of exocytosis 
(Koch, Blalock, & Schonbrunn, 1988; Pace & Tarvin, 1981; Sims, Lussier, & Kraicer, 1991; Yamashita, 
Shibuya, & Ogata, 1986; Yatani, Codina, Sekura, Birnbaumer, & Brown, 1987). The Gi and Go protein 
subtypes mediate the inhibitory action of SST on Ca2+ (Kleuss, et al., 1991; Schlegel, Wuarin, Zbaren, 
Wollheim, & Zahnd, 1985). Another pathway involving a cyclic GMP –dependent protein kinase also 
mediates the inhibitory action of SST on neuronal calcium channels (Meriney, Gray, & Pilar, 1994). 
All SSTRs with the exception of SSTR3 couple to voltage-gated K+ channels with SSTRs 2 and 4 being 
the most potent in increasing K+ currents (Yang, Parkington, Blake, Keating, & Chen, 2005). SSTRs 1, 
2, 4 and 5 have a direct effect via coupling to N and L-type voltage sensitive Ca2+ channels (Fujii, et 
al.; Hou, Gilbert, & Barber, 1994; P. A. Smith, 2009; Tallent, et al., 1996). SST also affects exocytosis 
distal to secondary messengers by the downregulation of Ca2+-dependent phosphatase calcineurin 
(Jesper Gromada, Høy, Buschard, Salehi, & Rorsman, 2001; Renström, Ding, Bokvist, & Rorsman).  
The antiproliferative actions of SST result from cell cycle arrest and/or apoptosis downsteam from 
SSTR activation. SST triggers both common and unique signalling cascades upon binding to the 
different SSTRs. A detailed discussion of the signalling cascades for each SSTR is beyond the scope of 
this discussion and we refer you to Theodoropoulou et al 2013 for an excellent review of the subject. 
However, below is a summary of the signalling cascades leading to antiproliferative activity. SST 
inhibits growth factor receptor signalling through protein tyrosine phosphatases (PTPS) (Pan, Florio, 
& Stork, 1992). They are central to this process by causing the dephosphorylation of growth factor 
bound tyrosine kinase receptors (Pan, et al., 1992). In multiple cell systems, SST treatment increased 
PTP activity (Buscail, et al., 1994; T Florio & Schettini, 1996; D. B. Reardon, et al., 1996). PTPs were 
shown to be activated by Gαi (Pan, et al., 1992) and Gαi/o (Dent, et al., 1996) and SSTRs associate 
with the PTPs containing the cytosolic src homology 2 (SH2) domain, SHP-1 (PTP1C) and SHP-2 
(PTP1D), and the membrane-anchored PTPη (DEP1) (Delesque, et al., 1995; T. Florio, et al., 2001; 
Frédéric Lopez, et al., 1997; F. Lopez, et al.; Massa, et al., 2004; Pagès, et al., 1999; Dean B. Reardon, 
Dent, Wood, Kong, & Sturgill, 1997; Srikant & Shen, 1996). Through PTPs, SST binding at SSTRs 1,2,4 
and 5 lead to cell cycle arrest at G1/S boundary and at the G2/M boundary via SSTR3 (N. W. Cheung 
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& Boyages, 1995; Srikant, 1995). SSTRs 2 and 3 also induce apoptosis (Ferrante, et al., 2006; K. 
Sharma, Patel, & Srikant, 1996; Teijeiro, et al., 2002). SSTRs induce acidification which results in 
apoptosis via a SHP-1 dependent mechanism (Thangaraju, et al., 1999). SSTRs 1, 3 and 4 inhibit the 
Na+/H+ exchanger (NHE1), leading to increased intracellular acidification (C.-Y. Lin, et al., 2003; X. 
Lin, et al., 1996) which may be responsible for the anti-cell-migration properties of SST in certain 
tumor cell types (Cattaneo, Gentilini, & Vicentini, 2006; Pola, Cattaneo, & Vicentini, 2003). SSTR1 
inhibits Rho GTPase, which regulates cytoskeleton organization, cell adhesion and cell motility 
through NHE1 (Buchan, Lin, Choi, & Barber, 2002). SSTRs 1, 2 3 and 5 block nitric oxide synthase 
(NOS), which is an additional pathway lending to the antiproliferative action of SST (Arena, 
Pattarozzi, Corsaro, Schettini, & Florio, 2005; F. Lopez, et al., 2001). Also worthy of mention is the 
mitogen-activated protein kinase (MAPK) pathway. The MAPK pathway mediates the mitogenic 
action of growth factors, cytokines and hormones (Seger & Krebs, 1995). The MAPK pathway can 
also halt cell growth in order to promote cell differentiation depending on the cell system and 
extracellular environment. SSTRs 2, 3 and 5 mediate inhibition of MAPK activity while SSTRs 1 and 4 
mediate the activation of MAPK (Moller, Stidsen, Hartmann, & Holst, 2003). Figure 1.7 below 
summarizes the signalling pathways of SST receptors. 
 
Figure 1.7: Intracellular signalling cascades associated to somatostatin receptors in pituitary cells 
(reprinted with permission from D Ferone et al, 2009)(Ferone, et al., 2009) 
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1.4.3.4 Somatostatin analogues 
The β-turn in somatostatin structure is the pharmacophore (Modlin, Pavel, Kidd, & Gustafsson, 
2010) (Figure 1.8). Amongst the variety of hexa- and octapeptide analogues that were developed, 
the most potent molecules are cyclic and bear a β-turn.  
 
 
Figure 1.8 Structures of SST analogues 
 
Within the β-turn motif of somatostatin, only phenylalanine and threonine can be substituted 
without compromising biological activity (Modlin, et al., 2010). The first synthetic SST agonist to be 
approved by the FDA was the octapeptide octreotide (SMS 201-995), marketed as Sandostatin®. 
Octreotide is available in both conventional and modified release injection (Sandostatin LAR®) 
formulations, approved in 1988 and 1998, respectively. Sandostatin LAR® contains octreotide 
distributed within polymer microspheres (Sandostatin, 2000), currently approved in the treatment of 
acromegaly and hormone-dependent tumors, especially those associated with the secretion of 
growth hormone-releasing factor and vasoactive intestinal peptide, or glucagonomas, gastrinomas, 
and insulinomas (Sandostatin, 2000). Thereafter was approved the octapeptide, lanreotide (BIM 
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23014), under the trade name Somatuline®. Initially licensed for the treatment of acromegaly, 
approval in Europe is extended for the treatment of symptoms associated with neuroendocrine 
tumors (Ipsen, 2015).  Lanreotide is marketed as a slow release hydrogel formulation, under the 
trade name Lanreotide Autogel® or Somatuline Depot® depending on countries (Ipsen, 2015; Valéry, 
et al., 2003). This formulation was approved by the FDA in 2014 for the treatment of 
gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. 
Both octreotide and lanreotide bind primarily to SSTR2, with a lower affinity to SSTR3 and 5. 
Compared to somatostatin, both exhibit greatly-extended half-lives of 1-2 hours. In 2005, vapreotide 
(RC160) marketed as Sanvar®, an SST-analog with similar binding affinities to SSTR2, 3, and 5 to 
lanreotide and octreotide but moderate affinity to SSTR4 (Y. C. Patel, 1999a) was approved for the 
treatment of acute oesophageal variceal bleeding secondary to portal hypertension (Patch & 
Burroughs, 2002). The latest SST agonist to be approved in the EU and the USA is pasireotide (SOM-
230, December 2012). This cyclohexapeptide exhibits high affinities for SSTRs 1, 2, 3 and 5 (Hasskarl, 
Kaufmann, & Schmid, 2011). Marketed by Novartis under the trade name Signifor®, pasireotide is 
licensed for the treatment of patients with Cushing’s disease. Signifor® is available as subcutaneous 
injection. Most recently, a novel tetradecapeptide somatostatin agonist in which the disulfide bridge 
has been replaced by a carbon-carbon double bond has been reported. This peptide possesses 
greater conformational flexibility than SST itself, and retains selectivity against SSTRs 1 and 5 
(Martin-Gago, et al., 2014). Table 1.4 provides a summary of the currently available somatostatin 
analogues.  
Table 1.4-Summary of the currently marketed SST analogues  
Name  
 
Structure Trade name Formulation Indications Receptor 
affinity 
Half-
life 
Referenc
-es 
Octreotide 
(SMS 201-
995) 
Cyclic 
octapeptide 
Sandostatin® 
Sandostatin 
LAR® 
Octreotide 
acetate, 
microsphere 
formulation   
Acromegaly, 
hormone-
dependent 
tumors  
 
SSTR2 > 
SSTRs3,5  
1.7-
1.9h  
(Sandost
atin, 
2000) 
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Lanreotide 
(BIM 
23014) 
Cyclic 
octapeptide 
Somatuline® 
Somatuline 
Depot®/ 
Autogel® 
 
Lanreotide 
acetate, 
hydrogel 
formulation 
AcromegalyS
omatuline 
Depot® for 
treatment of   
GEP-NETs  
Somatuline 
Autogel is 
also 
indicated  
treatment of 
symptoms of 
carcinoid 
syndrome 
associated 
with 
carcinoid 
tumours 
 
SSTR2 > 
SSTRs3,5  
2.5 h (Ipsen, 
2015) 
Vapreotide 
(RC 160) 
Cyclic 
octapeptide 
Sanvar® 
 
Immediate-
release SC 
injections 
and slow-
release IM 
formulation 
Esophageal 
variceal 
bleeding 
secondary to 
portal 
hypertensio
n 
SSTR2 > 
SSTR3, 
SSTR5 > 
SSTR4 
 2.7 – 
3.8 h  
(Debiop
harm, 
2015) 
("Vapreo
tide," 
2003) 
(Patch & 
Burroug
hs, 
2002) 
(Y. C. 
Patel, 
1999b) 
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Pasireotide 
(SOM- 
230) 
Cyclohexane Signifor® 
Signifor LAR® 
0.3mg, 
0.6mg, 
0.9mg 
solution for 
SC injection 
to be 
administere
d twice daily 
IM injection 
administere
d once 
monthly 
Acromegaly, 
Cushing’s 
disease 
SSTRs1,2, 
3,5 
12 h (Novarti
sEuroph
arm, 
2012)  
(Hasskar
l, et al., 
2011) 
 
1.4.3.5 SST-receptor  antagonists 
Advances in the understanding of SST receptor antagonists have been slow. The main impetus 
behind the design of SST receptor antagonists is to elucidate the functions of each receptor subtype. 
However, due to lack of receptor specificity or mixed antagonist-agonist profile, efforts continue in 
the synthesis and testing of structures with antagonist activity. Below is a brief discussion of the 
current knowledge of SST antagonists. 
 A non-peptide antagonist, SRA-880, was shown to be a selective and high-affinity SSTR1 antagonist. 
Active in behavioural tests of anxiety, depression and bipolar disorders, SRA-880 reduced aggressive 
behaviour in mice without sedation or impairment of motor function. Another SST3-selective non-
peptide antagonist BN-81674 competitively blocked SST-14-mediated inhibition of cAMP 
accumulation in a CHO-K1 cell line (Poitout, et al., 2001). It has been suggested that SSTR3 
antagonists therefore have potential use as anti-apoptotic agents.  
Non-peptide, highly potent and SSTR3-selective antagonists have been synthesized that show 
promising pharmacokinetic properties in rodents (Troxler, et al., 2010). The SST antagonist, 
cyclosomatostatin, has been employed in studies. One such study postulated there may be a link 
between somatostatin deficiency frequently detected in patients with Parkinson’s disease and 
extrapyramidal symptoms.  Cyclosomatostatin potentiated haloperidol-induced catalepsy in aged 
but not young rats. This action was inhibited by the SST analogue, octreotide, suggesting a link 
between aging, SST deficiency and extrapyramidal symptoms in the disease (Ionov & Severtsev, 
2012).  
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Cyclosomatostatin was found to exert opioid-agonist activity in the guinea pig intestine and rat 
stomach fundus strip(Benko, Antwi, & Bartho, 2012). It did not exhibit the antagonist activity 
expected in the preparations tested. It was suggested that this opioid agonist activity of 
cyclosomatostatin might explain the observed antinociceptive effect when administered centrally 
(Bartsch, Levy, Knight, & Goadsby, 2005).  
Given the role somatostatin plays in glucose homeostasis by inhibiting secretion of insulin and 
glucagon-like peptide 1, two novel orally bioavailable SSTR5 antagonists were studied in rodents 
(Sprecher, et al., 2010). These compounds are non-peptidic and exhibited receptor specificity and 
nanomolar binding affinity. Zucker fatty fa/fa rats and diet-induced obese mice models of diabetes 
were employed in these studies. The two compounds A and B performed differently in the different 
species. In the Zucker rats, compound A decreased glucose and insulin excursions after a single 
treatment in a dose-dependent manner following an oral glucose tolerance test. However, in obese 
mice there was a dose-dependent increase in insulin secretion by up to 72%. Compound B did not 
show any significant effects in the rat model. In the mouse model it showed a dose-dependent 
reduction of glucose excursion after 3 weeks of treatment. Hence further exploration of the role of 
SST antagonists in the treatment of diabetes in humans may be of value. 
A highly selective SSTR2 antagonist PRL2903 was used to elucidate the anxiolytic effect of SST in the 
amygdala and septum of the rat brain. The complete reversal of the anxiolytic effects of SST by 
PRL2903 confirmed that the aforementioned effects are mediated by SSTR2 (Yeung & Treit, 2012). 
1.4.4 Potential Use in Diabetic Retinopathy  
1.4.4.1 Pharmacological Role of SST and SST receptors in diabetic retinopathy 
SST is one of the most important neuroprotective factors synthesized by the retina, the retinal 
pigment epithelium (RPE) being the main source in the human eye (Hernandez, Simo, & European 
Consortium for the Early Treatment of Diabetic, 2013). The human retina produces significant 
amounts of SST with high levels reported within the vitreous fluid (Simo, et al., 2002). SSTRs are also 
expressed in the retina, with SSTR1 and SSTR2 being the most widely expressed (Cervia, Casini, & 
Bagnoli, 2008a; Klisovic, et al., 2001; Lambooij, et al., 2000). SST-28 is the main form produced in 
human retina (Hernandez, et al., 2005). Production of both SST and its receptors suggests a relevant 
autocrine action in the human retina. SST acts as a neuromodulator, regulates various ion/water 
transport systems and has potent anti-angiogenic properties (Hernandez, Simo-Servat, & Simo, 
2014). 
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Retinal neurodegeneration is an early event in the pathogenesis of diabetic retinopathy (Simo, 
Hernandez, & European Consortium for the Early Treatment of Diabetic, 2012). Amongst other 
neuroprotective factors, SST which functions as an endogeneous neuroprotective peptide is 
downregulated in the diabetic eye (Carrasco, et al., 2007). The main hallmarks of retinal 
neurodegeneration are apoptosis and glial activation, which are already present in the retinas of 
diabetic donors without any microcirculatory abnormalities (J. Ambati, et al., 1997; Pulido, et al., 
2007). Glutamate is the main excitatory neurotransmitter in the retina and elevated levels are linked 
to “excitotoxicity” which leads to neurodegeneration (Kowluru, Engerman, Case, & Kern, 2001; Lieth, 
LaNoue, Antonetti, & Ratz, 2000). This excitotoxicity of glutamate is mediated by the over-activation 
of ionotropic glutamate receptors, over-expressed in streptozotocin-induced diabetic rats (Ng, Zeng, 
& Ling, 2004; Santiago, et al., 2009). Oxidative stress, advanced glycation end-product receptor 
upregulation and renin-angiotensin-aldosterone system (RAAS) activation also play a role in the 
retinal neurodegeneration induced by diabetes mellitus.  
SST has been shown to inhibit glutamate release via the STTR2 receptor (Bigiani, et al., 2004; Cervia, 
Martini, et al., 2008; Kokona, et al., 2012; N. Mastrodimou, Lambrou, & Thermos, 2005). 
Consequently SST may ameliorate glutamate neurotoxicity by regulating the amount of glutamate 
available to glutamate receptors. There is also evidence that shows that SST, via SSTR2, protects 
against ischemic damage to the retina by limiting vascular endothelial growth factor (VEGF) release 
under ischemic conditions (D. Cervia, E. Catalani, M. Dal Monte, & G. Casini, 2012).  SST and 
analogues may also exert an antiangiogenic effect by reducing endothelial cell proliferation and 
neovascularization.  Amongst multiple mechanisms, this effect may have contributed to the 
inhibition of postreceptor signalling events of peptide growth factors observed, including IGF-1, 
VEGF, epidermal growth factor, bFGF and PDGF (Baldysiak-Figiel, Lang, Kampmeier, & Lang, 2004; 
Davis, Wilson, & Grant, 2001; L. E. Smith, et al., 1997; Wilson, Davis, Caballero, & Grant, 2001). 
Studies in transgenic mice have shown that SSTR2 activation may protect against angiogenesis (Dal 
Monte, Cammalleri, Martini, Casini, & Bagnoli, 2007). However, this has not been demonstrated in 
murine diabetic models. It is worth noting that non-diabetic models are usually used to mimic retinal 
neovascularization instead (Ramos, et al., 2013). 
Additionally, SST has a potential anti-permeability effect in the retina that has not been widely 
explored. On the apical side of the RPE there are various ion/water transport systems and SSTR2 is 
highly expressed there (Lambooij, et al., 2000).  Thus there is a role for SST in the prevention of 
diabetic macular edema may be postulated. 
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1.4.4.2 Efficacy of SST analogues in models of diabetic retinopathy and clinical significance 
Several studies have been conducted in animal models of diabetes to investigate the efficacy of SST 
analogues in diabetic retinopathy. Although a twice daily administration of octreotide injection in 
rats failed to inhibit hypoxia-induced retinal neovascularization (Averbukh, et al., 2000), beneficial 
effects were reported for SST analogues in other animal models. In a mouse model of oxygen 
induced retinopathy, Woc4D and octreotide decreased blood vessel tufts and extra-retinal 
neovascularization in an equally effective manner (Higgins, Yan, & Schrier, 2002). Normal mice 
treated with a SSTR2 agonist, seglitide (MK 678), showed a 44% decrease in ischemia induced retinal 
neovascularization (L. E. Smith, et al., 1997). A nonpeptide SST agonist (L-779976) selective for SSTRs 
2 and 3 was studied in neonatal mice. Oxygen-induced retinal neovascularization was found to 
decrease by about 50% (Grant & Caballero, 2002). Wu et al demonstrated a reduction in bFGF-
induced corneal angiogenesis by SST in a rat corneal pocket model (P. C. Wu, et al., 2003). SST eye 
drops have been administered to streptozocin-induced diabetic rats and it was demonstrated that 
SST reaches the vitreous and retina after topical administration and prevents retinal 
neurodegeneration (Hernandez, Garcia-Ramirez, et al., 2013). The effect of SST on changes in the 
electroretinograms of early streptozocin-induced diabetic rats was investigated by Sun et al. The 
latent periods of the a-wave and the b-wave in the SST treatment group were shorter than those in 
the control group at the 8th week of treatment, although still longer than in non-diabetic rats (Y. D. 
Sun, et al., 2014).  
In a case report, Lanreotide Autogel® (Somatuline® Autogel®) was administered to two diabetic 
patients with bilateral persistent cystoid macular edema.   Authors reported improved vision in 3 out 
of 4 eyes. Foveal thickness was reported to be reduced and Health Related Quality of Life (HRQOL) 
scores increased, although, visual acuity was not shown to be significantly improved (Hernaez-
Ortega, Soto-Pedre, & Pinies, 2008). However, in 2001, a larger study showed that 3 years of 
octreotide treatment in type 1 diabetes patients with advanced proliferative retinopathy 
significantly reduced vitreous haemorrhage and improved visual acuity (Boehm, Lang, Jehle, 
Feldman, & Lang, 2001).  Grant et al demonstrated that octreotide treatment retarded the 
progression of advanced retinopathy and delayed the time to laser photocoagulation (Grant, et al., 
2000) Earlier clinical studies on diabetic patients are summarized in Table 1.5. Together, these 
studies present a strong case for the therapeutic use of SST or a suitable analogue in diabetic eye 
conditions such as retinopathy or macular edema. A multicentric phase II-III randomized controlled 
clinical trial has recently been completed in Europe to compare the efficacy of brimonidine and SST 
eye drops in retinal neurodegeneration and microvascular impairment (EUROCONDOR -278040). 
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Eligible patients with type 2 diabetes (n = 449) were randomly allocated to one of 3 investigation 
groups: placebo, somatostatin 0.1% and brimonidine tartrate 0.2%. They all had one drop 
administered to each eye twice daily. The primary outcome was the change in implicit time assessed 
by multifocal electroretinography (mfERG) between baseline and at the end of follow-up (96 weeks). 
The results of this clinical trial revealed that SST and brimonidine were only useful in patients with 
pre-existing retinal neurodysfunction, in which the worsening of implicit time was prevented (Simó-
Servat, Hernández, & Simó, 2018).  
Table 1.5 – Summary of studies of SST analogues in the eye 
DR stage Study 
duration 
No. of 
patients 
Treatment Results Reference  
Type 1 diabetes Group A: 
20 weeks 
 
Group B: 
3 days – 
16 weeks 
15 patients Group A: 
octreotide 
sc injection 
3 x 50 
µg/day 
Group B: 
Octreotide 
continuous 
sc infusion 
500µg/day  
Group A:  Visual 
acuity minus 2 
lines in 3 out of 4 
patients 
Group B: no 
change in visual 
acuity in 5 
patients, 
improvement in 1 
patient. Retinal 
haemorrhages and 
further laser 
treatment not 
prevented. 
(Hyer, Sharp, 
Brooks, Burrin, 
& Kohner, 
1989) 
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Early diabetic 
Retinopathy 
12 
months 
11 IDDM 
9 controls 
7 pts and 
7 controls 
completed 
the 
study 
Octreotide 
Continuous 
sc infusion 
(up to 400 
µg/day) 
No effects, no 
observable 
difference 
between groups  
(Kirkegaard, et 
al., 1990) 
Proliferative 
retinopathy 
3 months 8 patients Continuous 
infusion of 
SSTR2-
specific 
agonist 
BIM23014 
Significant 
abrogation of 
vascular leakage in 
2 patients 
(McCombe, 
Lightman, 
Eckland, 
Hamilton, & 
Lightman, 
1991) 
PDR progressing 
despite 
photocoagulation 
6-20 
months 
4 IDDM 
no controls 
Octreotide 
Continuous 
infusion 
44µg/ day  
Neovascularization 
stopped in 2 
patients 
(Mallet, et al., 
1992) 
Severe non-
proliferative DR, 
non- high risk 
PDR 
15 
months 
16 pts 
(8 pts: 
treated 
8 pts: 
controls 
Octreotide 
600–3000 
µg/day. 
Continuous 
infusion or 
sc injection 
Failure to 
eliminate the need 
for 
photocoagulation 
therapy though 
levels of GH or 
IGF-1 reduced in 
all patients 
(Grant, 
Mames, 
Cooper, 
Caballero, & 
Fitzgerald, 
1996) 
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Case report, type 
1 diabetic 
3 months  Octreotide 
sc injection  
3 x 50µg/ 
day 
Hemorrhages 
completely 
resorbed, 
numbers of 
microaneurysms 
reduced 
(H. K. Lee, et 
al., 1988) 
Idiopathic cystoid 
macular edema 
12 weeks Case report 
1 patient 
Octreotide 
Sc injection  
3 x 100µg/ 
day 
Macular edema 
dried, visual acuity 
improved 
(Kuijpers, 
Baarsma, & 
van Hagen, 
1998) 
IDDM 6 months 27 patients Octreotide 
200 µg/day  
Reduced 
endothelial 
dysfunction and 
attenuation of 
vitreous 
haemorrhages 
after full scatter 
laser coagulation 
(Clemens, et 
al., 1999) 
 
1.5 Thesis Objectives 
The hypothesis that somatostatin may prevent or slow down the progression of diabetic retinopathy 
if an effective formulation for delivery to the retina can be developed is advanced. The ultimate aims 
of the current work are development of an extended-release formulation of somatostatin with the 
potential for delivery of somatostatin to the retinal pigment epithelium cells and to investigate the 
modulation of a key receptor subtype implicated in diabetic retinopathy. To this end the following 
aims and objectives are advanced: 
Aim 1: Determine the impact of SST self-assembly on release and formulation characteristics of the 
self-assembled hydrogels. 
Objective: To perform rheological characterization, morphological studies, and investigate the 
reversibility of SST hydrogel formation for formulation optimisation. 
Aim 2: Design and optimise an ocular formulation of SST. 
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Objective 1: To assess the suitability of SAW devices and traditional methods to manufacture 
microparticles encapsulating SST and perform stability and release studies upon these. 
Objective 2: To produce a hydrogel formulation of SST in a polymeric carrier that extends the 
duration of release and perform characterisation and release studies on the formulation candidate. 
Aim 3: Assessment of in vitro toxicity and effect on vascular endothelial growth factor receptor-2 
(VEGF-R2) expression and VEGF secretion. 
Objective: To perform in vitro studies on ARPE-19 cells to assess the cytotoxicity of an extended-
release formulation and to investigate the effect of SST released from an extended-release 
formulation on VEGF-R2 expression and VEGF secretion. 
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CHAPTER 2: PHYSICOCHEMICAL CHARACTERIZATION OF SELF-ASSEMBLED SOMATOSTATIN 
HYDROGELS 
2.1 Introduction  
In this chapter, the rheological properties of self-assembled somatostatin hydrogels are studied and 
related to structure with transmission electron microscopy. The reversibility of somatostatin 
nanofibril formation as well as the kinetics of release of somatostatin monomers from hydrogels 
formed in different media are investigated. The purpose of physicochemical characterization is to 
provide an insight into the mechanical and flow properties of the self-assembled hydrogels and their 
influence on the mechanism and rate of somatostatin release in vitro. 
2.1.1 Rheology 
Peptide-based hydrogels are an important class of biomaterials with potential use in drug delivery. A 
primary experimental method to explore the physical properties of these hydrogels is rheology. 
Rheology provides gain a fundamental understanding of peptide hydrogel mechanical properties and 
underlying molecular mechanisms. This is important for determining whether these biomaterials are 
potentially suitable for biotechnological applications. Rheology is the primary experimental method 
with which researchers explore the viscoelastic properties of hydrogels.  
The field of rheology theory, measurements and equipment is well introduced in books on the 
subject, e.g. Mezger(Mezger, 2006). Small deformation rheology experiments are performed on 
hydrogels to assess mechanical properties quantitatively (Ross-Murphy, 1994). By small 
deformation, the measurement is meant to be carried out within linear viscoelastic region of a 
material, a window of applied strain values within which the measured hydrogel properties are 
independent of the magnitude of imposed strain (Mezger, 2006). Typical small deformation tests are 
small amplitude oscillatory shear (SAOS) measurement as well as creep and creep recovery tests. 
For controlled-strain rheometers, shear strain is applied to the sample in a sinusoidal oscillation,  
 ɣ(t) = ɣ0(sin ωt)                                                                                                                    Equation 2.1 
and the measured shear stress is a phase-shifted sine wave with  
𝜏(𝑡)  =  𝜏0(𝑠𝑖𝑛 𝜔𝑡 + 𝛿)                                                                                                     Equation 2.2 
in which ω is the applied angular frequency and δ is the phase difference between the two waves 
whereas for stress-controlled rheometers, the shear stress is applied as  
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𝜏(𝑡)  =  𝜏0(𝑠𝑖𝑛 𝜔𝑡)                                                                                                             Equation 2.3 
and the resulting shear strain is measured as 
 ɣ(𝑡)  = ɣ0(𝑠𝑖𝑛 𝜔𝑡 +  𝛿).                                                                                                  Equation 2.4 
For a purely elastic material, the strain and stress waves are in phase (δ = 0°) while a purely viscous 
response has the two waves out of phase by 90° (δ = 90°). Viscoelastic materials give rise to a phase-
angle between 0° and 90° (Kavanagh & Ross-Murphy, 1998; Mezger, 2006). 
In small amplitude oscillatory shear measurements, the shear storage modulus, G’, loss modulus, G’’, 
and loss factor, tan δ, are critical hydrogel properties monitored against time, frequency and strain. 
G’, the storage modulus, measures the deformation energy stored during shear process of a test 
material (i.e. the elasticity of the material) and G”, the loss modulus, is representative of the energy 
dissipated during shear (i.e. the flow response of the material). If G” > G’ (tan δ > 1), the sample 
behaves more like a viscous liquid while, conversely, when G’ > G”, and, thus, tan δ˂ 1, the sample 
behaves more like an elastic solid (Mezger, 2006). 
For gel samples, these parameters are often measured as a function of time, strain and frequency. 
Gelation can be actively observed by monitoring the temporal evolution of G’ and G”. Monitoring 
the moduli vs. strain helps one determine the linear viscoelastic region within which G’ and G” are 
independent of shear strain. Frequency sweeps (measurement of the moduli vs. frequency) 
elucidate the behaviour of the hydrogel at short vs. long time scales. The frequency dependence of 
the moduli is a critical hydrogel characteristic to observe since a single material behaves like an 
elastic solid (G’ ˃G”) at a high frequency/fast timescale but behave more like a liquid (G” > G’) at low 
frequency/longer time scales. It is thus imperative to observe rheological behaviour in a time-frame 
of relevance to the application. 
In addition to the measurements described above, it is essential to assess the properties of 
hydrogels during flow as well as their abilities to retain or recover their solid form morphology and 
rigidity after experiencing shear flow or large strain. Shear-thinning thixotropic hydrogels can be 
excellent candidates for injectable therapeutic delivery vehicles. Monitoring rheological behavior 
and structural evolution of these gels during and after flow can help delivery during syringe injection 
and the ability of the material to stay localized after injection against possible biological forces in 
vivo. 
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2.1.2 Models of release 
Drug release models can be empirical or mechanistic models. Empirical models are based on the 
experimental behaviour of the system studied without considering any physical mechanisms. 
However such a model does not provide any information on the mechanisms that control the 
process and therefore cannot be used to predict the effect of a change in conditions on the release 
rate. 
Mechanistic or mathematical models are based on the physical mechanisms that influence the 
release process and therefore can be used to make predictive stimulations. To be employed, the 
validity of the model against experimental data must be established. 
While many models are predicated upon diffusion equations, models also need to account for the 
morphology of the structure through which diffusion takes place (Langer & Peppas, 1983b; 
Narasimhan & Peppas, 1997). Drug release mechanisms can be classified as diffusion-controlled, 
chemically controlled, osmotically controlled and swelling-and/or dissolution-controlled. The 
commonly used models of release are discussed briefly below. 
Zero-order kinetics 
𝐶𝑡  =  𝐶0  +  𝐾0 𝑡                                                                                                                            Equation 2.5 
where Ct represents the amount of active agent released during the time t, C0 is the initial 
concentration of active released (generally, C0 = 0), and K0 is the zero-order constant. 
For zero-order kinetics, the release of an active agent is only a function of time and the process takes 
place at a constant rate independent of the concentration of the active agent. 
First-order kinetics 
𝑙𝑛 (
𝑄𝑡
𝑄0
) = 𝑘𝑡                                                                                                                                   Equation 2.6 
where Qt is the amount of active agent released at time t, Q0 is the initial amount of active agent 
dissolved and k is the first-order release constant. 
This states that the change in concentration of the active agent with respect to time is dependent 
only on the concentration. 
Higuchi model 
 𝑄𝑡 =  𝐾𝐻 𝑡½                                                                                                                                 Equation 2.7 
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where  Qt is the amount of active agent released at time t and KH is the release constant of Higuchi. 
The Higuchi model (Higuchi, 1961) relates the concentration of the active agent to the square root of 
time, representing a linear function. However this model makes a number of assumptions which 
make it only valid in the case of polymers that do not swell significantly on contact with water. 
Hixson-Crowell model 
(1 −  𝑓1)
1/3  =  1 −  𝐾𝛽 𝑡                                                                                                            Equation 2.8 
 
where 𝑓1  =  1 −  (𝑊𝑖/𝑊0)                                                                                                   Equation 2.9 
and represents the fraction of drug dissolved on time t, W0 is the initial amount of the drug in the 
system; Wi is the amount remaining in the system on time t and Kβ is a release constant.  
This model (Hixson & Crowell, 1931) applies to dosage forms in which dissolution happens in planes 
parallel to the surface of the dosage form e.g. tablets. The surface decreases proportionally over 
time and the geometrical form remains constant. A linear function is represented when the cube 
root of the non-released fraction is related with time. When this model is used, it is assumed that 
drug release is limited by dissolution velocity and not by diffusion, which can occur through the 
polymeric matrix.  
Korsmeyer-Peppas model  
𝑀𝑡/𝑀∞  =  𝑘𝑡
𝑛                                                                                                                               Equation 3.0 
Where Mt and M∞ are cumulative amounts of drug released at time t and infinite time, respectively. 
This is a comprehensive semi-empirical equation (Ritger & Peppas, 1987) to describe drug release 
from polymeric forms. It was developed specifically for the release of drug molecules from polymeric 
matrices like a hydrogel. It is useful when the release mechanisms are unknown or more than one 
type of phenomenon of drug release is involved. This model involves the superposition of drug 
transport, relaxation and diffusion mechanisms. The exponent n relates the release is by drug 
diffusion (n =0.5) or zero-order (n=1) and due to swelling/relaxation of polymer chains. When 
0.5<n<1, the release is defined by both diffusion and swelling.  
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2.1.3. Release kinetics  
Somatostatin-14 reversible self-assembly into nanofibrils was previously reported (Anoop, et al., 
2014; Maji, et al., 2009; W. van Grondelle, et al., 2007; van Grondelle, et al., 2013). This intrinsic 
propensity of the peptide is currently thought to be biologically relevant to its conditions of storage 
within normal hypothalamic secretory granules, as a wide range of other human neuropeptide 
hormones (Anoop, et al., 2014; Maji, et al., 2009). The spontaneous assembly of somatostatin-14 
into flexible liquid crystalline nanofibrils was shown in water (above 3% w/w) and in 150mM sodium 
chloride (NaCl) (0.5% w/v and above) (W. van Grondelle, et al., 2007). Nanofibril self-assembly was 
therein mentioned to result in the formation of hydrogels in water with or without NaCl or other 
salts (calcium and phosphate). The width of the nanofibrils was found to decrease in the presence of 
these salts, coupled with an enhanced propensity to form nanofibrils - decrease in critical 
concentration of assembly - and an enhanced nanofibril lateral association. Both phenomena were 
attributed to the screening of electrostatic repulsions between the cationic self-assembling peptides 
by the additional ions in the media (W. van Grondelle, et al., 2007; van Grondelle, et al., 2013).  
 
It is of interest to investigate if the propensity of somatostatin to self-assemble would lend to a 
depot formulation of the peptide, which can release monomers at a controlled rate. However, the 
fibrils would have to release the peptide monomers at a rate sufficient for therapeutic activity to 
occur. Of the somatostatin analogues, lanreotide has been shown to self-assemble into large 
nanotubes and form self-assembled hydrogels (Valery, et al., 2004; Valéry, et al., 2003), from which 
lanreotide monomers are released in a sustained manner. This property led to the formulation 
marketed as Lanreotide Autogel® (Wolin, et al., 2016). Although the release of somatostatin-14 from 
nanofibrils formed in the presence of heparin and mannitol has been previously shown for low 
peptide concentrations (0.2% w/w) (Anoop, et al., 2014), there is currently no published data on the 
rheology and release kinetics of somatostatin hydrogels.  
Hydrogels for the delivery of non-peptide actives in the treatment of ocular disorders have been 
investigated, both self-assembling supramolecular nanofibers as well as nano-composite hydrogels 
(Li, et al., 2014; Li, Zhang, & Chen, 2013). 
This study aims to investigate the release kinetics of somatostatin-14 from the hydrogels it 
spontaneously forms in aqueous media and in the presence of electrolytes. As discussed above, SST 
was shown to prevent retinal neurodegeneration following topical administration to diabetic rats at 
concentrations of 0.2% and 1% (Hernandez, Garcia-Ramirez, et al., 2013). It has been reported that 
daily administration is required for up to 16 days to achieve this response (Hernandez, Garcia-
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Ramirez, et al., 2013). In this study, we investigate the release kinetics of SST from SST gels formed 
at higher peptide concentrations (1%, 2.5% and 5%), in order to determine its potential to provide a 
platform for sustained release of SST.  The gels were formed in either water or simulated lachrymal 
fluid (SLF) to determine the effects of electrolytes present in ocular tissue on release of the peptide.  
While investigating the feasibility of ocular formulations for the treatment of diabetic retinopathy 
from somatostatin self-assembled hydrogels, we report on the correlation between the monomer 
release kinetics and the rheological properties of the hydrogels. 
2.2 Materials and Methods 
 
2.2.1. Materials 
 
Somatostatin-14 of sequence Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (cyclic, 
MW=1638 Da) was purchased as an acetate salt from Polypeptide Laboratories (Sweden). According 
to the Manufacturer’s certificate of analysis, the peptide purity is 99.6%. 
Sodium azide and the chemicals used to prepare the simulated lachrymal fluid were purchased from 
Sigma Aldrich (St Louis, MO). MilliQ water was used in the preparation of all media. The composition 
of simulated lachrymal fluid can be found in Table 2.1 (Ceulemans & Ludwig, 2002). 
 
Table 2.1 Composition of simulated lachrymal fluid (Ceulemans & Ludwig, 2002). 
 
Composition (in water) Amount (g/L) 
NaCl 6.3118  
KCL 1.7893  
NaHCO3 2.1842  
CaCl2 0.0444  
MgCl2 0.0477  
Adjusted to pH 7.4 (+/- 0.1) with 0.1N 
HCL  
 
 
2.2.2 Methods 
2.2.2.1. Preparation of somatostatin hydrogels  
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Somatostatin 2.5% w/w and 5% w/w were investigated in 0.9% w/v NaCl and in simulated lachrymal 
fluid. Somatostatin 5% w/w was also prepared in distilled water as this is above the minimum 
concentration required for nanofibril formation in the absence of electrolytes (SST 3% w/w)  (W. van 
Grondelle, et al., 2007). The concentrations are expressed in weight per weight as the volume 
changes during the gelation process. 
Somatostatin acetate powder was weighed and dissolved in the relevant medium to reach the 
required concentration in Eppendorf tubes. The tubes were then vortexed for 30 seconds to ensure 
complete dissolution of the somatostatin powder and then incubated at 37 °C.  
The gels (SST 2.5% w/w and 5% w/w) formed in 0.9% w/v NaCl and in simulated lachrymal fluid took 
48 hours to form and were analysed by rheometry on days 1, 2 and 8. Higher concentration gels (SST 
5% w/w) formed in water took a longer time to form (16 days) and were analysed on days 1, 2, 8 and 
16. 
2.2.2.2 Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) was used to characterise the morphology of the nanofibrils. 
Negative staining by uranyl acetate was performed to contrast the nanostructures, using the same 
protocol as reported in van Grondelle et al. 2007. Stained samples deposited on formvar and carbon 
–coated 200 mesh copper grids (Proscitech, Australia) were examined with a JEOL 1010 transmission 
electron microscope operating at 100 kV. 
2.2.2.3. Oscillatory rheology  
The rheological properties of the somatostatin gels were determined using an ARG2 Rheometer (TA 
Instruments, UK). A stainless steel 40mm parallel plate geometry with gap of 500 μm was employed. 
The removal of the gels was performed as gently as possible from the containers to minimize 
disruption of the structure. The gels were given an hour to equilibrate at the investigated 
temperature to relax to the resting condition prior to analysis.  According to the review by Pochan et 
al (Sathaye, et al., 2015), parallel plate rheometers are a good choice for hydrogels containing large 
domain sizes like hierarchically assembled fibers. Zero gap calibration and same gap was set for all 
measurements as recommended by the authors. A solvent trap was used to eliminate the 
evaporation of water from the gel periphery. Oscillation amplitude sweeps were used to confirm the 
linear viscoelastic region. Frequency sweeps (0.1-10 Hz) at 25°C and 37 °C and temperature sweeps 
(1 Hz, 20-50 °C) were then conducted. Measurements were performed in triplicate. 
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2.2.2.4. Monomer release protocols  
The release characteristics of self-assembled somatostatin hydrogels were investigated in both 
water and simulated lachrymal fluid (Table 2.1) with 0.01% sodium azide to prevent microbial 
growth in the media. As the rheological properties of the somatostatin hydrogels in 0.9% w/v NaCl 
and SLF were similar and our interest is in simulating release in a media relevant to the physiological 
environment of the eye, only SLF was used to investigate release. 
SST monomer release was investigated using two previously reported methods for peptide self-
assembled hydrogels; either with the hydrogel in direct contact with the relevant medium in a 1.5 
mL Eppendorf tube (Branco, Pochan, Wagner, & Schneider, 2009) or in a Slide-A-Lyzer mini dialysis 
unit system comprising a dialysis regenerated cellulose and polypropylene membrane with a 3.5kDa 
cut-off (Thermo Fisher Scientific, USA) (Anoop, et al., 2014). 
Prior to both release protocols, somatostatin-14 samples were incubated at 37° C, for 48 hours for 
the gels prepared in SLF or 16-20 days for the gels prepared in water, to allow gelation to occur. The 
study was commenced when the gels formed completely on visual observation. As this is a variable 
process depending on nucleation (Harper & Lansbury, 1997), the time taken for the gels to 
completely form ranged from 16-20 days in water.  
Release medium (water or SLF; 500 μL) with 0.01% w/v sodium azide was placed directly on top of 
the gels in Eppendorf tubes. The Eppendorf tubes were then closed and sealed with Parafilm. The 
gels formed in the Slide-A-Lyzer units were dialysed against the same volume of release medium in 
capped centrifuge tubes. The assembled units were then placed in a shaking water bath at 37° C. At 
various time intervals (1, 2, 4, 6, 9, 24 and 48 h), an appropriate aliquot 400 µL of 500 µL) was 
removed for analysis by UV spectrophotometry. Given the high solubility of somatostatin in aqueous 
media (> 70mg/mL) and the turnover of 80% of buffer volume at each sampling point, this 
approaches sink conditions in vivo in the ocular environment with tears or blood flow. The units 
were reassembled and replaced in the shaking water bath. We have followed the protocol reported 
by Anoop et al who investigated the reversibility of somatostatin fibril formation (Anoop, et al., 
2014). The experiments were performed in triplicate. 
2.2.2.5. HPLC  
The stability of somatostatin in the media at 37 °C over 48 hours was determined by HPLC (Flexar, 
Perkin Elmer, USA). The method described by Valery et al (W. van Grondelle, et al., 2007) was 
adapted and modified to suit the instrument used. This method was validated according to ICH 
guidelines. Chromatography was performed on a Phenomenex C18 column (5 µm particle size, 150 x 
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4.6 mm). Trifluoracetic acid (TFA) 0.1% v/v in water was used as mobile phase and acetonitrile with 
0.1% v/v TFA was used as organic eluent. Separation was carried out at ambient temperature, at a 
flow rate of 1 mL/min, with a gradient from 5% to 68% of organic eluent in the mobile phase in 55 
min. Detection was performed at 280 nm. The HPLC method was used to validate UV analysis. 
2.2.2.6. Assay by UV spectrophotometry 
Calibration curves obtained by dilutions of somatostatin (0.0005% w/w - 0.05% w/w) in both water 
and SLF (with 0.01% w/v sodium azide) were used. The aliquots taken from the release medium 
were diluted to 2000 µL with the corresponding medium to reach concentrations in the same range 
as the calibration curves. The diluted aliquots were placed in quartz cuvettes and subjected to 
analysis by UV in a T60U Spectrophotometer (PG Instruments, UK). 
Absorbance at 280nm was measured and the cumulative percentage released over 48 hours was 
calculated based on calibration curves. The experiments were performed in triplicate. 
2.2.2.7. Statistical analysis 
A two-way ANOVA with Tukey’s multiple comparisons test was performed to assess if the 
differences in the cumulative percentage released at 48 hours were significant amongst the different 
concentrations of SST and medium within each group. 
The analysis shows that the differences between all except the ones marked ‘ns’ were significant. 
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Figure 2.1: Comparison of cumulative percentage release of somatostatin in Slide-A-Lyzer units at 48 
hours (ns-not significantly different) (n=3, error bars= SD) 
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Figure 2.2: Comparison of cumulative percentage release of somatostatin in Eppendorf tubes at 48 
hours (ns-not significantly different) (n=3, error bars= SD, 5% water gel vs simulated lachrymal fluid 
not represented because the experiment ended at 9hrs) 
2.3. Results and Discussion 
2.3.1. Nanofibril structural characterisation (TEM)                         
                  
Figure 2.3. Transmission electron micrographs of (a) Somatostatin 5% w/w in water (magnification 
5000x) (b) Somatostatin 5% w/w in 0.9% w/v NaCl (magnification 5000x (c) Somatostatin 5% w/w in 
simulated lachrymal fluid (magnification 4000x). Scale bars (a, b and c) 0.5 µm. Samples were 
equilibrated for 8 days. 
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The morphology of somatostatin nanofibrils in water, NaCl and SLF was investigated by transmission 
electron microscopy on gelled samples. Figure 2.3 shows that the nanofibrils in the presence of 
electrolytes are narrower and more dense in appearance compared to the nanofibrils formed in the 
absence of electrolytes. The average width of the nanofibrils in water was 15.8nm, 12.6nm in NaCl 
and 10.8nm in SLF (Image J)(Abràmoff, Magalhães, & Ram, 2004). These are larger than the mean 
widths reported by W. van Grondelle et al (W. van Grondelle, et al., 2007) of somatostatin 
nanofibrils in water and 150 mM NaCl. This could be due to the density of the nanofibrils in our 
samples which made it harder to distinguish between single nanofibrils and laterally associated 
ones. W. van Grondelle, et al  also observed a reduced nanofibril width in the presence of 
electrolytes. As discussed by van Grondelle et al (W. van Grondelle, et al., 2007), this is likely to be 
due to the electrostatic shielding of the postive charges on the peptide by the electrolytes, 
enhancing lateral association.  As published in our paper “Release kinetics of somatostatin from self-
assembled nanostructured hydrogels” (Rai, Thrimawithana, Dharmadana, Valery, & Young, 2017) in 
Section 3.1, the small angle X-ray scattering (SAXS) patterns obtained for the different somatostatin 
hydro-gels (Figure 5 in the paper) show an increase in intensity as a function of the ionic strength of 
the buffers, especially at low q range. The corresponding scattering patterns do not correspond to 
the Guinier regime (q0) for molecular species but rather to scattering by large semi-flexible 
structures q-1–q-2). This trend confirms the higher density of assembled structures/nanofibrils as a 
function of the ionic strength. The pH of somatostatin solutions in aqueous media is pH 4.7 ± 0.3(W. 
van Grondelle, et al., 2007). At this pH, the peptide exhibits a net charge of 2. Chloride ions in both 
NaCl and SLF solutions and carbonate ions in SLF are likely to shield this positive charge and enhance 
lateral association. Figures 2.4,2.5 and 2.6 are TEM images of SST hydrogels at different 
magnifications. 
 
Figure 2.4. Transmission electron micrographs of SST 5% w/w water samples on day 8. Scale bars for 
(a and b) -0.2 µm (12,000x magnification) and (c) -100 nm (20,000x magnification) 
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Figure 2.5. Transmission electron micrographs of SST 5% NaCl samples on day 8. Scale bars for (a and 
b) -0.5 µm (5,000x magnification) and (c) -0.2µm (12,000x magnification).  
 
Figure 2.6. Transmission electron micrographs SST 5% SLF samples on day 8. Scale bars for (a) - 
0.5µm (4000x magnification), (b) - 0.2µm (10,000 magnification) and (c) - 200nm (15,000 
magnification). 
 2.3.2. Oscillatory rheology 
The rheological studies showed that somatostatin formed a gel with higher storage modulus (G’) at 
higher SST concentrations and in the presence of electrolytes as shown in Figure 2.7. All the 
concentrations tested exhibited shear-thinning properties, with declining viscosity as shear rate 
increased (Figures 2.8a and 2.8b). The frequency sweeps showed a trend to increase in moduli with 
increasing frequency (Figure 2.9). As high frequencies represent shorter timescales and low 
frequencies are representative of longer timescales, this indicates a lowering of the stiffness of the 
gel over longer time period. For example, the G’ of SST 5% in NaCl hydrogel at 1 Hz was 80888 
compared to 89816 at 10 Hz. Similarly, for SST 2.5% hydrogel in SLF the G’ was 42882 at 1 Hz and 
52145 at 10 Hz. However the G’ remained higher than G” at all frequencies indicating the SST 
hydrogel structure was not destroyed. At a frequency of 1 Hz, the G’ of SST 2.5% in NaCl was 5809 
compared to the G” of 2277. The G’ remained higher than the G” at a frequency of 10 Hz (10381 vs 
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4591 respectively). Temperature sweeps showed a progressive decrease in G’ and G” with increasing 
temperature from 20 °C to 50 ° C characteristic of materials in the absence of thermogelation (Figure 
10). The G’ of SST 5% hydrogel in NaCl decreased from 159406 at 20 °C to 43531 at 50 °C and from 
16190 at 20 °C to 2735 at 50 °C for SST 2.5% hydrogel in NaCl. Thixotropic behavior was observed in 
plots of shear rate against stress. Several examples of hydrogel moduli are available for comparison 
(Aggeli, et al., 1997; Caplan, Schwartzfarb, Zhang, Kamm, & Lauffenburger, 2002; Collier, et al., 
2001). The moduli of the SST hydrogels are equal to, or greater than, that of moduli reported for 
comparable hydrogel systems. 
Pochan, Schneider and co-workers have developed 2 self-assembling peptides, MAX1 and MAX8, 
with β-hairpin turns as possessed by SST (Yan, et al., 2010). These hydrogels exhibited shear-thinning 
behaviour and flowed easily when injected through a syringe with recovery of the structure after 
flow. Thixotropic behaviour was also observed and a theory was advanced as to the mechanisms of 
shear-thinning in the hydrogels. It was proposed that the hydrogel network fractures into domains 
as shear is applied to allow for flow and upon removal of shear, the fractured domains percolate and 
self-heal into gels of original stiffness(Yan, et al., 2010). Loveday and co-workers investigated the 
rheological characteristics of β-lactoglobulin, which forms amyloid-like fibrils upon heating. Fibrillar 
samples also demonstrated shear-thinning properties  (Loveday, Wang, Rao, Anema, & Singh, 2012). 
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Figure 2.7. Comparison of the G’ (storage modulus) of the SST hydrogels on day 8 at a frequency of 1 
Hz at 37°C (n=3, error bars represent standard deviation). SST 5% w/w in water formed viscous 
solutions with negligible G’ (elasticity) below reliable instrument detection and are therefore, not 
included for comparison. 
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Figures 2.8a and 2.8b: Flow sweep at 25°C and 37°C respectively (n=3) 
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Figure 2.9 Frequency sweep of the SST hydrogels on day 8 at 37°C (n=3) 
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Figure 2.10 Temperature sweep of the SST hydrogels (day 8) from 20°C to 50°C (n=3). 
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2.3.3. Monomer release 
Table 2.2 Comparison of cumulative percentage somatostatin released at 48 hours in the Eppendorf 
tubes and Slide-a-Lyzer units 
Gels tested Average of cumulative 
percentage somatostatin 
released at 48 hours in 
Eppendorf tubes 
Average of cumulative 
percentage somatostatin 
released at 48 hours in Slide-a-
Lyzer units 
SST 5% SLF 3.37% 0.99% 
SST 2.5% SLF 2.95% 0.74% 
SST 1% SLF 3.60% 0.53% 
SST 5% water vs water 49.99% 25.8% 
SST 5% water vs SLF  38.03% (at 9 hours) 3.01% 
 
From Table 2.2, it can be seen that the SST gels in water released significantly higher percentage of 
SST monomers compared to the SST gels formed in SLF both in the Eppendorf tubes and the Slide-a-
Lyzer units (p<0.0001)( Figures 2.1 and 2.2). There were no significant differences amongst the 
cumulative percentage released by the SST gels formed in SLF in the Eppendorf tubes or the Slide-a-
Lyzer units.   Rheological studies demonstrate that that SST forms stiffer gels in the presence of 
electrolytes (Figure 2.7). This could be due to the favouring of self-assembly as reported by van 
Grondelle et al(W. van Grondelle, et al., 2007) supported by our observation that these gels formed 
more quickly at 48 hours compared to 16 days required for the gels formed in water. The 
experiment with the water gels against SLF in the Eppendorf tubes was concluded at 9 hours as solid 
layer of opaque gel had formed at the release interface.  
A similar observation was made with the water gels in the Slide-A-Lyzer units dialysed against SLF. 
The initially transparent gel turned opaque as the electrolytes from the SLF outside diffused through 
the dialysis membrane into the somatostatin sample rendering it identical to the gels formed in the 
presence of electrolytes. This may account for the lower cumulative percentage released from the 
SST 5% water gel dialysed against SLF at 48 hours compared to the SST 5% water gel dialysed against 
water.  
There was a higher percentage of release from the gels in the Eppendorf tubes compared to the 
Slide-a-Lyzer units (Table 2.2). While it is likely that somatostatin was released from the samples in 
both the Eppendorf tubes and Slide-a-Lyzer units via erosion and diffusion release mechanisms 
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(Bamba, Puisieux, Marty, & Carstensen, 1979; Gohel, Panchal, & Jogani, 2000; Roy & Rohera, 2002), 
possible obstruction of cellulose membrane in the Slide-A-Lyzer units may have contributed to the 
observed low release and be a limitation of this method of investigating release from hydrogels. 
Cumulative percentages of SST release versus time in and against different media are shown in 
Figures 2.11 and 2.12. From the variation in release of SST between the SST gels in direct contact 
with the medium versus the ones in the Slide-a-Lyzer units, certain mechanistic inferences can be 
made. Primarily, that erosion plays a significant role in release of SST monomers from the water gels.  
Erosion also plays a role in the release of SST from the gels in SLF, though the difference is only 
three-fold between the Eppendorf tubes and Slide-a-Lyzer units. This can be attributed to the 
viscoelasticity of gels formed in the presence of electrolytes. Also, the nanofibrils in the presence of 
electrolytes are possibly more stable due to the enhancement of lateral association. 
 
  
Figures 2.11a and 2.11b: Comparison of cumulative percentage SST released in Slide-a-Lyzer units at 
48hrs and 9hrs respectively (n=3, error bars represent standard deviation) 
 
 
Figures 2.12a and 2.12b: Comparison of cumulative percentage SST released in Eppendorf tubes at 
48hrs and 9hrs respectively (n=3, error bars represent standard deviation) 
A B 
A B 
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2.3.4 Release kinetics 
 
 
Figure 2.13: Fitting of the SST 5% w/w water vs water release over 48 hours in Slide-a-Lyzer units to 
different models of release (n=3) 
In order to elucidate the mechanism of release of the SST monomers, the data was fitted to zero and 
first-order models as well as Higuchi (Higuchi, 1961), Korsmeyer-Peppas (Korsmeyer, Gurny, Doelker, 
Buri, & Peppas, 1983) and Hixson-Crowell (Hixson & Crowell, 1931) cube root models.  The SST 5% 
water gel dialysed against water in the Slide-a-Lyzer unit is shown as a representative in Figure 2.13 
fitted to the different release models. 
The mean R2 values are provided in Tables 2.3 and 2.4 for the release in both the Slide-a-Lyzer units 
and Eppendorf tubes respectively. For the majority, the best R2 values were obtained for the Higuchi 
model, which is typical for systems where drug release is governed purely by diffusion (Higuchi, 
1961). 
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Table 2.3: Mean R2 (and standard deviation) values and desorption half time in minutes in Slide-a-
Lyzer units. 
  Mean R2 ± SD         
  SST 5% SLF SST 2.5% SLF SST 1% SLF SST 5% 
Water vs 
Water 
SST 5% 
Water vs SLF 
Zero-order  0.780±0.0487 0.858±0.031 0.751±0.023 0.868±0.005 0.408±0.037 
First-order 0.780±0.039 0.859±0.031 0.752±0.024 0.889±0.004 0.408±0.035 
Higuchi 0.893±0.033 0.959±0.019 0.894±0.016 0.968±0.003 0.588±0.039 
Korsmeyer-Peppas 0.919±0.056 0.976±0.011 0.946±0.018 0.967±0.005 0.764±0.032 
Hixson-crowell 0.779±0.05 0.859±0.031 0.752±0.024 0.882±0.005 0.409±0.038 
Hybrid release 
model 0.880±0.076 0.989±0.005 0.966±0.039 0.998±0.001 0.791±0.296 
Half-time of 
diffusional release 
process 
(hours-1) 0.284 2.27 1.734 8 2.086 
Total diffusional 
release % 0.749± 0.213 
0.405± 
0.071 0.398± 0.179 22.8± 2.72 2.69± 0.739 
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Table 2.4: Mean R2 values (and standard deviation) and desorption half-time in minutes in Eppendorf 
tubes. 
  Mean R2 ± SD         
  SST 5% SLF SST 2.5% 
SLF 
SST 1% SLF SST 5% Water 
vs water 
SST 5% 
Water vs 
SLF 
Zero-order  0.821±0.144 0.967±0.022 0.467±0.118 0.793±0.069 0.949±0.024 
First-order 0.822±0.144 0.967±0.023 0.468±0.118 0.850±0.068 0.964±0.022 
Higuchi 0.928±0.095 0.958±0.067 0.634±0.125 0.899±0.048 0.982±0.021 
Korsmeyer-
Peppas 0.969±0.043 0.966±0.038 0.771±0.088 0.887±0.054 0.983±0.019 
Hixson-crowell 0.821±0.144 0.967±0.022 0.468±0.118 0.833±0.069 0.959±0.023 
Hybrid release 
model   0.896±0.033 0.9±0.158 0.909±0.068 0.896±0.088 0.974±0.045 
Half-time of 
diffusional 
release process 
(hours-1)  0.706 0.95 3.227 3.128 0.662 
Total diffusional 
release % 1.62± 0.22 0.711±0.177 3.79± 0.638 25.4± 12.1 20.5± 5.53 
 
The pattern of release appears to be bimodal consistent with the hypothesis that different release 
mechanisms predominate at different times rather than the same mechanism determining the rate 
of release. As release from most gel samples demonstrated bimodal properties, a hybrid model 
conceived as being the sum of adsorbed material release (first-order) and erosional release (zero-
order) was developed. We advance that the observed rapid but incomplete initial release may 
proceed as a result of the more rapid release of material adsorbed onto the surface of the gel with 
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the expectation that such adsorption follows a Langmuir Adsorption Isotherm(Foo & Hameed, 2010). 
As the release of adsorbed material is depleted, release then slows to a zero-order rate, perhaps 
related to the erosion of the gel matrix. The hybrid model conceived is represented by: 
𝑅 =  𝑘0𝑡 𝐴𝐷 +   (1 − 𝑒𝑥𝑝
−𝑘1𝑡 )                                                                                        Equation 2.10 
 
Where: 
R = cumulative release (%) 
k0 = zero-order release constant (erosion) 
Ad = total diffusional release 
k1 = first-order release rate constant (diffusion) 
t = time 
and  
t 1/2r = ln (2)/ k1                                                                                                                                                                                               
where t 1/2r = half-time of diffusional release process 
k1 = first-order release rate constant (diffusion) 
Such a model has no linear solution or approximation. Rather, to fit experimental data to such a 
model requires iterative curve fitting to be employed. In this work, GraphPad Prism was employed to 
optimize model parameters to experimental data. 
Testing the fit of experimental data to accepted release models and the novel hybrid release model 
demonstrated mean R2 values obtained by fitting the data to the novel hybrid release model to be 
superior except in the case of 5% SST gels (the most rigid tested) where erosional release would be 
anticipated to be minimal. Moreover, this observation is consistent with the Langmuir Adsorption 
Isotherm where higher concentrations of SST would be anticipated to result in higher adsorbed 
surface concentrations of release. Alternatively, such first-order release ordinarily may be explained 
by diffusional release where an increase in concentration of releasing substrate would result in a 
corresponding increase in release rate. However, in this case, the diffusing substrate and the 
structural component of the gel are the same such that increasing the concentration of the diffusing 
substrate above the gel threshold would reduce diffusional release. These observations establish the 
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first-order release (or first-order region of release in the case of biphasic release patterns) to be 
more likely to be due to the release of adsorbed material from the cortex rather than the diffusional 
release of material from the core. 
From the fit achieved to the novel hybrid model, the half-time of diffusional release process (t 1/2r) 
may be estimated from the first-order release rate constant (k1). This demonstrates that the times 
were shorter for the release in the Eppendorfs compared to the Slide-A-lyzer units. This is likely to be 
due to direct contact of the gel with the medium which would facilitate both desorption and 
erosional release. Moreover, the 5% SLF gels released more quickly than the 2.5% SLF gels. Whilst 
from rheological tests it may be inferred that 5% SLF gels would erode more slowly (having a higher 
G’), there may be more SST monomers adsorbed on the surface of the gel and closer to the surface 
compared to the 2.5% SLF gels. In contrast, for 1% and 2.5% SLF gel release times are similar in the 
Slide-a-Lyzer units but are significantly more rapid in the Eppendorf tubes with the lower 
concentration gels releasing more quickly. These lower concentration gels demonstrate greatly 
reduced G’ thus, having a lesser structure, erode readily in direct contact with the medium. 
It is difficult to compare the data of the SST 5% water gels directly between the Eppendorf tubes and              
Slide-a-Lyzer units due to the variation in time scale of the experiments. The observation of reduced 
release rate with time in contact with the electrolytes in solution is consistent with the increase in 
nanofibril structure observed in an environment of higher electrolyte presence (Figure 2.3). This 
suggests some diffusion of ions into the SST gel of lower structure (Figure 2.7).  
2.4. Conclusions 
The rheological tests indicate that the SST hydrogels are shear-thinning. The storage modulus (G’) of 
the SST hydrogels increases with increasing SST concentration and in the presence of electrolytes. 
Here, for the first time, we have investigated the rheological properties and release kinetics from 
self-assembled SST hydrogels. We propose that the release kinetics of SST monomers from the 
hydrogels follow a hybrid model where both zero-order and first-order release occur, predominating 
at different times.  
This study indicates that SST self-assembled hydrogels have the potential to act as a depot for SST 
delivery as the release of monomers has been demonstrated. However, it remains questionable that 
the amount released is adequate to achieve therapeutic benefit in the retina. The cumulative 
percentage of release ranging from 2.95% to 3.60% from the self-assembled SST hydrogels in SLF at 
48 hours seems low; although release over an extended period of time may be sufficient. The 
amount of SST in the vitreous of non-diabetic human subjects has been found to be 113.5 pg/mL 
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(Hernandez, et al., 2005), which is lower than the amount of SST released from the hydrogels. It has 
been observed that the presence of electrolytes results in a slower release, which has to be 
considered as electrolytes will be present in the physiological milieu. 
While there are no clinical formulations of somatostatin for ocular use currently on the market, 
there are a number of studies of somatostatin on retinal cultures and animal models. The 
concentrations studied ranged from 10-11 to 10-5 M on retinal cell cultures (Davide Cervia, Elisabetta 
Catalani, Massimo Dal Monte, & Giovanni Casini, 2012; Cervia, Martini, et al., 2008; Niki 
Mastrodimou, Kiagiadaki, Hodjarova, Karagianni, & Thermos, 2006). Therefore the amount released 
from SST hydrogels investigated in this study may be of clinical relevance, however this warrants 
further investigation using cell culture studies and/or in-vivo experiments.  
Given the above considerations, formulation strategies were explored in the following chapters to 
extend the duration of release as well as to increase the cumulative amount released in comparison 
to the self-assembled SST hydrogels studied in this chapter. The next chapter (Chapter 3) 
investigates a hydrogel formulation of SST in a polymeric carrier while Chapter 4 explores two 
different methods to manufacture microparticles encapsulating SST with the same intent of 
extending duration and amount of SST released. 
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CHAPTER 3: FORMULATION OF SOMATOSTATIN AND HPMC HYDROGELS 
3.1. Introduction 
Hydrogels are described as cross-linked networks of hydrophilic polymers capable of retaining large 
amounts of water yet remaining insoluble and maintaining their three-dimensional structure. 
Hydrogels have been studied for a wide range of biomedical and pharmaceutical applications, 
including contact lenses, tissue engineering, diagnostics, drug delivery, vascular prostheses, and 
coating for stents and catheters. There are a number of comprehensive reviews on hydrogels 
available in the literature (Censi, Di Martino, Vermonden, & Hennink, 2012).  The hydrophilic 
polymers used to create hydrogels need to be physically and/or chemically cross-linked to prevent 
dispersion. Hydrogels can be prepared from natural and synthetic polymers and can consist of 
homopolymers, copolymers, and interpenetrating or double polymeric networks (Censi, et al., 2012).  
The high water content and soft nature of hydrogels render them as biocompatible materials. They 
are similar to natural extracellular matrices and minimize tissue irritation and cell adherence (Park & 
Park, 1996). Their porous structure and high water content allow them to accommodate high loads 
of water-soluble compounds, including therapeutically active proteins and peptides. Unlike other 
delivery systems (microparticles, emulsions, etc.), where preparation conditions are sometimes 
detrimental to proteins due to the use of organic solvents and protein denaturating processes, like 
homogenization, exposure to interfaces, and shear forces, hydrogel preparation procedures are 
beneficial in preserving protein stability. Finally, proteins have a limited mobility or are immobilized 
in the hydrogel network, which is favorable for preservation of their mostly fragile 3D structure. All 
these unique properties of hydrogels have raised increasing interest in their use as reservoir systems 
for proteins that are intended to be released from the hydrogel matrix in a controlled fashion to 
maintain a therapeutic effective concentration of the protein drug in the surrounding tissues or in 
the circulation over an extended period of time. Proteins can be physically incorporated in the 
hydrogel matrix, and their release is governed by several mechanisms, such as diffusion, swelling, 
erosion/degradation, or a combination of these mechanisms (Censi, et al., 2012).  
Changes in the concentration, molecular weight or polymer architecture of the hydrogel allow fine-
tuning of protein release. Other strategies to tailor drug release from hydrogels exist; these rely on 
reversible protein−polymer interaction or encapsulation of the protein in a secondary delivery 
system such as micro- or nanoparticles dispersed in the hydrogel network (Holland, Tabata, & Mikos, 
2005; Singh, Suri, & Roy, 2009).  
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In addition, injectable hydrogels that can be administered in a minimally invasive manner are of 
interest due to patient acceptance. Syringeability, defined as the ability to pass easily through a 
hypodermic needle or transfer from a vial prior to injection, and ease of delivery for pre-formed 
hydrogels are desirable.  
Cellulose derivatives such as methylcellulose (MC), carboxymethylcellulose sodium (CMC) and 
hydroxypropyl methylcellulose (HPMC) are naturally occurring polymers with thermoresponsive 
properties. The structure of Methocel 65 HG® used in this study is provided in Figure 3.1. These are 
commercially available in various products for the treatment of dry eyes, including Celluvisc® (CMC 
sodium 1%), Genteal® gel (HPMC 0.3%) and PAA HPMC gel® (HPMC 0.3%). Aqueous solutions of MC 
and HPMC form gels at lower concentrations (1–10% w/w) (Sarkar, 1979) and temperatures of 40–
50 °C and 75–90 °C, respectively (Pal, Paulson, & Rousseau, 2013). The presence of salts or a higher 
degree of cellulose ether substitution decreases the phase transition temperature of cellulose 
derivatives (Ambrosio, Demitri, & Sannino, 2011; Bain, et al., 2012). The inclusion of salts and 
alterations in concentration influence sol-gel transition temperature of MC (Arvidson, et al., 2013; 
Xu, Li, Zheng, Lam, & Hu, 2004), with the transition occurring at a lower temperature in the presence 
of certain salts (salt-assisted) and at higher temperatures in the presence of others (salt-
suppressed).  
Preclinical studies have been done with anti-VEGF agents bevacizumab and ranibizumab incorporate 
in in situ gelling formulations using polymers like hyaluronic acid-dextran (Yu, Lau, Lo, & Chau, 2015), 
alginate-chitosan hydrogel (Osswald & Kang-Mieler, 2016), silk-based hydrogels (Lovett, et al., 2015) 
and diels-alder hydrogels (Kirchhof, et al., 2015). There is strong interest in peptide delivery through 
hydrogels for the reasons outlined above, with special focus on stimuli sensitive delivery (Mandal, et 
al., 2018). 
In this study, a hydrogel of somatostatin in HPMC was formulated in an attempt to modulate the 
release of somatostatin monomers compared to the self-assembled hydrogels that were studied in 
Chapter 2. The release kinetics were studied using the protocol described in Chapter 2 and the gels 
were further characterised by rheological studies, transmission electron microscopy (TEM) and FTIR. 
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Figure 3.1: Chemical structure of Methocel 65 HG® with 5.5-7.5% hydroxypropyl substitution 
(Reference: Sigma-Aldrich product information) 
3.2 Materials and methods 
3.2.1 Materials 
Somatostatin-14 of sequence Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (cyclic, 
MW=1638 Da) was purchased as an acetate salt from Polypeptide Laboratories (Sweden). According 
to the Manufacturer’s certificate of analysis, the peptide purity is 99.6%. 
Methocel 65 HG®, sodium azide and all the chemicals used to prepare the simulated lachrymal fluid 
were purchased from Sigma Aldrich (St Louis, MO, USA). Milli-Q water was used in the preparation 
of all media. The composition of simulated lachrymal fluid can be found in Chapter 2, Table 2.1. 
(Ceulemans & Ludwig, 2002). 
3.2.2 Methods 
3.2.2.1 Preparation of HPMC gel 
HPMC 3% w/w gel was prepared by dispersing the appropriate quantity of Methocel 65 HG powder 
into hot (freshly boiled) water. Powder was added to the water gradually to avoid clumping. Sodium 
azide was added to a concentration of 0.01% w/v to prevent any bacterial growth. The suspension 
was then refrigerated at 4°C for 7 days to allow the entanglement network to relax and for aging to 
occur.  
3.2.2.2 Rheological characterization of blank HPMC gels and SST 5% w/w in HPMC hydrogels 
The aging process of the HPMC 3% w/w and 6% w/w gels was characterised over the course of 15 
days for the 3% w/w gel and 19 days for the 6% w/w gel. The rheological properties of all the gels 
investigated were determined using an ARG2 Rheometer (TA Instruments, UK). A stainless steel 
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40mm parallel plate geometry with gap of 500 μm was employed. The removal of the gels was done 
as gently as possible from the containers to minimize disruption of the structure. The gels were then 
given an hour to equilibrate prior to analysis. A solvent trap was used to eliminate the evaporation 
of water from the gel periphery. Oscillation amplitude sweeps were used to confirm the linear 
viscoelastic region. Frequency sweeps (0.1-100 Hz) at 20°C were then conducted. In addition for the 
SST 5% in HPMC hydrogels, temperature sweeps (1 Hz, 20°C to 80°C) were conducted. 
Measurements were performed in triplicate. 
3.2.2.3 Preparation of SST 5% w/w in HPMC hydrogels 
After the aging of the blank HPMC 6% gels at 4°C for 7 days, 0.5g of SST 5% w/w and HPMC 3% w/w 
gels were prepared. This was done by adding a 0.25 g solution of SST in Milli-Q water to 0.25g of 
HPMC 6% w/w gel in an Eppendorf tube. The SST 5% w/w in HPMC 6% w/w gels were prepared by 
diluting HPMC 8% w/w gel to yield the final concentration. The mixture was then vortexed until 
thoroughly mixed and then allowed to equilibrate at 4°C for an additional 7 days.  
3.2.2.4 Investigation of SST conformation before and after exposure to simulated lachrymal fluid 
Based on the release profile of SST from the hydrogels, FTIR characterization was performed on Days 
1 and 7 after preparation of the SST 5% HPMC hydrogels and during the release studies every 24 
hours for up to 4 days. 
ATR-FTIR spectra were measured using a Tensor II Bruker Spectrometer equipped with an ATR 
attachment. The spectra are shown to result from the average of 32 scans. Each spectrum was 
scanned over the range of 4000-1000 cm-1, using a 4 cm-1 resolution. All spectra were baseline 
corrected and the water signal was removed by subtraction of respective solvent (blank) spectrum 
recorded the day of the experiment. Spectragryph 1.2 was used to obtain the second derivative of 
the spectrum.  
3.2.2.5 Morphological characterization of hydrogels  
Transmission electron microscopy (TEM) was used to characterise the morphology of the hydrogels. 
Negative staining by uranyl acetate was performed to contrast the nanostructures, using the same 
protocol as reported in van Grondelle et al. 2007. Stained samples deposited on formvar and 
carbon–coated 200 mesh copper grids (Proscitech, Australia) were examined with a JEOL 1010 
transmission electron microscope operating at 100 kV. 
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3.2.2.6 Release study of somatostatin monomers from HPMC hydrogels 
Release medium (SLF; 500 μL) with 0.01% w/v sodium azide was placed directly on top of the gels 
which were prepared in 1.5mL Eppendorf tubes. The Eppendorf tubes were then closed and sealed 
with Parafilm. The assembled units were then placed in a water bath at 37 °C, agitated at 30 RPM. At 
various time intervals (1, 2, 4, 6, 24, 48, 72, 96h and every 24 hours up to day 10), the receptor 
compartment/medium (500 µL) was removed for analysis by HPLC. The receptor medium was 
replenished with fresh medium immediately. Given the high solubility of somatostatin in aqueous 
media (> 70mg/mL) and the replacement of the whole buffer volume at each sampling point, this 
approaches sink conditions in vivo in the ocular environment with tears or blood flow. The units 
were reassembled and replaced in the shaking water bath. The experiments were performed in 
triplicate. 
3.2.2.7 Mass spectrometry of released samples investigating SST conformation upon release  
Mass spectrometry was performed on the release samples from SST 5% w/w in HPMC 6% w/w at 
Release Day 1 and Release Day 10 to confirm that the native structure of somatostatin released from 
the hydrogels was preserved. The samples were compared to a freshly-made solution of SST 5% w/w 
in water. Bruker AutoFlex Matrix Assisted Laser Desorption/Ionisation (MALDI) Time of Flight (TOF) - 
Mass Spectrometer (MALDI-TOF-MS) was used to perform the experiment. Sample size of 1 µL was 
spotted onto the target. 
3.3 Results and discussion 
3.3.1 Rheological characterization of aging process of blank HPMC gels 
The amplitude sweeps of the HPMC 3% w/w and 6% w/w gels show that a torque of 50 µN.m is 
within the linear viscoelastic region of the gels at all time points tested. The frequency sweeps of 
both the HPMC 3% w/w and 6% w/w gels show a progressive decline of the G’ (storage modulus) at 
higher frequencies indicating that the gels tend to stiffen over longer time periods (Figure 3.3). There 
is an increase in the G’ of the HPMC 3% gel until day 7 after which it remains stable until day 15 
(Figure 3.2). This data shows that the entanglement network is not sufficiently relaxed and requires 
7 days for aging to occur. Hence, the gels are aged for 7 days before and after mixing with 
somatostatin. The G’ of the HPMC 6% w/w gel on the other hand was unstable although displaying 
an upward trend until day 14 (Figure 3.2). The HPMC 6% w/w gels were aged in the same way as the 
HPMC 3% w/w gels as the total aging time before and after mixing in somatostatin adds up to 14 
days. The aging of HPMC gels has been documented (Hakert, Eckert, & Müller, 1989) and it has been 
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shown that the rheological behaviour of HPMC gels in water does not change after aging for up to 
140 days (Daneluzzi). The purpose of allowing the HPMC gels to be fully aged is to eliminate the 
impact of the aging process on the release of somatostatin monomers. 
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Figure 3.2: Changes in G’ (storage modulus) of HPMC 3% w/w and 6% w/w gels during the aging 
process 
3.3.2 Rheological characterization of somatostatin-loaded HPMC hydrogels 
Rheological studies as described in section 3.2.2.2 were conducted on SST 5% w/w water solutions, 
HPMC 3% w/w and 6% w/w gel and SST 5% w/w in HPMC 3% w/w and 6% w/w gels on Days 1 and 7 
after being prepared and every day for the first 4 days of release. The amplitude sweeps show that a 
torque of 50 µN.m falls within the linear viscoelastic region for all the samples tested. Therefore, 
subsequent studies were performed at 50 µN.m. The frequency sweeps show a progressive decline 
in the G’ (storage modulus) of the blank HPMC 3% w/w and 6% w/w gels and SST 5% w/w in HPMC 
3% w/w and 6% w/w gels. This indicates that the gels are stiffer at longer time frames (low 
frequencies) and less at shorter time frames (higher frequencies). This means that the inclusion of 
SST in the HPMC gel does not alter this property of the HPMC gels. The frequency sweeps of the SST 
5% w/w aqueous solution on the other hand shows an increase in G’ as the frequency increases. This 
finding supports data presented in Chapter 2 of the frequency sweeps done on SST aqueous 
solutions and those in the presence of electrolytes. The flow sweeps indicate that all samples tested 
are shear-thinning and will flow more easily with the application of shear as the viscosity falls. This is 
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a desirable property should the formulation be administered as an injection. The temperature 
sweeps show that the gels with HPMC undergo thermogelation ca. 65°C. There is an increase in G’ 
from 65°C onwards. This is a characteristic property of HPMC matrices (Joshi, 2011).This is not 
observed with the SST 5% w/w aqueous samples where there is a decline in G’ with increasing 
temperatures. This is consistent with materials that do not undergo thermogelation. A comparison 
of the G’ of the SST 5% w/w in HPMC 3% w/w gels at 1Hz at the different time points tested show 
that the G’ initially decreases as the gel is diluted with the addition of the SLF on top then 
significantly increases on Day 4 of release. This correlates with the end of the release of 
somatostatin monomers as detected by HPLC based on our release data. This may be attributed to 
formation of nanofibrils, resulting in an increase in the stiffness of the gel.  The same applies to the 
SST 5% w/w aqueous samples where the G’ is highest on Day 4 of release. Data from Rai et al (Rai, et 
al., 2017) shows that SST in the presence of electrolytes forms stiffer hydrogels which explains the 
highest G’ of the sample exposed the longest to electrolytes. For all blank HPMC samples, the trend 
is opposite with the lowest G’ after 4 days of release. This can be attributed to the dilution of the 
HPMC hydrogels with the presence of SLF on top removed and replaced every 24 hours. The SST 5% 
w/w in HPMC 6% w/w gels show the same trend in the change in G’ as the SST 5% w/w in HPMC 3% 
w/w gels. Although there is an initial decrease in G’ upon exposure to SLF when the release study is 
commenced and an increase on Day 4 of the release, these changes are smaller in magnitude. This is 
can be attributed to the higher stiffness of the SST 5% w/w in HPMC 6% w/w gels (G’ of 510.4 Pa) at 
the starting point of release studies (Day 7) compared to a G’ of 96.8 Pa of the SST 5% w/w in HPMC 
3% w/w gels at the same time point. The difference in magnitude of G’ of the SST 5% w/w in HPMC 
3% w/w gels between release day 3 and 4 was 927 Pa whereas for the SST 5% w/w in HPMC 6% w/w 
gels the difference was 178 Pa. When HPMC matrix comes in contact with water, the polymer begins 
to swell and forms a protective gel around the drug content, leading to a sustained release of drugs 
(J. L. Ford, 1999). The stiffer 6% w/w HPMC matrix would be more resistant to the diluting effects of 
the SLF and provide a stronger barrier to the interaction of the electrolytes in the SLF with the 
entrapped somatostatin. This may be a possible reason for the longer duration of release (over 10 
days) compared to 4 days for the SST 5% w/w in HPMC 3% w/w gels. 
In similar work, Liang and co-workers (Liang, et al., 2010) investigated the potential ocular 
application  of self‐assembled peptide containing a RGD (arginine‐glycine‐aspartic acid) sequence as 
well as a hydrophobic FMOC tail in the rabbit eye. The G’ of the hydrogel studied was between 200-
250 Pa. The G’ of the self-assembled hydrogel studied falls between the G’ of the SST 5% w/w in 
HPMC 6% w/w hydrogel and SST 5% w/w in HPMC 3% w/w in our work. Subconjunctival and intra-
cameral injection of the peptide hydrogel into the rabbit eye showed that the biocompatibility was 
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similar to that of commercial sodium hyaluronate injection. A more extensive discussion of similar 
hydrogels in the literature is found in Chapter 2. 
 
                                      
 
 
Figure 3.3: Comparison of the G’ (storage modulus) of the different gels tested at Days 1, 7 and days 
1-4 after exposure to SLF in release conditions (n=3; error bars = SD) 
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Figure 3.4: Comparison of the frequency sweeps of the different gels tested at Days 1, 7 and days 1-4 
after exposure to SLF in release conditions (n=3; error bars =SD) 
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Figure 3.5: Comparison of flow sweeps of different gels tested at Days 1, 7 and days 1-4 after 
exposure to SLF in release conditions (n=3) 
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Figure 3.6: Comparison of temperature sweeps of different gels tested at Days 1, 7 and days 1-4 
after exposure to SLF in release conditions (n=3) 
3.3.3 Investigation of SST conformation before and after exposure to simulated lachrymal fluid (FTIR 
characterization of hydrogels) 
The SST 5% in HPMC 3% and 6% were characterized on Days 1 and 7 after being prepared and every 
day for the first four days of release studies. This was performed to investigate the transition of SST 
from a random coil conformation to structured β-sheets. 
The analysis was focused on amide I vibrations (1600–1700 cm-1), which are attributed to vibrational 
stretching modes of the backbone carbonyl groups. The corresponding wavenumbers can be 
assigned to different strengths/types of hydrogen bonds and can indicate secondary structure types 
(Hiramatsu & Kitagawa, 2005; Krimm & Bandekar, 1986). The vibration at 1643 cm-1 is assigned to 
random conformations while the combination of vibrations around 1615 and 1675 cm-1 is attributed 
to antiparallel β-sheet secondary structure and the vibration around 1663 cm-1 to a turn secondary 
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structure. This combination is typical of a β -hairpin backbone conformation, which corresponds to 
the bioactive Somatostatin-14 conformation (Barth, 2007; Holladay & Puett, 1976; Holladay, Rivier, 
& Puett, 1977; W. van Grondelle, et al., 2007). 
The FTIR data below (Figure 3.7) shows the SST becomes more structured once the gel is exposed to 
SLF. There are less of the random conformations and a transition to more structured organisations 
of the parallel and anti-parallel β-sheets. This has been discussed at length by Valery and co-workers 
(W. van Grondelle, et al., 2007).  They have found that the self-assembly process of somatostatin is 
sensitive to the presence of electrolytes (such as those found in SLF). The self-association into higher 
structures and nanofibril lateral association is enhanced in the presence of electrolytes compared to 
in pure water. Our data supports the observations by Valery et al. Figure 3.8 is a secondary 
derivative plot which shows that the transition from a random coil conformation to structured β-
sheets is hindered when somatostatin is entrapped within the HPMC matrix, thus delaying the 
formation of nanofibrils. 
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Figure 3.7: FTIR data of the transition in conformation from random coil to more structured β-sheet 
conformations for SST 5% in water, SST 5 % w/w in HPMC 3% w/w and SST 5% in HPMC 6% w/w 
upon exposure to release conditions in contact with SLF. Water/SLF spectrum was subtracted. 
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Figure 3.8: Secondary derivative plots of FTIR data comparing the difference in structure between 
Day 7 and Day 4 of release after exposure to SLF for SST 5% w/w in water, SST 5% w/w in HPMC 3% 
w/w and SST 5% w/w in HPMC 6% w/w. Water/SLF spectra has been subtracted. 
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3.3.4 Morphological characterisation of hydrogels 
SST 5% w/w in water, SST 5% w/w in HPMC 6% w/w and blank HPMC 6% w/w gels were observed by 
transmission electron microscopy at Days 1 and 7 and Day 4 of the release study after exposure to 
SLF. The method of preparation of the stained gels is as described above and is the same as used for 
morphological characterization of the self-assembled SST hydrogels in Chapter 2.  
There were no structures observed in SST 5% in water at Day 1. This is consistent with our 
observations from Chapter 2 that in pure water, self-assembly of somatostatin takes about a week. 
 
 
Figure 3.9: Transmission electron micrographs of SST 5% in water at Day 7 (a) magnification 2000x (b 
and c) magnification 1200x.  
 
Figure 3.10: Transmission electron micrographs of SST 5% in water at Release Day 4 (a) magnification 
1500× (b) magnification 4000× and (c) magnification 1000×. 
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Figure 3.11: Transmission electron micrographs of blank HPMC 6% w/w at Release day 4 (a) 
magnification 1000× (b and c) magnification 2000×. Scale bars (a and c) 5 µm and (b) 2 µm.  
 
Figure 3.12: Transmission electron micrographs of SST 5% w/w in HPMC 6% w/w at Release day 4 (a 
and c) magnification 600×and (b) magnification 750×. Scale bars (a and c) 10 µm and (b) 5 µm. 
Figure 3.9 demonstrates that at Day 7 prior to release studies, self-assembly of somatostatin into 
nanofibrils in SST 5% w/w in water samples has begun. After exposure to SLF on release Day 4, the 
extensive network of nanofibrils is apparent as per Figure 3.10. The TEM micrographs of blank HPMC 
6% w/w consist of a thick entanglement network that is dense and heavily stained with uranyl 
acetate. It was a challenge to perform TEM on the HPMC-containing samples as the gels were highly 
viscous. The SST 5% w/w in HPMC 6% w/w and blank HPMC 6% w/w gels on day 7 could not be 
viewed as the gels were too heavy for the grids and the mesh was torn or they were stained too 
strongly for any structures to be differentiated. However, some images of the SST 5% w/w in HPMC 
6% w/w on release day 4 were obtained although in most of the grids the mesh was torn. Figure 3.12 
demonstrates the presence of a network similar to the blank HPMC 6% w/w gels although less 
dense. There are no apparent fibrillar structures such as found in Figure 3.10. 
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Bodvik et al (Bodvik, et al., 2010) have studied the aggregation and network formation of HPMC 
using cryo-TEM, amongst other techniques. In comparison to methylcellulose which forms fibrillar 
structures, the bulkiness of the hydroxypropyl groups leads to the formation of globular aggregates 
in HPMC. The TEM images appear to support the hypothesis from the FTIR results that the presence 
of HPMC delays the nanofibril formation of somatostatin when exposed to electrolytes. However, it 
is impossible to make a definitive conclusion given the difficulties of characterising a thick hydrogel 
with TEM. Cryo-TEM, performed properly, may provide more information about the structural 
characteristics of the SST and HPMC hydrogels. 
3.3.5 Release profile of somatostatin monomers from SST in HPMC hydrogels 
The release study was conducted as described above on SST 5% w/w solution, SST 5% w/w in HPMC 
3% w/w and HPMC 6% w/w gels. Conditions were kept the same for all samples. The SST 5% w/w 
solution reached a 100% release at 6 hours. The SST 5% w/w in HPMC 3% w/w gels released a total 
of 45.6% at 96 hours and there was no further release (no detectable peaks by HPLC) whereas the 
SST 5% w/w in HPMC 6% w/w gels continued to release a total of 37.6% at 10 days when the 
experiment was stopped, however, the release was ongoing.  
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Figure 3.13: Comparison of the release profiles of SST 5% in water, SST 5% w/w in HPMC 3% w/w 
and SST 5% w/w in HPMC 6% w/w. (n=3, Error bars = SD) 
 80 | P a g e  
 
 
Figure 3.14: Release profiles of SST 5% w/w in HPMC 3% w/w and SST 5% w/w in HPMC 6% w/w gels 
fitted to hybrid model of release (equation 4.1) (n=3) 
 
3.3.6 Release kinetics of SST 5% release from HPMC gels  
Based on prior published work relating to a hybrid model of release (Rai, et al., 2017), the graphs 
were fitted to the equation below using GraphPad (version 7.02). 
Cumulative percentage released = 𝑟 +  (𝑅𝑚𝑎𝑥  −  𝑟)  × (1 − 𝑒
−𝑘𝑡)                                     equation 3.1  
Where  
r = the cumulative percentage released when time is zero.  
Rmax = cumulative percentage released at infinite times. 
k = the first-order release rate constant (diffusion) 
t = time  
and  
𝑡 90 =  𝑙𝑛 (100/90)/𝑘                                                                                                                        equation 3.2 
where t90  is the time to release 90% of SST from the core of the gel and k is the first-order release 
rate constant (diffusion). 
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Table 3.1: The goodness of the fit (mean R2) of the above model to the samples as well as the t90 
(time to release 90% of SST from the core of the gel), k and Rmax. 
 
Gel tested  Mean R2  ± SD  Mean k ± SD Mean Rmax. ± SD Mean t90 ± 
SD 
SST 5% HPMC 3% 
n= 3 
0.998 ± 0.0002 0.118 ± 0.008 45.2 ± 2.19 19.6 ± 1.46 
SST 5% HPMC 6%  
n= 3 
0.997 ± 0.002 0.067 ± 0.013 37.3 ± 2.94 35.3 ± 6.29 
    
As can be seen from Table 3.1, the release kinetics of the somatostatin monomers from the SST in 
HPMC gels fit well (R2 values between 0.997-0.998) to the proposed hybrid model of release. The 
time taken for 90% of SST to be released from the core (t90) of the SST 5% w/w HPMC 3% w/w gels 
averages 19.6 hours while the t90 for the SST 5% w/w HPMC 6% w/w gels averages 35.3 hours. This is 
consistent with the observation that a higher concentration of HPMC produced gels that could 
release somatostatin for 10 days compared to 4 days for the lower HPMC concentration hydrogels. It 
is hypothesized that the swelling of the HPMC matrix when in contact with the SLF acts as a barrier 
to the ease of interaction of the electrolytes in the SLF with SST. This is more effective when the G’ 
of the HPMC matrix is higher, as in the case of the SST 5% w/w in HPMC 6% w/w gels which have a 
G’ of ca. 500 Pa at day 7 compared to G’ ca. 100 Pa of the SST 5% HPMC 3% w/w gels (Figure 3.4).  
The initial higher percentage of release for both sets of gels tested can be attributed to the 
diffusional release of SST monomers adsorbed on the surface of the hydrogels. However, with 
continued release conditions, erosional release would come into play with the expectation that the 
more rigid HPMC 6% w/w matrix would erode more slowly than the HPMC 3% w/w matrix. Results in 
Chapter 2 have shown that release of SST monomers becomes undetectable once nanofibrils are 
formed which are stable in the presence of electrolytes (W. van Grondelle, et al., 2007). This is likely 
to be the explanation for no further detected release from the SST 5% HPMC 3% w/w gels after 4 
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days. The SST 5% w/w HPMC 6% w/w gels offer a formulation candidate that delays SST nanofibril 
formation in the presence of electrolytes and extends the duration of release. 
In comparison to the self-assembled somatostatin hydrogels studied in Chapter 2, these hydrogels 
have demonstrated a longer duration of release of somatostatin monomers. Although the SST 5% 
w/w in water gel released ca. 38% SST monomers in SLF at 9 hours (Chapter 2, Table 2.2), the 
entrapment of SST in HPMC has extended the duration of release to 4 and 10 days (experiment 
stopped) with a similar cumulative amount released. The concentrations released are in the order of 
10-5 M, which fall in the upper range of concentrations reported to be effective in cell and animal 
studies. Chapter 5 discusses the results of such studies in more detail. 
Such extended release has been previously reported with polymers of erosional degradation. Foer 
example, Misra and co-workers (Misra, et al., 2009) synthesized a series of water-based small 
dimensional hydrogel systems composed of NIPAAm monomer and Dex-lactateHEMA macromer 
using UV photopolymerization at room temperature. These thermoresponsive hydrogels were 
hydrolytically degradable and were able to load insulin with up to 98% loading efficiency during 
synthesis. The hydrogels achieved one week of insulin release which involved both diffusion and 
degradation mechanisms of the hydrogels.  
Comparing our data to an extended release self-assembled hydrogel, the somatostatin analogue, 
lanreotide, is formulated as a supersaturated aqueous solution in a ready-to-use prefilled syringe for 
deep subcutaneous injection under the trade name Somatuline Autogel®. It is administered once 
every 28 days (Castinetti, Saveanu, Morange, & Brue, 2009; Roelfsema, Biermasz, Pereira, & Romijn, 
2008). The injection exhibited linear pharmacokinetic profiles in healthy subjects with a half-life of 
about 21-22 days (Hu & Tomlinson, 2010). Although the longest duration of release exhibited in this 
study was 10 days in vitro, further work in vivo remains to be investigated. 
On the other hand, Pochan and Schneider (Branco, et al., 2009) studied the release of probes of 
different sizes from a class of self-assembling peptides that undergo triggered hydrogelation in 
response to physiological pH and salt conditions (pH 7.4, 150 mM NaCl) to form mechanically rigid, 
viscoelastic gels. It was found that the mechanism of release was by solely by diffusion and 
dependent on the size of the probe. The full release from these hydrogels ranged from days to 
months, increasing with an increase in the size of the probe. This is in contrast to our SST in HPMC 
hydrogels where erosion plays a role in the release of SST monomers, particularly in the later stages 
of release. 
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A commercial example of an in situ gelling thermosensitive hydrogel for delivery of a glycoprotein is 
ReGel® (made up of PLA-PEG-PLGA triblock copolymer). It was used to deliver commercially available 
interleukin-2, proleukin (Chiron®) in a depot formulation. The fully bioactive protein was released in 
a 3−4-day period and weekly administration in animal models improved tumor stasis and survival 
and was purported to have negligible side effects as compared to conventional interleukin-2 
administration (Rathi, Zentner, & Jeong, 2000). 
In this work, we have shown that extended release of somatostatin, which is otherwise challenging 
to deliver due to its short half-life and self-assembly in the presence of electrolytes, is possible via 
entrapment in HPMC. This formulation retains the advantages of hydrogels as previously discussed 
in Section 3.1 and having the potential to be delivered via topical or intra-ocular administration, 
pending animal studies. 
3.3.7 Mass spectrometry of released samples investigating SST conformation upon release  
Mass spectrometry was performed on the release samples from SST 5% w/w in HPMC 6% w/w at 
Release Day 1 and Release Day 10 as described above. This was done to confirm that the native 
structure of somatostatin released from the hydrogels was preserved. The samples were compared 
to a freshly-made solution of SST in water. The mass spectra revealed that the native structure of 
somatostatin was preserved upon release from the HPMC gel matrix. 
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Figure 3.15 Mass spectra of (a) SST standard (b) Release Day 1 sample from SST 5% w/w in HPMC 6% 
w/w and (c) Release Day 10 sample from SST 5% w/w in HPMC 6% w/w. Note: the SST peak in 
spectra (c) is very small reflecting the amount released at Day 10. 
3.4 Conclusion  
A hydrogel formulation of somatostatin in a higher concentration of HPMC (6% w/w) that could 
release somatostatin for 10 days compared to 4 days for the lower HPMC (3% w/w) concentration 
was developed and characterized. The total cumulative percentage released from these hydrogels 
was similar to that from a SST 5% w/w in water hydrogel but over a period of days rather than hours. 
A release model was developed that fits well to the release profile of somatostatin from the 
hydrogels. Here, we have a formulation candidate that delays somatostatin nanofibril formulation in 
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the presence of electrolytes and extends the duration of release. Hence, the SST 5% w/w in HPMC 
6% w/w hydrogels were chosen to proceed with safety and efficacy tests on an in vitro cell line. 
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CHAPTER 4: PREPARATION AND CHARACTERIZATION OF SOMATOSTATIN 
MICROPARTICLES  
4.1 Introduction 
4.1.1 Microparticles  
4.1.1.1 Rationale for use of microparticles 
Delivery of a protein drug may require multiple daily administrations to achieve therapeutic efficacy. 
In order to improve patient compliance and convenience, sustained release dosage forms have been 
developed (Cohen, Yoshioka, Lucarelli, Hwang, & Langer, 1991; Leach, et al., 2005). In the last three 
decades, many therapeutic proteins and peptides have been microencapsulated in biodegradable 
polymers, mainly poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and poly(lactic-co-glycolic acid) 
(PLGA) (Lam, Duenas, Daugherty, Levin, & Cleland, 2000; Morlock, Kissel, Li, Koll, & Winter, 1998; 
Pean, et al., 1999; Takada, Yamagata, Misaki, Taira, & Kurokawa, 2003). The use of biodegradable 
polymers as a carrier for peptide drugs assumes that the release of a loaded peptide drug depends 
mainly on the degradation kinetics of the polymer. The degradation kinetics of PLGA can be adjusted 
by changing the lactide/glycolide ratio and molecular weight (MW) (Frangione-Beebe, Rose, 
Kaumaya, & Schwendeman, 2001). This is not always the case because other factors of the 
formulation can also affect the drug release kinetics, and can be more dominant than the 
degradation kinetics of a polymer. These factors include interactions between the polymer and the 
drug, size of the microspheres and excipients present (Varde & Pack, 2004). 
4.1.1.2 Characteristics of microparticles 
An ideal microparticle formulation should have reasonably high encapsulation efficiency, loading 
capacity, and sustained release of the loaded protein with retained bioactivity (Jain, 2000). The high 
protein loading and high encapsulation efficiencies are most critical simply due to the high price of 
therapeutic proteins (Jain, 2000). 
For an injectable formulation, the size of microparticles should be small enough for going through a 
fine needle. While intravitreal injection of solutions or liquid formulations like Verisome® can be 
delivered via 30G needles (Section 1.2.1.4), polymeric steroid implants have been delivered using 
22G and 25G needles (Section 1.3.1). Similarly, polymeric microparticles would have to be delivered 
through needles of 22–25G (inner diameters of 394–241μm) to facilitate syringeability and 
injectability. Microparticles with diameters much smaller than that of a needle are essential, in order 
to minimize potential blockage of the needle as well as vascular blockages. The particle size and size 
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distribution are also important for protein release rate as the total surface area for protein delivery 
depends on the particle size (Berkland, Kim, & Pack, 2001). As particle size decreases, the surface 
area-to-volume ratio increases. Thus, for a given rate of drug diffusion through the microsphere, the 
movement of drug out of the microsphere increases with decreasing particle size. In addition, water 
may penetrate more quickly due to the shorter distance from the surface to the centre of the 
particle. For poorly water-permeable polymers like polyanhydrides, a decrease in particle size 
increases surface area-to-volume ratio resulting in faster release rates (per mass of polymer) from 
smaller polyanhydride microspheres (Varde & Pack, 2004).  
Microparticles fall in the size range of 1-1000 µm and can be termed microcapsules for reservoir 
structures or microspheres for matrix systems (Figure 4.1) (Yasukawa, et al., 2004). Microcapsules 
are formed by a core that contains the drug and is surrounded by a layer of a polymer or a mixture 
of several polymers. In the microspheres, the active substance is dispersed in the polymeric network. 
Matrix structure is preferred for biodegradable systems as the drug is dispersed in the polymer. 
 
Figure 4.1: Structure of microparticles (microspheres and microcapsules). In the microspheres, the 
active substance is dispersed within the polymeric matrix, while microcapsules have drug in the core, 
which is surrounded by a polymeric layer. Reprinted with permission from Herrero-Vanrell et al. (R. 
Herrero-Vanrell, Bravo-Osuna, Andres-Guerrero, Vicario-de-la-Torre, & Molina-Martinez, 2014) 
Once administered, microparticles can disappear or remain at the site of administration after 
releasing the drug depending on the characteristics of the polymer.  
Microspheres are good candidates to be used in personalized medicine as different amounts of 
particles can be administered depending on patient needs. For intraocular purposes, they must be 
biocompatible, safe and stable, demonstrating predictable degradation kinetics. All these 
requirements can be achieved by the adjustment of the manufacturing parameters (R. Herrero-
Vanrell, et al., 2014). 
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4.1.1.3 Administration of microparticles 
Microspheres are usually injected as a conventional suspension with Balanced Salt Solution or 
phosphate buffer but sometimes viscous vehicles, such as hydroxypropyl methylcellulose or 
hyaluronic acid are used to prevent clogging of needles during microsphere injections and improve 
syringeability and injectability (dos Santos, et al., 2006; Rocio Herrero-Vanrell & Refojo, 2001). A 
force of 12N over 10s is considered acceptable (Xie, et al., 2014). 
4.1.1.4 Microparticle use in ocular applications  
In the management of chronic posterior eye diseases biodegradable microspheres are preferred 
since they are degraded in vivo, either enzymatically or chemically to produce biocompatible, 
toxicologically safe by-products which are further eliminated by the normal metabolic pathways (X. 
S. Wu, 1995). For this reason, biodegradable polymers such as gelatin, albumin, polyorthoesters, 
polyanhydrides and polyesters are preferred for the synthesis of intraocular microspheres, as they 
do not require removal from the injection site after delivering the drug (R. Herrero-Vanrell, et al., 
2013). The derivatives of poly (lactic) acid (PLA), poly (glycolic) acid (PGA) and their copolymers poly 
(lactic-co-glycolic) acid (PLGA) are the most employed and have been approved for clinical use by the 
U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Different 
devices such as implants, scleral plugs, pellets, discs, films, and rods have been prepared from these 
erodible polymers for delivery of therapeutics to the posterior segment of the eye (Yasukawa, et al., 
2004). Their use as injectable devices has become more popular over the last few decades.  
For intraocular administration, a large variety of bioactive compounds has been included in 
microspheres (e.g. antiproliferatives, antiinflammatories, immunosuppressants, antibiotics and even 
biological therapeutic agents). Some examples are dexamethasone, budesonide, cyclosporine, anti-
VEGF aptamers and ganciclovir (R. Herrero-Vanrell, et al., 2014). For the treatment of posterior 
segment diseases, microspheres can be administered by intravitreal, periocular or suprachoroidal 
injection (Rocío Herrero-Vanrell, 2011; Rocio Herrero-Vanrell & Refojo, 2001; Paganelli, et al., 2010; 
Yasukawa, et al., 2004).  
Intraocular microspheres allow the release of the encapsulated drug, bypassing the blood ocular 
barrier. The main advantage of these formulations is that they can release the drug over weeks or 
months with a single administration, achieving the same therapeutic effect as multiple injections. 
For example, Veloso et al (Veloso, Zhu, Herrero-Vanrell, & Refojo, 1997) tested the antiviral effect of 
ganciclovir released from PLGA microspheres to avoid frequent intravitreal ganciclovir injections. 
The study showed that the microspheres controlled the progression of the disease in treated rabbit 
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eyes over 14 days with no adverse tissue reaction observed after 8 weeks. Control eyes were 
injected with blank microspheres. Sustained release of active substances from microspheres reduces 
the need for frequent administrations and enhances patient compliance. This strategy has gained 
attention, especially in chronic diseases that require low concentrations of the active substances for 
a long period of time (Patricia Checa-Casalengua, et al., 2011). Injection volumes of 50-100 µL can be 
delivered, although larger volumes can be accommodated in periocular spaces. Microparticles with 
sizes 1 µm and 10 µm in a volume of 50 µL were administered into the suprachoroidal space of New  
Zealand white rabbits with no inflammation or abnormalities observed and persisted for 2 months 
(S. R. Patel, et al., 2012). 
4.1.1.5 Manufacture of microparticles 
Microparticles can be manufactured by a variety of techniques including solvent 
extraction/evaporation from emulsion, aggregation by pH adjustment/heat, coacervation (phase 
separation), interfacial polymerization, ionic gelation and spray-drying. For encapsulation of 
proteins, double emulsion (water-in-oil-in-water) method (described further in Figure 4.2), inclusion 
of stabilizers (Freitas, Merkle, & Gander, 2005) or the formation of a solid-in-oil-in-water emulsion 
are preferred as these techniques have shown effective protection of the biologically active 
(secondary, tertiary or quarternary) structure of the protein (Patricia Checa-Casalengua, et al., 2011). 
Table 4.1 below provides a summary of the advantages and disadvantages of the aforementioned 
methods. This provides a rationale for the SAW technique being explored in this chapter. The 
advantage of this technique is the avoidance of the use of high temperatures or residual organic 
solvents that may denature thermolabile peptides or proteins. It is also time efficient due to the 
reduction in the number of steps and processing time required in comparison to traditional 
techniques like double solvent emulsion evaporation(Benoit, Baras, & Gillard, 1999), phase 
separation(Coccoli, et al., 2008; Morita, Sakamura, Horikiri, Suzuki, & Yoshino, 2000) or spray 
drying(Gander, Johansen, Nam-Trân, & Merkle, 1996). 
A final sterilization step is preferred for microparticles with autoclaving, gamma irradiation and 
ethylene oxide being most commonly employed. Thermally-sensitive microparticles are 
preferentially sterilised by gamma irradiation (25 kGy), however, this can induce structural changes 
in both the polymer and drug through dose-dependent chain scission as well as reduction of the 
polymer molecular weight. This can affect the behaviour of the final product. Strategies like the use 
of dry ice during sterilization of microspheres with low molecular weight drugs and use of 
antioxidants combined with protein drugs can help minimise the aforementioned changes (Amrite, 
Ayalasomayajula, Cheruvu, & Kompella, 2006; P. Checa-Casalengua, et al., 2012; Rocio Herrero-
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Vanrell & Ramirez, 2000; Martıńez-Sancho, Herrero-Vanrell, & Negro, 2004; Mohanan, Gander, 
Kündig, & Johansen, 2012). 
 
 
Figure 4.2: Schematic illustration of the w/o/w double-emulsion method used to prepare PCL-PEG-
PCL microparticles. Adapted from Thatcher et al, (Thatcher, Welch, Eberhart, Schelly, & DiMaio, 
2012) 
4.1.1.6 Surface acoustic wave atomization 
Surface acoustic wave (SAW) atomizers can be utilised for the straightforward, rapid, and energy 
efficient production of protein-loaded polymer microparticles. The apparatus consists of a drop of 
liquid on a device.  A SAW is a sound wave transmitted through a piezoelectric substrate (solid) 
which results in longitudinal waves being diffracted into the liquid at an angle (Rayleigh) due to the 
mismatch between the velocities of sound in solid and liquid.  As power is increased, the surface of 
the liquid drop vibrates and the entire drop may move or simply atomize (Figure 4.3). An increase in 
power and vibration amplitude of the SAW causes atomization of the drop, producing a fine 
continuous mist of droplets ejected from the surface of the drop.  The device used is an interdigital 
transducer (IDT) with aluminium/titanium electrodes sputter-deposited on a pizoelectric substrate. 
A sinusoidal electrical signal matching the operating frequency is applied to the IDT using a RF signal 
generator and RF power amplifier.  The strong acoustic streaming drives effective mixing within the 
pre-atomized drop. Therefore, the protein polymer solution is well mixed prior to atomization and it 
is conceivable that the protein is atomized together with the polymer solution and encapsulated 
within the polymer shell. It was found that there was a decrease in the particle size produced with 
an increase in SAW frequency. A higher polymer concentration also showed smaller and more 
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homogeneous particles. In one study by Alvarez et al (Alvarez, Friend, & Yeo, 2008), approximately 
55% of  bovine serum albumin (BSA) survived atomization and emerged intact from the particles. 
SAW devices are already widely employed in a host of telecommunications applications, for 
example, as inexpensive multiplexing signal filters in mobile phones, demonstrating how they may 
be mass produced through standard microfabrication technology and the potential of these devices 
in the development of a miniaturized integrated device for in situ protein encapsulation for portable 
drug delivery. 
 
 
 
Figure 4.3: Schematic of the Rayleigh wave propagation and the atomization process. Reprinted with 
permission from L Yeo (Alvarez, et al., 2008) 
Table 4.1: Comparison of the traditional methods of peptide encapsulation in microparticles 
Method Advantage Disadvantage Commercial application 
Phase 
separation 
Suitable for 
water-soluble & 
water-insoluble 
drugs 
Selection of 
solvents easier  
Agglomeration of 
particles 
Complex process 
depending on 
several kinetic 
parameters 
Requires removal 
of large quantities 
of organic phase 
Sandostatin® LAR 
Trelstar™ depot 
Decapeptyl® SR 
Somatuline® LA 
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from the 
microspheres 
Spray Drying Rapid 
Convenient 
Easy to scale up 
Mild conditions 
Significant loss of 
product-adhesion 
of microparticles 
to the inner walls 
of the spray-dryer 
Parlodel LAR ™ 
Double-emulsion 
method  
Successful 
encapsulation of 
peptides 
Traces of organic 
solvents 
Various 
formulation & 
process variables 
significantly affect 
encapsulation & 
release 
RISPERDAL® CONSTA® 
Vivitrol® 
Lupron Depot® 
Enantone Depot® 
Trenantone® 
Enantone Gyn 
 
 
4.1.2 Polycaprolactone   
Polycaprolactone (PCL) is a biocompatible polymer with a slow biodegradation caused by its 
molecular weight dependent surface hydrophobicity and crystallinity (Dash & Konkimalla, 2012). 
Polycaprolactone has a glass transition temperature of 60°C and melting point ranging between 59°C 
and 64°C, depending on its crystalline nature (Barbato, La Rotonda, Maglio, Palumbo, & Quaglia, 
2001; Sinha, Bansal, Kaushik, Kumria, & Trehan, 2004). PCL is a bioerodible polymer that undergoes 
type III erosion, which means that it leads to the formation of small, soluble molecules, by cleavage 
of the polymeric chains. There are 2 distinct phases, namely non-enzymatic cleavage and enzymatic 
fragmentation (Chen, Bei, & Wang, 2000; Jenkins & Harrison, 2006; Sinha, et al., 2004). In PCL 
formulations, the random nonenzymatic cleavage starts in the amorphous region that is auto-
catalyzed by carbonyl end groups of fragmented polymeric chain and needs water to occur (Chen, et 
al., 2000; Sinha, et al., 2004). The internal fragmentation produces fragments of length depending on 
the initial molecular weight of polymer. The weight loss from the formulation starts when the length 
of PCL fragments produced becomes small enough (below 5000) to be diffused through the 
polymeric matrix to the media at a much later stage (4–6 months) of PCL degradation. This bulk 
process is generally accompanied by enzymatic surface erosion characterized by grooves and cracks 
on the surface. Hydrolysis of ester bonds in the PCL matrix leads to break down to their constituent 
monomer, the ε-hydroxycaproic acid that then undergoes phagocytosis (Merkli, Tabatabay, Gurny, & 
Heller, 1998). 
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The compatibility of PCL with a wide range of drugs enables uniform drug distribution in the polymer 
matrix and the slow degradation facilitates drug release up to several months (Hakkarainen & 
Albertsson, 2002; Sinha, et al., 2004). The physical, chemical and mechanical properties of PCL can 
be modified by co-polymerization which can help tailor a desired crystallinity, solubility and 
degradation pattern(Dash & Konkimalla, 2012). Poly (ethylene glycol) (PEG), which is hydrophilic, 
non-toxic and absent of antigenicity and immunogenicity is a candidate to be attached to PCL, 
forming PCL–PEG copolymers. The PCL-PEG copolymers have better hydrophilicity and shorter 
degradation times than PCL alone (Chen, et al., 2000; Huang, et al., 2004; Koenig & Huang, 1995; 
Moon, Lee, Han, & Byun, 2002). Many researchers have investigated thermosensitive triblock (TB) 
copolymers (A-B-A or B-A-B) composed of PLA/polycaprolactone (PCL)/PLGA blocks (A) and PEG 
block (B) for their applicability in the development of sustained delivery formulation (Ghalanbor et 
al., 2012; Kapoor et al., 2015; Lucke et al., 2002). In general, one may expect that increasing the 
content of the more rapidly degrading monomer would increase the release rate and this is often 
the case (S. Y. Lin, Chen, Teng, & Li, 2000; Shen, Kipper, Dziadul, Lim, & Narasimhan, 2002; 
Spenlehauer, Vert, Benoit, & Boddaert, 1989).  In this study, we have investigated PCL-PEG-PCL 
triblocks of two different molecular weights, namely PCL1k-PEG2k-PCL1k and PCL5k-PEG2k-PCL5k. 
PCL is widely used in the pharmaceutical and biomedical fields as a biomaterial (e.g., suture, 
osteosynthetic material, artificial skin, or support of cellular regeneration) or in extended-release 
drug delivery systems targeting specific tissues within the body because of its lack of toxicity 
(Hiljanen‐Vainio, Karjalainen, & Seppälä, 1996; Sinha, et al., 2004).The utilization of PCL in 
ophthalmology, especially for delivery through the intraocular route has been poorly explored. 
Beeley and co-workers (Beeley, et al., 2005) developed a subretinal drug delivery system made of 
PCL encapsulating triamcinolone acetonide as the drug. The developed device was implanted into 
the subretinal space of six rabbits. No complications were observed during the 4-week follow-up 
period showing that PCL is well tolerated by the retinal tissue and that the implant can provide 
sustained drug release for a period of at least 4 weeks. Silva-Cunha et al (Silva-Cunha, Fialho, Naud, 
& Behar-Cohen, 2009) investigated the in vivo release profile obtained from dexamethasone loaded 
PCL implants into the vitreous of pigmented rabbits. The study showed that the drug was released 
slowly for 25 weeks, possibly controlled by diffusion through the channels and pores. The release 
profile obtained showed long-term, well-controlled, stable release of dexamethasone in the vitreous 
humour with no significant peaks or valleys of drug release that could result in toxicity or no 
therapeutic effect. At 55 weeks, approximately 79% of dexamethasone was still present in the 
implants confirming the slow release of the drug and also the possibility of drug release for a period 
of 2 years. The use of PCL-PEG copolymers as drug delivery systems has been reviewed in detail by 
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Wei and co-workers (Wei, et al., 2009), including the delivery of biomacromolecules. In one study 
(Zhou, Deng, & Yang, 2003a), PCL-PEG microparticles containing human serum albumin were 
prepared by the double emulsion (water-in-oil-in water) method and it was found that the loading 
efficiency for PCL-PEG microparticles was higher compared with the PCL homopolymer. In another 
study (Erdemli, Usanmaz, Keskin, & Tezcaner, 2014), PEG-PCL-PEG microparticles were prepared by 
double emulsion-solvent evaporation method and their properties were compared with those of PCL 
microparticles. Immunoglobulin G (IgG) was loaded into the microparticles. PEG-PCL-PEG 
microparticles had higher encapsulation efficiency of ca. 74% compared to ca. 54% for PCL 
microparticles. In vitro cytotoxicity tests revealed that both PEG-PCL-PEG and PCL microparticles had 
no toxic effects on 3T3 fibroblastic cell line and fibroblast-like synoviocytes. 
 
4.2 Materials and methods 
4.2.1 Materials 
Somatostatin-14 of sequence Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (cyclic, 
MW=1638 Da) was purchased as an acetate salt from Polypeptide Laboratories (Sweden), with a 
peptide purity of 99.6%. 
FITC-DEAE-Dextran (MW= 3-5kDa) and Polyvinyl alcohol (87-90% hydrolyzed, mw 30-70 kDa) (PVA) 
were from Sigma-Aldrich (USA). Poly (ε−Caprolactone)-Polyethylene Glycol-Poly (ε−Caprolactone) of 
two different weights (PCL5k-PEG2k-PCL5k and PCL1k-PEG 2k-PCL1k) were from Polysciences (USA). 
Dichloromethane was from RCI Labscan (Thailand). Water purified with Milli-Q system (Merck, 
Millipore Australia) with a resistivity of 18.2 MΩ.cm (at 25°C) was used in the preparation of all 
reagents and experiments. Ethanol absolute was from Merck (Germany) and glacial acetic acid was 
from Fagron Pharmaceuticals (USA). 
4.2.2. Methods 
4.2.2.1 Optimization of polymer concentration and molecular weight 
The PCL1k-PEG 2k-PCL1k triblock polymer was chosen as the candidate for production of microparticles 
via the SAW technique as this is readily soluble in ethanol. Ideally, the polymer and the drug would 
be soluble in the same solvent for optimum results. Since somatostatin is soluble in ethanol but not 
in dichloromethane, we proceeded with the lower molecular weight triblock copolymer. The 
concentration of the polymer that could be used with the SAW technique was limited by the 
resulting viscosity of the polymer solution in ethanol. A series of polymer solutions (0.5% w/v, 1 % 
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w/v, 2% w/v) were prepared and nebulised on the hydra device. It was found that 1% w/v of the 
PCL1k-PEG 2k-PCL1k dissolved in ethanol could be nebulised easily and was selected as the 
concentration to proceed with. 
4.2.2.2 Production of microparticles loaded with FITC-DEAE-Dextran (model drug) 
4.2.2.2.1 Preparation of microparticles using SAW 
Polymer 1%w/v (PCL1k-PEG2k-PCL1k) and 0.5% w/v of FITC-DEAE-Dextran, (mw: 3-5kDa) were 
dissolved in 50% ethanol and 50% of Milli-Q water (0.6mL in total). The solution was vortexed. A 
volume of 0.1 mL of the solution was nebulised into a glass bottle using a hydra device at a 
frequency of 14.4 Mhz and an amplitude of 110 mV on an Agilent N9310A RF Signal Generator. Each 
bottle was immediately wrapped in aluminium foil. 
4.2.2.2.2 Preparation of microparticles using water-in-oil-in-water (w/o/w) double emulsion method  
Briefly, an aqueous solution of FITC-DEAE-Dextran and sodium chloride was prepared. The required 
amount of high molecular weight (PCL5K-PEG2K-PCL5K) polymer or low molecular weight (PCL1K-PEG2K-
PCL1K) polymer was weighed and then dissolved in dichloromethane (DCM) forming the oil phase. 
The primary emulsion was formed through probe sonication (QSONICA LLC, United States) at three 
different time intervals (2, 4 and 8 seconds), with an amplitude of 35%. The external aqueous phase 
consisted of a 1% w/w PVA and 5% w/w NaCl in Milli-Q water which was added to the primary 
emulsion in separate quantities up to 7.1 mL. The mixture was then magnetically stirred at high 
speed for 3 hours in a fume hood to allow the evaporation of the organic solvent. The remaining 
microparticles were then wrapped in aluminium foil to protect them from light and stored at 4°C for 
further analysis. 
  
4.2.2.3 Determination of encapsulation efficiency 
4.2.2.3.1 Encapsulation efficiency of microparticles loaded with FITC-DEAE-Dextran produced by 
SAW technique 
Glass bottles were rinsed out with 2 mL of Milli-Q water in small increments and the contents 
transferred to centrifuge tubes. The tubes were centrifuged at 4000 RPM for 10 minutes. The 
supernatant was removed and analysed in plate reader for fluorescence. 2 mL of Milli-Q water was 
added to each tube and vortexed to resuspend and wash the particles. The centrifugation was 
repeated twice more with the supernatant being removed for analysis after each wash.  A drop 
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containing the particles from each tube was placed on a glass slide to look under the fluorescence 
microscope and SEM. The particles were then dissolved in 0.5 mL ethanol and 0.5 mL SLF was added 
for the FITC-DEAE-dextran to preferentially partition into. The solution was vortexed. The aliquots of 
the solution were analysed using fluorescence spectrophotometer at excitation 485nm and emission 
at 538nm (Flexstation 3 Molecular Devices LLC, USA). 
4.2.2.3.2. Encapsulation efficiency of microparticles loaded with FITC-DEAE-Dextran produced by 
w/o/w double emulsion method 
The slurry obtained after 3 hours of high speed stirring was centrifuged at a speed of 4000 RPM for 
10 minutes. The resulting supernatant was then analysed using a fluorescence spectrophotometer 
(Flexstation 3 Molecular Devices LLC, USA) plate reader at excitation 485nm and emission 538nm to 
determine the amount of FITC-DEAE-Dextran that was not encapsulated. The microparticles were 
then resuspended in 2mL of the external aqueous phase and centrifuged again at 4000rpm for 10 
minutes. The supernatant was removed for analysis as Wash 1. This step was repeated once more to 
obtain Wash 2. Two washes were performed to remove any model drug adsorbed on the surface of 
the microparticles. 
Appropriate aliquots of the supernatant after each washing step were analysed in the 
abovementioned plate reader for fluorescence at excitation wavelength of 485nm and emission at 
538nm. Concentrations were determined with reference to calibration curves (R2 = 0.9952). 
4.2.2.4 Morphological analysis of microparticles 
Scanning electron microscopy was performed to analyse particle morphology. Briefly, dried 
microparticles were applied to carbon film positioned on an aluminium stub. Surface of particles on 
carbon film was sputter-coated for 60s with Au-Pd alloy followed by imaging with a scanning 
electron microscope (SEM, Tescan Vega). 
Fluorescence microscopy (Olympus BX60) was also used to visually confirm encapsulation of the 
model drug as well as the shape of the microparticles generated using the SAW technique.  
4.2.2.5 Sizing of microparticles 
The size distribution of the microparticles was determined using a wet dispersion technique in a 
Mastersizer 3000 (Malvern Instruments, United Kingdom). The sizing was performed at room 
temperature (22°C) at a 1.46 refractive index of PCL-PEG- PCL and an absorbance index of 0.01 nm.  
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4.2.2.6 Production of somatostatin-loaded polymer microparticles  
The double emulsion (w/o/w) method as previously described (Section 4.2.2.2.2) was followed to 
encapsulate somatostatin in the microparticles as this method provided high encapsulation of model 
drug in comparison to the SAW technique. Somatostatin 2.5 % w/v and 5% w/v were investigated.  
The high molecular weight polymer, PCL5K-PEG2K-PCL5K was investigated at 2 % w/v and 5 % w/v 
concentrations. 
4.2.2.7 Release studies 
In vitro release profiles of somatostatin were conducted by adding 3 mL of SLF to the microparticles 
and placed in a shaking water bath (Paton industries, Australia) at 37 ℃. Two mL of the SLF was 
removed for analysis at each time point with replacement of an equal volume of fresh SLF to 
maintain sink conditions. Analysis of the amount of somatostatin released was performed using the 
validated HPLC method described in Chapter 2. Calculations were performed with respect to the 
area under the curve of a known standard concentration (0.25 mg/ml of somatostatin dissolved in 
0.1% v/v glacial acetic acid in Milli-Q water) assayed on the same day. 
4.3 Results and Discussion 
4.3.1. Encapsulation efficiency of FITC-DEAE-Dextran in microparticles prepared by SAW technique 
Fluorescein isothiocyanate–dextran-DEAE (FITC-dextran-DEAE) was used as a model drug due to a 
similar molecular weight and cationic charge to somatostatin. It was used in place of somatostatin in 
preliminary work to identify the most appropriate sonication time, polymer molecular weight and 
polymer concentration required to produce microparticles with the highest drug encapsulation 
efficiency. Table 4.2 below provides a comparison between somatostatin and FITC-DEAE-Dextran. 
Table 4.2: Comparison of properties between somatostatin and FITC-DEAE-Dextran 
Properties FITC-DEAE-Dextran Somatostatin 
Molecular weight (Da) 3000-5000 1638 
Aqueous solubility >25mg/mL >70mg/mL 
Charge at pH 7.4 +2 +2 
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Table 4.3: Encapsulation efficiency of FITC-DEAE-Dextran in microparticles prepared by SAW 
technique analysing the amount of drug remaining in buffer (sample replicates are defined as S1, S2 
and S3 respectively) 
Wash # S=1 
% of drug not 
encapsulated (w/v) 
S=2 
% of drug not 
encapsulated (w/v) 
S=3 
% of drug not 
encapsulated (w/v) 
Pre-wash 8.85% 7.95% 5.70% 
1 0.11% 0.048% 0.132% 
2 0.005% 0.004% 0.008% 
 
Table 4.4: Encapsulation efficiency of FITC-DEAE-Dextran in microparticles prepared by SAW 
technique from dissolved microparticles 
Wash # Average % of drug encapsulated (w/v) 
(n=3) 
1 0.322% 
2 0.035% 
3 0.028% 
 
Based on the data above (Table 4.3), approximately 6% - 9% of the FITC-Dextran-DEAE was detected 
in the washing steps. That would mean that there should be approximately 94% of the model drug 
should be encapsulated. However, upon dissolution of the microparticles, it was revealed that only 
0.03% of the drug is actually encapsulated after 3 washes (Table 4.4). In this instance, the polymer-
drug solution was manually deposited in volumes of 10 µL at a time on the SAW device until the 
entire 100 µL was nebulised. The set-up was not enclosed which resulted in loss of the nebulised 
drug and polymer to the environment and may explain the poor encapsulation efficiencies in our 
results.  
4.3.2 Encapsulation efficiency of microparticles produced by double emulsion (w/o/w) method 
The optimisation and characterisation of microparticle preparation was conducted in two phases. As 
shown in Table 4.5, the highest encapsulation efficiency (ca. 65%) was achieved with 5% of the HMW 
polymer when the sample was sonicated for 2 seconds. The HMW 5% sample sonicated for 2 
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seconds and the HMW 2% samples also produced relatively high encapsulation efficiencies. The 
LMW samples generally produced no encapsulation. A possible reason for this could be the similar 
molecular weights of FITC-DEAE-Dextran (3000-5000 Da) and the LMW polymer (4000 Da). Due to 
the lack of favourable encapsulation efficiencies with the LMW samples, their size was not 
characterized. The size of the microparticles produced by the HMW polymer at different sonication 
times has been provided below in Table 4.5. 
Table 4.5: Encapsulation efficiency and particle size of FITC-DEAE-Dextran in microparticles prepared 
by w/o/w method 
Polymer 
Concentration (% 
w/v) 
Sonication Time 
(seconds) 
Encapsulation 
Efficiency (%) 
 
Average Particle 
Size (µm) 
LMW HMW LMW HMW 
1% 2 0 57.0 - - 
4 0 55.8 - 22.6 
8 0 53.7 - 63.7 
2% 2 NA 56.6 - 27.9 
4 NA 61.5 - 26.5 
8 NA 64.8 - 62.9 
5% 2 NA 64.9 - 50.1 
4 NA 56.7 - 51.4 
8 NA 50.0 - 47.0 
 
4.3.3 Morphological analysis of microparticles with FITC-DEAE-Dextran using SAW technique 
Figure 4.4 demonstrates the formation of polydisperse polymer-drug conjugates from the SAW 
technique that do not resemble microparticles. This may be due to the nebulized droplets impacting 
on the surface of the collection vessel i.e. the glass bottle before getting a chance to dry and form 
completely. In the work done by Alvarez et al (Alvarez, Yeo, Friend, & Jamriska, 2009), the set-up 
included a drying tube with a trajectory length of 50cm. In our case, the SAW device had to be 
inserted into the glass collection bottle as far in as possible to prevent loss to the atmosphere. 
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Figure 4.4: Images under fluorescence microscope after first centrifugation (A-pre-wash), (B- wash 
#1) and (C-wash #2) from left to right respectively. Scale bars for A, B and C- 18 µm. 
          
4.3.4 Morphological analysis of microparticles produced by double emulsion (w/o/w) method 
 
 
 
 
 
 
 
Figure 4.5: Scanning electron micrographs of HMW 1% polymer microparticles. Sonication times - A- 
4 seconds, B- 8 seconds and C- 10 seconds. Scale bars for A, B and C- 20 µm. 
 
A B C 
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Figure 4.6: Scanning electron micrographs of HMW 2% polymer microparticles. Sonication times –  
A- 2 seconds, B- 4 seconds and C- 8 seconds. Scale bars for A and C- 100 µm, B – 50 µm. 
 
Figure 4.7: Scanning electron micrographs of HMW 5% polymer microparticles. Sonication times –  
A- 2 seconds, B- 4 seconds and C- 8 seconds. Scale bars for A and C- 10 µm, B – 20 µm. 
The microparticles prepared using the double-emulsion method (Figures 4.5-4.7) are better formed 
morphologically and more spherical in appearance.  However, a longer sonication time of 8 seconds 
reveals more of the polymer being present in a “mesh” compared to the samples subjected to 
shorter sonication times. Although the encapsulation efficiencies were not significantly different, the 
SEM images reveal more discrete microparticles formed in the 4 second sonication duration 
compared to samples from 8 seconds of sonication, particularly in Figures 4.5A and 4.6B. Figure 4.5C 
illustrates that 10 seconds of sonication results in a tangled network of polymer rather than discrete 
microparticles. This is likely to be due to more heat generated with a longer duration of sonication, 
leading to change in the morphology of the microparticles. In the case of Figure 4.7 (high molecular 
weight polymer 5%), the microparticles are better formed at 2 seconds sonication (Figure 4.7A) 
compared to 4 seconds (Figure 4.7B) and 8 seconds (Figure 4.7C). However, the average size of the 
HMW 5% microparticles was 50.1µm which was larger than HMW 2% microparticles with an average 
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size of 26.5µm. Comparing to other microparticles administered periocularly (R. Herrero-Vanrell, et 
al., 2014) with particle sizes of about 30 µm, the latter particle size is preferable. For this reason, 
HMW 2% with a sonication time of 4 seconds was selected as the candidate for somatostatin 
encapsulation, with Figure 4.6B demonstrating the formation of discrete microparticles with a mean 
size of 26.5µm (sized by laser diffraction analysis). 
 
4.3.5 Encapsulation efficiency of SST microparticles prepared with double emulsion (w/o/w) method  
HMW polymer at 2% w/w and 5% w/w with a sonication time of 4 seconds was investigated with SST 
2.5% and 5% w/w. There were a number of strategies employed in an attempt to improve the 
encapsulation efficiency. Both the drug and the polymer were tested at 2 different concentrations to 
see if increasing the concentration of either drug or polymer would improve the percentage 
encapsulated. It was found that SST 5% w/w produced a very low encapsulation of 4.3%. The SST 
solution transitioned from a solution to gel rapidly after dissolution in water and the gel was not 
adequately dispersed by the probe sonication or high speed mixing. Based on the work done by 
Hermann et al (Herrmann & Bodmeier, 1998), SST was dissolved in acetate buffer instead of Milli-Q 
water in the dissolution step. This did not result in a significant improvement in the encapsulation 
efficiency. Based on preliminary work done with SST in combination with HPMC, it was hypothesized 
that the positive charges on SST may be shielded by HPMC in solution and therefore may improve 
encapsulation of the hydrophilic SST into the hydrophobic triblock co-polymer. This also yielded a 
negative result with no encapsulation produced. This information is summarised in the table below 
(Table 4.4). Based on the encapsulation efficiency, SST 2.5% w/w in HMW polymer 2% w/w 
microparticles were manufactured for release studies and further characterization.  
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Table 4.6: Encapsulation efficiency of different concentrations of somatostatin and HMW polymer 
using w/o/w method  
Concentration of SST (% w/w) Concentration of HMW 
polymer (% w/w) 
Encapsulation efficiency 
2.5% 2% 43.4% 
2.5% 5% 19.7% 
2.5% (dissolved in acetate 
buffer) 
2% 21.1% 
2.5% (dissolved in HPMC 0.5% 
solution) 
2% 0% 
5% 2% 4.31% 
 
Table 4.7: Encapsulation efficiency of SST 2.5% HMW polymer 2% (n=3) using w/o/w method  
Sample Encapsulation efficiency  Mean ± SD 
1 43.4% 29.8 ± 12.2  
2 26.6% 
3 19.6% 
 
The data in Table 4.5 shows that the method of production of the microparticles produces 
encapsulation efficiencies with a large standard deviation. This could be due to the very small 
volumes that are being investigated where a small variation in a particular condition (e.g. the 
position of the probe during sonication) can lead to a large effect on the final amount encapsulated. 
The probe sonicator was not fixed in place and had to be set up manually for each sonication. For 
each sample sonicated, the tilt of the probe and the depth of the probe into the sample would vary 
despite best attempts at consistency.  The high encapsulation achieved in Sample 1 indicates that a 
good encapsulation with this method is achievable providing that conditions are kept favourable and 
scale-up for industrial manufacture is also possible. 
Vaishya et al (Vaishya, Mandal, Patel, & Mitra, 2015) investigated the encapsulation of octreotide in 
PCL-PEG-PCL triblocks (PCL10k-PEG2k-PCL10k ) amongst other polymers. The purpose was to determine 
the effect of polymer type on the release kinetics and acylation of octreotide. The method of 
microparticle production was the double-emulsion method. The encapsulation efficiency achieved 
was 45% with a complete release of octreotide over 3 months.  In the work done by Vaishya and co-
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workers, triethyl amine (TEA) was used to make the octreotide hydrophobic by adjusting the pH and 
it was dissolved in methanol to keep it in solution.  
The encapsulation of FITC-DEAE-Dextran was improved by using sodium chloride in the aqueous 
solution. The chloride ions shielded the positive charges on the model drug and allowed more of it to 
be entrapped within the hydrophobic polymer matrix. However, this approach did not work with 
somatostatin due to its propensity to self-associate and transition into a gel in the presence of 
electrolytes. As discussed earlier, the somatostatin solution with sodium chloride gelled quickly and 
could not be dispersed by probe sonication process or high-speed mixing. Acetate buffer, which is 
weaker electrolyte solution, was then investigated. The results in Table 4.4 show there was no 
significant improvement in the encapsulation efficiency. Another option was to adjust the pH of the 
solution to the isoelectric point (pI) of somatostatin. The calculated pI of somatostatin is 8.3 (W. van 
Grondelle, et al., 2007). However, increasing the pH to 8.3 accelerates the degradation of 
somatostatin (Herrmann & Bodmeier, 2003) and the effect on the native structure is unknown.   
Herrmann et al (Herrmann & Bodmeier, 1998) formulated microparticles of somatostatin in PLGA 
and PLA using various modifications of the oil-in-water solvent evaporation method. They achieved 
high encapsulation efficiencies of 63.7% to 84.4%. The theoretical drug loading was 2% w/w. The 
hydrophilic nature of PLGA and PLA may have contributed to the better entrapment of somatostatin 
within the polymer. Somatostatin analogues currently on the market, for example Sandostatin LAR®, 
Signifor LAR® and Somatuline LA®, are all microspheres prepared with PLGA as the polymer matrix. 
However, PCL-PEG-PCL was picked as the polymer candidate for this study due to a possible longer 
degradation time than PLGA and the fact that it does not acidify the microenvironment as it 
degrades. PLGA degrades into lactic and glycolic acids resulting in the acylation of the drug 
(Ghassemi, et al., 2012) as well as acidification of the area of administration which may cause 
inflammation. This is an undesirable effect in diabetic retinopathy, where inflammatory mediators 
contribute to deterioration (X. Zhang, Wang, Barile, Bao, & Gillies, 2013).     
4.3.6 Release studies  
4.3.6.1 Release of FITC-DEAE-Dextran (model drug) from microparticles prepared with SAW 
technique 
Release studies were conducted on the microparticles with LMW polymer 1% w/w and FITC-DEAE-
Dextran 0.5% w/w. Although the encapsulation efficiency was very low as discussed above, the 
release studies were conducted to investigate the release profile. The release studies were 
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conducted as described above with the additional protection of the microparticles from light by 
wrapping the centrifuge tubes in aluminium foil.  
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Figure 4.8a:  Cumulative percentage release of FITC-DEAE-Dextran 0.5% w/w from LMW polymer 1% 
w/w microparticles with SAW technique (n=3; error bars = SD) 
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Figure 4.8b:  Cumulative percentage release of FITC-DEAE-Dextran 0.5% w/w from LMW polymer 1% 
w/w microparticles with SAW technique fitted to equation 4.1. 
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The study revealed a very low percentage release- ca. 3% cumulative release at day 7. The 
experiment was concluded at day 7 as fluorescence was undetectable after that. 
Due to the poor results of the encapsulation and release study, this technique was not further 
investigated as a possible candidate for formulation of SST microparticles. 
In comparison to our results, Alvarez et al (Alvarez, et al., 2008) demonstrated the encapsulation of 
BSA (molecular weight of 66 kDa) in PCL (molecular weight 65 kDa). The microparticles produced 
were in the order of 10µm in size and the encapsulated protein survived the process with a yield of 
55%. Confocal microscopy was used to visually confirm the uniform distribution of the fluorescent-
conjugated protein within the polymer shell. Although they did not investigate the release kinetics of 
the encapsulated BSA from the microparticles, ELISA was used to assess if the native conformation 
of BSA was preserved by dissolving the microparticles. The encapsulation efficiency was not 
reported. 
There are a number of possible reasons that the SAW technique did not work well in our endeavours 
to encapsulate somatostatin and FITC-DEAE-Dextran. The set-up used by Alvarez and co-workers was 
sophisticated and involved 2 separate syringes containing the polymer dissolved in an organic 
solvent and protein in aqueous solution respectively. The mixture was dispensed onto the SAW 
devices at a fixed flow rate and the nebulized mist was passed through a drying tube before being 
collected at the end. 
In this instance, the polymer-drug solution was manually deposited in volumes of 10 µL at a time on 
the SAW device until the entire 100 µL was nebulised. The set-up was not enclosed which resulted in 
loss of the nebulised drug and polymer to the environment and may explain the poor encapsulation 
efficiencies in our results. The bottle for collection of the microparticles generated was held at close 
proximity. This does not allow sufficient drying time for the microparticles but was necessary to 
minimise loss to the environment. We were limited to using the same solvent for drug and polymer 
which excluded investigation of the high molecular weight polymer. In the case of somatostatin, 
there was a visible thick deposit of the peptide on the SAW device during the nebulisation of the 
polymer-peptide solution which resulted in a failure of efficient encapsulation. The images from 
fluorescence microscopy show polydisperse polymer-drug conjugates (Figure 4.4).  
It is possible that results may be improved with the use of an enclosed experimental set-up that 
minimises loss to the environment and an automatic dispensing device that would make the process 
more efficient. Given that the molecular weight of somatostatin is a fraction of that of BSA and both 
exhibit a net positive molecular charge, these factors should not adversely affect encapsulation. The 
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set-up would also have permitted experiments with the higher molecular weight polymer to enable 
comparison with the current results. The combination of poor results and the interests of time and 
economy with regards to the amount of somatostatin expended led to this technique not being 
further explored. 
4.3.6.2 Release of SST from microparticles prepared by double emulsion (w/o/w) method  
SST 2.5% w/w HMW polymer 2% w/w microparticles were tested for release. The method used was 
as previously described (Section 4.2.2.7). HPLC was used to quantify the amount of somatostatin 
released as per the method described in Chapter 2. 
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Figure 4.9a: Cumulative percentage release of somatostatin 2.5% w/w from HMW polymer 5% w/w 
(n=3) 
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Figure 4.9b: Cumulative percentage release of somatostatin 2.5% w/w from HMW polymer 5% w/w 
(n=3) modelled to equation 4.1. 
The results above show us that the sample (S=1) with the highest percentage of somatostatin 
encapsulated produced the longest duration of release for 24 days but the lowest cumulative release 
at about 1.4%. The highest cumulative percentage of somatostatin released was from sample S=2 at 
about 4% for 18 days. Sample S=3 had a cumulative release of about 3.3% for 16 days. The sampling 
was stopped when no further released somatostatin was detected by the HPLC for 3 consecutive 
days. 
Fitting of the data from Figures 4.8 and 4.9 was done to the equation below (a first-exponential 
decay to plateau model) using GraphPad Prism (Version 7.02) curve-fitting software.   
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = 𝐴 (1 − 𝑒−𝑘𝑡)                                                             equation 4.1  
where A = cumulative percentage released at infinite times 
k = first-order release rate constant   
t = time 
and t1/2 = ln 2/k 
The tables below report the goodness of the fit (R2) of the above model to the individual samples as 
well as the t1/2 (time to release 50% of SST from the microparticles) and k (the rate constant). 
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Table 4.8: Mean R2, t1/2 and rate constant values with standard deviation for FITC-DEAE-Dextran 0.5% 
w/w release from LMW 1% w/w polymer microparticles. 
Sample R2 Mean R2± 
SD 
t1/2 (hours) Mean t1/2 ± 
SD 
k Mean k ± 
SD 
S=1 0.957 0.957 ± 
0.006 
3.98 3.74 ± 
0.641 
0.174 0.189 ± 
0.035 S=2 0.951 4.23 0.164 
S=3 0.963 3.01 0.229 
 
Table 4.9: Mean R2, t1/2 and rate constant values with standard deviation for SST 2.5% w/w release 
from HMW 2% w/w polymer microparticles. 
Sample R2 Mean R2± SD t1/2 (hours) Mean t1/2 ± 
SD 
k Mean k ± 
SD 
S=1 0.975 
 
0.979 ± 0.004 
 
20.8 26.4 ±4.81 0.033 
 
0.027 ± 
0.006 
S=2 0.978 
 
29.1 0.024 
S=3 0.983 
 
29.2 0.024 
 
In general, the drug release from a modified release system such as microparticles can be controlled 
by various mechanisms, such as dissolution, diffusion, partitioning, osmosis, swelling, and erosion. 
Diffusion of the drug is dependent on the structure through which the diffusion takes place, and 
polymer morphology has to be considered (Langer & Peppas, 1983a). A hydrophilic drug 
incorporated in a matrix can be released easily by diffusion compared to a hydrophobic or less 
water-soluble drug. Hydrophobic drug release is dependent on polymer swelling and/or matrix 
erosion. The same active agent, when incorporated in a polymeric matrix, can present different 
behaviours due to differences in solubility and participation of the different processes outlined 
above (Agnes, 2003). 
The mechanism of PCL biodegradation has been discussed above. Hydrophilic drugs like 
somatostatin tend to accumulate at the interface of the microparticles during the formulation 
processes and are released by desorption at the initial period of release (Dash & Konkimalla, 2012). 
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This results in a biphasic pattern of release where the initial burst release is much higher than for 
lipophilic drugs. This can be seen from the release profile of the drugs in Figures 4.8 and 4.9 where 
there is a higher percentage released initially which then slows to lower rate of release.  
In comparison, Sandostatin LAR® exhibited a concentration-time profile with a limited initial burst 
release of octreotide, an erosion phase from weeks 3-5, and a slowly declining concentration to day 
52 (Petersen, Bizec, Schuetz, & Delporte, 2011). This is a once-monthly formulation that is 
administered intramuscularly. Somatuline LA® which contains PLGA microparticles of biodegradable 
polymer containing lanreotide exhibits drug release in a biphasic pattern, that is, an early release of 
the peptide localized at the surface of the copolymer during the first 2 days after administration, 
followed by sustained release of lanreotide for about 1 week, starting at day 4, as a result of 
enzymatic breakdown of the microspheres, and then followed by an exponential decrease in drug 
release over the course of 14 days(Roelfsema, et al., 2008). 
4.4 Conclusion 
Based on the results from our work, the following conclusions can be drawn. Firstly, only the low 
molecular weight polymer (PCL1K-PEG2K-PCL1K) was suitable for use with the SAW technique. This is 
due to the requirement that both the peptide and polymer had to be soluble in the same solvent 
(ethanol). The high molecular weight polymer (PCL5K-PEG2K-PCL5K) could not be used because it 
would not dissolve in ethanol and somatostatin is not soluble in dichloromethane. Hence the 
suitability of use for that particular triblock copolymer (PCL5K-PEG2K-PCL5K) for the SAW technique 
could not be evaluated. It must be mentioned that Alvarez et al (Alvarez, et al., 2009) have 
demonstrated encapsulation of BSA in PCL (molecular weight 65 kDA) with 54% of the BSA surviving 
the atomization process. The low molecular weight polymer (PCL1K-PEG2K-PCL1K) encapsulated a 
negligible amount of FITC-DEAE-Dextran using the SAW technique. Although we did not succeed 
with the triblock copolymers using the SAW technique, it does not mean it will not work with a more 
sophisticated set-up with an enclosed apparatus, long drying tube and an automatic dispensing 
system for the polymer-peptide solution/dispersion as demonstrated by Alvarez et al (Alvarez, et al., 
2009). The double-emulsion method worked better with the high molecular weight polymer 
compared to the low molecular weight polymer. As previously discussed in Section 4.3.1, the low 
molecular weight samples produced no encapsulation, possibly due to the similar molecular weights 
of FITC-DEAE-Dextran (3000-5000 Da) and the LMW polymer (4000 Da). The high molecular weight 
polymer produced good encapsulation efficiencies with the FITC-DEAE-Dextran ranging from 50% to 
ca. 65% at different polymer concentrations and sonication times (Table 4.5). However, with 
somatostatin, the encapsulation efficiency was lower and variable, ranging from 19%-43%. Vaishya 
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et al (Vaishya, et al., 2015) attempted the encapsulation of a synthetic somatostatin analogue-
octreotide in a PCL10k-PEG2k-PCL10k triblock copolymer using the same double-emulsion method. An 
encapsulation efficiency of 45% was achieved with this triblock polymer and the release studies 
demonstrated complete release of octreotide over 3 months. In their case, they were able to 
increase the hydrophobicity of octreotide using TEA, thus achieving a higher encapsulation 
efficiency. It cannot be assumed that the molecular weight of their chosen triblock copolymer 
affected the encapsulation efficiency since they did not compare to another triblock with a different 
molecular weight although the degradation times are indeed affected by polymer molecular weight 
(Makadia & Siegel, 2011). While we attempted the use of counter-ions to shield the positive charges 
on somatostatin, the propensity of self-assembly proved to be a drawback. The calculated pI of 
somatostatin is 8.3 (Wilmar Van Grondelle, et al., 2007) and adjusting the pH to 8.3 may affect the 
stability of the peptide. Based on the results of Herrmann and Bodmeier (Herrmann & Bodmeier, 
1998), triblock polymers of PLGA may yield better encapsulation efficiencies using the double-
emulsion method. We cannot predict if all triblock polymers will behave the same way without 
experimentation but it is reasonable to postulate that a hydrophilic peptide may be more easily 
entrapped in PLGA-PEG triblock polymers due to the higher hydrophilicity of that polymer 
combination. The triblock polymer chosen in our study was selected based on work by Vaishya’s 
group encapsulating octreotide, a somatostatin analogue (Vaishya, et al., 2015). Wei, Qian and co-
workers (Wei, et al., 2009) have published a thorough review on the use of PCL-PEG copolymers as 
drug delivery vehicles. In terms of production by the double-emulsion method, different kinds of 
PCL-PEG microspheres containing human serum albumin (HSA) were successfully prepared (Zhou, 
Deng, & Yang, 2003b) and the experimental parameters of the methods were investigated 
(Zarnbaux, et al., 1998). Similarly, microspheres based on PCL–PEG copolymer containing bovine 
serum albumin were prepared by adopting double emulsion method (J.-H. Kim & Bae, 2004). Such 
PCL-PEG copolymers have also been studied for protein delivery, for example, human serum albumin 
(HSA) was encapsulated in PCL-PEG microparticles using the double emulsion method with higher 
encapsulation efficiencies than PCL. Anionic PCL-PEG nanoparticles were prepared by modified 
emulsion solvent evaporation method with human basic fibroblast growth factor (bFGF) adsorbed 
onto the surface of nanoparticles by electrostatic interaction. In vitro release studies indicated a 
controlled release of bFGF from PCL-PEG-bFGF complex. 
This study attempted the encapsulation of somatostatin in a PCL-PEG-PCL triblock polymer which 
has not been done before. A non-traditional technique using surface acoustic waves and a 
traditional double emulsion method were used. The results show that encapsulation and release of 
somatostatin is possible with the use of this triblock polymer, although low. The encapsulation 
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efficiency as well as the duration of release can be improved. Further work can be done to improve 
the amount of somatostatin entrapped by the polymer and that may also help to extend the 
duration of release. This was demonstrated by the sample 1 with SST 2.5% w/w and HMW polymer 
2% w/w. In addition Wei and group (Wei, et al., 2009) suggest that addition of lipases to release 
buffers for studies with PCL microparticles more closely simulate the in vivo milieu. In vitro 
degradation profiles of biodegradable polymers frequently do not sympathize with the data of in 
vivo degradation experiments due to the presence of enzymes (M. P. Wu, Tamada, Brem, & Langer, 
1994) and it has been reported that the in vivo degradation of PCL is significantly accelerated when 
in the presence of PCL-degrading enzymes, namely lipases, in the body (H. Sun, Mei, Song, Cui, & 
Wang, 2006). A study by Wu and co-workers (C. Wu, Jim, Gan, Zhao, & Wang, 2000) found that the 
presence of the microbial Pseudomonas lipase enhanced the degradation rate of PCL nanoparticles 
1000-fold compared with purely hydrolytic degradation. An investigation on the effect of PEG 
incorporation on the biodegradation characteristics of PCL demonstrated that (Li et al., 2002) in the 
presence of Pseudomonas lipase, enzymatic degradation of PCL was not altered by the incorporation 
of PEG for both diblock and triblock copolymers compared to a PCL homopolymer. Bei’s group, 
however, found that the degradation rate of PCL–PEG increased with increase in PEG content and in 
the presence of lipase (Bei, Li, Wang, Le, & Wang, 1998).The studies discussed provide 
considerations for future work, such as the addition of lipases to the release medium and difference 
in degradation times with higher PEG content. 
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CHAPTER 5 – INVESTIGATION OF THE EFFECTS OF SOMATOSTATIN ON THE EXPRESSION OF 
VEGF RECEPTOR-2 LEVELS AND VEGF SECRETION BY ARPE-19 CELLS IN HIGH GLUCOSE 
CONDITIONS  
5.1 Introduction 
The retinal pigment epithelium (RPE) plays a crucial role in retinal physiology and is responsible for 
the diffusion of nutrients to the retina from choroidal blood vessels by forming the blood–retinal 
barrier (BRB)(Luna, et al., 1997).  The RPE secretes various growth factors to maintain the 
extracellular environment of the photoreceptors (Sheedlo, Li, & Turner, 1992) and it is where the 
phagocytosis of outer segments of photoreceptors occurs (Bok, 1993). RPE cells also produce various 
cytokines (Adamis, et al., 1993; Rafael Simó, Villarroel, Corraliza, Hernández, & Garcia-Ramírez, 
2010) implicated in ocular diseases such as diabetic retinopathy,(Aiello, et al., 1994; Funatsu, 
Yamashita, Nakanishi, & Hori, 2002; Vogt, et al., 2006), choroidal neovascularization and diabetic 
macular edema (Funatsu, Yamashita, Ikeda, et al., 2002). Amongst the various growth factors and 
cytokines secreted by the RPE are vascular endothelial growth factor (VEGF), pigment epithelium-
derived growth factor (PEDF), fibroblast growth factor (FGF) and platelet derived growth factor 
(PDGF). Vascular endothelial growth factors (VEGF) comprise a family of mitogenic proteins 
consisting of multiple homologs (Rafael Simó, et al., 2014). The RPE is the main source of VEGF in the 
posterior eye and expresses diffusible isoforms of VEGF, namely VEGF165 and VEGF121 but not VEGF189 
which is the cell-associated form. VEGF165 is the predominant form and is found both circulating as 
well as bound to the cell and extracellular matrix. VEGF121 is freely soluble while VEGF189 and VEGF206 
are completely sequestered in the extracellular matrix (Rafael Simó, et al., 2014). 
RPE cells express both receptors VEGF-R1 and VEGF-R2 for VEGF (Kociok, et al., 1998). VEGF-R2 is 
expressed on the apical side of the RPE but the secretion of VEGF in response to high glucose or 
hypoxia is basal (Blaauwgeers, et al., 1999). This is thought to be directed towards the VEGF-R2 
receptors expressed by the endothelium of the choriocapillaris facing the RPE layer (Blaauwgeers, et 
al., 1999).  VEGF-R2 is mainly responsible for the mitogenic, angiogenic, and permeability-enhancing 
effects of VEGF(Ferrara, 2004). While there is some discussion about the VEGF-R2 possibly being 
autocrine in function (Klettner, Westhues, Lassen, Bartsch, & Roider, 2013), upregulation of VEGF-R2 
in early pre-clinical diabetic retinopathy was observed in streptozotocin-induced diabetic rats in 
ganglion cell layers, inner and outer nuclear layers as well as the RPE(Hammes, Lin, Bretzel, 
Brownlee, & Breier, 1998). There is increased expression of VEGF-R2 in human diabetic retinopathy 
correlated to the presence of leaky retinal vessels (Witmer, et al., 2002) which was linked to the 
effects of VEGF on vascular permeability (Schlingemann, Hofman, Vrensen, & Blaauwgeers, 1999). 
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VEGF produced by RPE cells has been implicated in the induction of choroidal neovascularization and 
macular degeneration (Grossniklaus, et al., 2002; Ohno‐Matsui, et al., 2001; Schwesinger, et al., 
2001). Increased VEGF expression has been noted to precede retinal proliferative changes in diabetic 
rats (Sone, et al., 1999). However, it should be noted that VEGF does have important constitutive 
functions in the healthy adult retina. VEGF is a survival factor for endothelial cells and important for 
the maintenance of the choroid (Gerber, et al., 1998; Saint-Geniez, Kurihara, Sekiyama, Maldonado, 
& D'Amore, 2009). Additionally, VEGF protects the RPE, Müller cells, photoreceptors, and retinal 
neurons from hypoxia-induced apoptosis via a direct trophic effect as well as through angiogenesis 
(Byeon, et al., 2010; K. M. Ford, Saint-Geniez, Walshe, Zahr, & D'Amore, 2011; Nishijima, et al., 2007; 
Saint-Geniez, et al., 2008), and may save axotomized ganglion cells from delayed cell death (Kilic, et 
al., 2006). 
ARPE-19 is a rapidly growing, spontaneously evolved human cell line which was purified by selective 
trypsinization of a primary RPE culture. ARPE-19, established by Dunn et al. (Dunn, Aotaki-Keen, 
Putkey, & Hjelmeland, 1996) retains many properties characteristic of RPE cells (Trevino, 
Schuschereba, Bowman, & Tsin, 2005) including defined cell borders, an overall ‘cobblestone’ 
appearance and noticeable pigmentation. The cell line  is widely used in cell biology and biochemical 
studies (Geiger, Waters, Kamp, & Glucksberg, 2005; R. K. Sharma, Orr, Schmitt, & Johnson, 2005). 
Lynn and co-workers (Lynn, et al., 2017) investigated if the secretion of VEGF-A was comparable to 
those from primary RPE cells isolated from human donors. Their study showed that ARPE-19 
monolayers secreted VEGF at levels comparable to VEGF levels secreted by the primary RPE cells 
(Blaauwgeers, et al., 1999). ARPE-19 cells have been used as in vitro models to study the effects of 
high glucose in diabetes in a number of studies which have been thoroughly discussed by Szabadfi 
and co-workers (Szabadfi, Pinter, Reglodi, & Gabriel, 2014). 
The physiological role of somatostatin in the retina and possible beneficial effects in diabetic 
retinopathy have been discussed at length in Chapter 1. Expression of SSTR1 and SSTR2 in RPE cells, 
both in vitro and in vivo, have been demonstrated (Katz, Klisovic, O'Dorisio, Lynch, & Lubow, 2002; 
Klisovic, et al., 2001). Somatostatin is produced in the human retina (van Hagen, et al., 2000) along 
with expression of its receptors, with SSTR1 and SSTR2 being the most widely expressed (Cervia, 
Casini, & Bagnoli, 2008b; Klisovic, et al., 2001; Lambooij, et al., 2000). It has been postulated that 
somatostatin acts through its receptors to downregulate VEGF secretion in human RPE cells, 
amongst other effects (Sall, Klisovic, O'Dorisio, & Katz, 2004), hence, ARPE-19 cells were chosen for 
this study. In this chapter, we investigate the possible effects on cell viability of somatostatin in 
solution, released somatostatin from the SST 5% w/w in HPMC 6% w/w hydrogels as well as blank 
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HPMC using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT )-based cell 
viability assay. The effect of somatostatin on VEGF-R2 expression by ARPE-19 cells in both high and 
normal glucose conditions is investigated. The amount of VEGF secreted by the ARPE-19 cells in the 
same conditions is quantified with an Enzyme‐Linked Immunosorbent Assay in the presence of 
somatostatin in solution as well as somatostatin released at 24 hours (Release Day 1) and 10 days 
(Release Day 10) from the SST 5% w/w in HPMC 6% w/w hydrogels.   
5.2 Materials and Methods 
5.2.1 Culture of ARPE-19 cells 
ARPE-19 was obtained from American Type Culture Collection (Manassas, VA) and cultured under 
conditions as  described by a number of studies (M. Villarroel, Garcia-Ramírez, Corraliza, Hernández, 
& Simó, 2011; Marta Villarroel, García-Ramírez, Corraliza, Hernández, & Simó, 2009).The cells were 
cultured under normoglycemic (5.5 mmol/L D-glucose) or hyperglycemic (25 mmol/L D-glucose) 
conditions at 37°C under 5% (v/v) CO2 in Dulbecco's Modified Eagle Medium (DMEM)(Thermo Fisher 
Scientific, Life Technologies Australia) supplemented with 10% (v/v) fetal bovine serum (FBS)(Gibco, 
Life Technologies Australia) and penicillin/streptomycin/glutamine (Gibco, Life Technologies 
Australia). ARPE-19 cells between passages 10- 20 were used and the media was changed every third 
day.  
5.2.2 MTT cell viability assay 
The effects on cell viability of 10 -7 M and 10 -6 M somatostatin, Release Day 1 and Release Day 10 
samples from SST 5% w/w in HPMC 6% w/w hydrogels and blank HPMC 6% w/w hydrogels was 
assessed in ARPE-19 cells using the In Vitro Toxicology Assay Kit; MTT based (Sigma-Aldrich, St Louis, 
MO) as per the manufacturer’s instructions. ARPE-19 cells seeded onto 96-well plates (Corning, USA) 
at a density of 104 cells per well were allowed to grow for 3 days. After serum starvation for 24h, 
cells were exposed to samples as above and incubated for 24 hours. Background control wells 
without cells contained 50 µL 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) 
reagent and 50 µL of cell culture media. After treatment with 50 µL of MTT reagent and 50 µL of cell 
culture media for 3 hours at 37 °C, 150 µL MTT solubilization solution was added to each well. Levels 
of formazan reaction product were determined by measuring the absorbance at 570 nm in a plate 
reader (Clariostar, BMG Labtech, Germany). 
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5.2.3 Immunofluorescence studies of VEGF-R2 expression 
The ARPE-19 cells were seeded in 12-well plates (Corning, USA) at a density of 104 cells per well. 
They were serum-deprived for 24 hours before stimulation with glucose for experiments. The 
confluent cells exposed to different concentrations of glucose (normal glucose [NG, 5 mM] or high 
glucose [HG, 25mM] in the presence or absence of somatostatin at 10-5 M to 10 -8 M for 24 hours and 
72 hours. The experiment was performed in triplicate for 10 -7 M and 10 -6 M somatostatin 
concentrations at 72 hours. The cells were fixed with methanol (which had been stored at -20°C 
prior to use) for 15 minutes at room temperature. The methanol was decanted and the wells were 
washed twice with ice-cold PBS. The cells were then incubated with 1% bovine serum albumin (BSA) 
(Sigma Aldrich, St Louis, MO) in PBS for 30 minutes at room temperature. This was done to block 
non-specific binding of the primary antibody. The 1% BSA solution was decanted and the wells rinsed 
with PBS. A rabbit polyclonal antibody to VEGF receptor 2 (ab2349) (Abcam, UK) was applied at a 
1/100 dilution to all wells except the negative controls. The cells were incubated with the primary 
antibody overnight at 4°C. The next morning, cells were washed thrice with ice-cold PBS. The 
secondary antibody, a goat polyclonal secondary antibody to rabbit IgG - H&L (Alexa Fluor® 488) 
(ab150077) (Abcam, UK) was applied to all the wells at a 1/500 dilution. The plates were incubated 
in the dark for one hour at room temperature. Both primary and secondary antibodies were diluted 
in 1% BSA in PBS. The cells were washed thrice again in ice-cold PBS for 15 minutes in the dark. The 
last step was the application of DAPI (4′, 6-Diamidino-2-phenylindole dihydrochloride) (Sigma-
Aldrich, St Louis, MO) at a concentration of 1 µg/mL into each well for the visualization of cell nuclei. 
The wells were then visualized using Nikon Eclipse Ti-E (inverted) confocal microscope (Nikon 
Instruments, Japan). The emission (bandwidth) for FITC ranged from 496 to 535 nm. The images 
were then analysed using the NIS-Elements Analysis Software (Nikon Instruments, Japan). Analysis of 
each image was done the same way by doing a count for the number of fluorescent objects. The 
background fluorescence was subtracted using the software and the “clean, smooth and separate” 
features were used for picking up distinct fluorescent spots. Restrictions for area and circularity were 
applied as well as using the same range for fluorescence intensity for all images analysed. The object 
count thus obtained for each image was then recorded and the mean calculated from the triplicate 
of wells. 
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5.2.4 Quantification of VEGF secretion by ELISA 
ARPE-19 cells were seeded on a 12-well plate (Corning, USA) and allowed to reach near confluence. 
The cells were grown in conditions as described above in HG and NG, as well as in the presence of 
somatostatin at 10-5 M to 10 -8 M for 72 hours, with triplicate wells for each condition. The study was 
repeated with Release Day 1 and Day 10 samples from SST 5% w/w in HPMC 6% w/w hydrogels and 
10 -7 M and 10 -6 M somatostatin with 24 hour incubation. The cell culture medium was collected and 
centrifuged at 1400 RPM for 1 minute to remove any debris. The resulting supernatant was used for 
the estimation of VEGF by solid‐phase sandwich Enzyme‐Linked Immunosorbent Assay (ELISA) 
(Invitrogen, Life Technologies, USA) according to the manufacturer’s protocol. This kit recognizes 
human VEGF165 and VEGF121 isoforms. At the end of the protocol, a plate reader (Clariostar, BMG 
Labtech, Germany) was used to read the absorbance of the wells at of 450 nm. 
 
5.2.5 Statistical analysis 
Results were subjected to statistical analysis with ANOVA (GraphPad Prism version 7.02, GraphPad 
Software, San Diego California USA), followed by post hoc analysis according to Dunett or Neuman-
Keuls and p < 0.05 was considered statistically significant. 
5.3 Results and Discussion 
5.3.1 MTT cytotoxicity assay 
The results of the MTT assay (Figure 5.1) were analysed using one-way ANOVA with multiple 
comparisons test. In both high and normal glucose conditions, only release Day 1 samples caused 
significantly more cytotoxicity (65% and 62% respectively) compared to control (p < 0.005). Release 
day 1 samples also caused more VEGF to be released in the ELISA assay as discussed in section 5.3.3. 
It was observed during the course of the release studies that when sampling the release buffer 
above the somatostatin 5% w/w in HPMC hydrogels at 24 hours, the sample withdrawn was of 
thicker consistency and more difficult to withdraw than that of simulated lachrymal fluid alone. The 
release Day 1 samples were very viscous when sampled from above the SST 5% w/w in HPMC 6% 
w/w hydrogels. This is likely to be due to the presence of diluted HPMC in the release buffer at the 
interface of the hydrogel by the SLF placed on the gel. The viability of the cells is likely to be 
adversely affected with a viscous layer applied on them. This would result in the high percentage of 
cytotoxicity observed. The concentration of SST that is present in the release Day 1 samples (in the 
order of 10-5 M) is higher compared to the other treatments, contributing to the effect caused by the 
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viscosity of the HPMC. In contrast, by release Day 10, lower levels of cytotoxicity were observed 
(11% vs 65% in high glucose and 62% vs 35% in normal glucose). The effect of macromolecules such 
as methylcellulose contributing to a higher viscosity in cell culture media is discussed by Khorshid et 
al (Khorshid, 2005). It is inferred that viscosity most likely affects the diffusional motions of 
molecules in and out of the space between cell and substratum.  Tuvia et al (Tuvia, et al., 1997) have 
found that extracellular fluid macroviscosity can affect cell membrane activities and have proposed 
that the effect of solvent viscosity on a solute (proteins or cells) is determined by the size ratio of the 
viscous cosolvent to the solute; while for proteins the macromolecules are too big to affect their 
microenvironment, for cells they can be viewed as a microenvironment. Yedgar’s group (Yedgar & 
Reisfeld, 1990) have proposed that extracellular fluid viscosity can affect cellular and biochemical 
processes as well. Hughes et al (P. Hughes, Delahaye, Boix, Chang, & Lyons, 2005) found that HPMC 
up to a concentration of 1.2% diminishes ARPE-19 cell viability by about 20-40% especially at 24 
hours incubation (as per the MTT assay). They hypothesize an effect on mitochondrial 
dehydrogenase by HPMC treatment. In this study, only the samples from Release Day 1 
demonstrated significant cytotoxicity. These samples had the highest concentration of somatostatin 
released as well as being highly viscous due to the dilution of the HPMC hydrogel at the interface 
with the release buffer.  
An additional explanation for the observed results is provided by a study done by Papadaki’s group 
(Papadaki, Tsilimbaris, Pallikaris, & Thermos, 2010). Their group investigated the effect of 
somatostatin in concentrations ranging from 10-10 M to 10 -4 M on the viability of human RPE cells 
(D407 cell line) using a MTT assay. They reported a decrease in cell viability in a concentration-
dependent manner for SST concentrations 10-8–10-4 M. The SST concentrations in the Release Day 1 
samples in our study fall within that range. While there was an observed decrease in cell number 
due to SSTR1 and SSTR5-mediated apoptosis, Papadaki et al found that activation of SSTRs 2, 3 and 4 
led to inhibition of cell growth via antiproliferative actions. The anti-proliferative actions of SST have 
been discussed in Chapter 1. A possible combination of the actions discussed by Papadaki and group 
coupled with the viscosity of the samples may have led to the results in this study. The SST 
concentrations found in the Release Day 10 samples are much lower, in the order of 10-8 M, below 
the range reported by Papadaki’s group. It must also be taken into account that other studies 
conducted on cells with somatostatin (as previously discussed in Section 5.3.2) have not reported 
any cytotoxicity with their tested concentrations. HPMC is generally regarded as safe (GRAS) and is 
widely applied in drug and food formulations. In fact, cellulose derivatives, specifically 
hydroxyethylcellulose and sodium carboxymethycellulose, were investigated as candidates for 
ophthalmic viscosurgical devices (Andrews, Gorman, & Jones, 2005). According to the authors, these 
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polymers were chosen due to their known biocompatibility and ocular acceptability. The MTT assay 
presents the results from the application of a static layer of viscous HPMC on the cells. This is not 
representative of the dynamic ocular environment in vivo. However, the MTT assay was conducted 
as part of the safety assessment of the SST 5% w/w in HPMC 6% w/w hydrogels, which have not 
been studied elsewhere in combination.  
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Figure 5.1: Results of MTT assay assessing cytotoxicity of applied treatments on ARPE-19 cells in high 
(25 Mm) (solid bars) and normal (5 mM) (spotted bars) glucose conditions. Data shown are mean ± 
SD (n = 3). The symbol * denotes a significant increase in cytotoxicity compared to control wells 
grown in same conditions with no treatments applied. 
 
5.3.2 Immunofluorescence studies of VEGF-R2 expression 
A pilot study was performed as previously described (Section 5.2.3) to determine the concentration 
of somatostatin that significantly affects the expression of the VEGF-R2 levels in the ARPE-19 cells. 
The cells were incubated with somatostatin 10-8 M TO 10-5 M in both high and normal glucose 
conditions. Although the supplier recommends culture of the cells at 18 mM glucose, in this study, 
5.5 mM glucose was picked as representative of physiological glucose levels and 25 mM glucose as 
high glucose conditions. A study by Heimsath Jr. et al (Heimsath Jr, et al., 2006) recommends that 
5.5 mM glucose be included as a euglycemic concentration when studying VEGF release from ARPE-
19 cells. Heimsath and co-workers found that a high level of glucose (18 mM) led to a significant 
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increase in VEGF secretion from the ARPE-19 cells compared to 5.5 mM glucose at all tested time 
points.  
The results of our pilot immunofluorescence study are shown in Figure 5.2. Statistical analysis as 
described above (Section 5.2.5) showed that treatment with SST 10-6 M and 10-7M produced a 
significant (p < 0.05) downregulation of the expression of VEGF-R2 compared to control wells in high 
glucose at 72 hours. In normal glucose media, there were no significant differences in VEGF-R2 
expression between the treatment and control wells. The experiment was then repeated further on 
two separate occasions at 72 hours with only the 2 concentrations of SST that had showed 
significant results in the pilot study. The VEGF-R2 expression assays were conducted on three 
different occasions on three different batches of ARPE-19 cells in order to give a true triplicate, with 
triplicate wells for each treatment. The data as presented is obtained from three separate assays ± 
S.D. It is acknowledged that the error bars are large, however, it is not uncommon for in vitro 
biological assays. The triplicate assays were performed with 2 different batches of antibodies and 
some variances may occur inevitably although all other conditions were kept the same. Similarly 
large error bars have been found in the following (Kannan, et al., 2006; Saenz-de-Viteri, et al., 2016; 
Senthilkumari, Sharmila, Chidambaranathan, & Vanniarajan, 2017).  
The results of the triplicate studies (Figure 5.3) reveal that only SST 10-7 M produced a significant 
downregulation of VEGF-R2 expression levels in high glucose conditions. There were no significant 
differences in VEGF-R2 expression between the control wells and the treatment wells in normal 
glucose conditions. The same experiment performed with 24 hours incubation with SST 10-6 M and 
10-7 M did not show any significant effects on the expression of VEGF-R2 in the ARPE-19 cells in both 
high and normal glucose conditions. This may mean that a change in the expression levels of the 
VEGF-R2 in response to high glucose conditions may possibly take longer than 24 hours to occur or 
may not be detected by the immunofluorescence study at 24 hours.  
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Figure 5.2: Dose-response of VEGF-R2 expression levels in the presence of somatostatin 10 -8 M to 
10-5 M in high glucose (25 mmmol/L) (solid bars) and normal glucose (5 mmol/L) (dotted bars) 
conditions. Results are presented as mean + SD. (* indicates the concentrations that were 
significantly different to control wells) 
 
 
Figure 5.3: Effect of somatostatin 10 -6 M and 10 -7 M on VEGF-R2 expression levels in high glucose 
(25 mmmol/L) (solid bars) and normal glucose (5 mmol/L) (dotted bars) conditions (n=3). Results are 
presented as mean + SD. (* indicates the concentrations that were significantly different to control 
wells) 
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The images below (Figures 5.4 to 5.7) are a representative of the confocal images taken of the cells 
in the treatment and control wells. SST 10-5 M formed a gel (Figure 5.6) in the presence of the 
electrolytes in the cell culture media which acted as a barrier to the binding of the primary antibody 
to the VEGF-R2. This is consistent with the reported self-assembly of SST at lower concentrations in 
the presence of electrolytes (Wilmar Van Grondelle, et al., 2007) such as those found in the culture 
medium than in the absence of electrolytes. Therefore, those wells were unable to be analysed as 
the gel layer on the cells prevented an accurate determination of the VEGF-R2 expression through 
the binding of the primary and secondary antibodies.  
 
 
                                                                
 
 
 
Figure 5.4: Confocal images of wells incubated with (A) SST 10-7 M (B) SST 10-6 M and (C) control in 
high glucose at 72 hours. 
 
 
Figure 5.5: Confocal images of wells incubated with (A) SST 10-7 M (B) SST 10-6 M and (C) control in 
normal glucose at 72 hours. 
A B C 
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Figure 5.6: Confocal images of SST 10-5 M SST gelled in (A) normal glucose (B and C) in high glucose at 
72 hours.
 
Figure 5.7: Confocal images of expression of VEGF-R2 in response to different SST concentrations in 
high glucose at 72 hours. (A) SST 10-8 M (B) SST 10-7 M (C) SST 10-6 M (D) high glucose only control 
To the best of our knowledge from a review of current literature, this is the first study investigating 
the effect of SST on the expression of VEGF-R2 in ARPE-19 cells in high glucose conditions alone. 
Figures 5.7 of representative wells illustrate the response of the ARPE-19 cells to the presence of SST 
with regard to VEGF-R2 expression in high glucose. The confocal images in Figure 5.7 show less 
fluorescence in the wells with SST 10-7 M and 10-6 M compared to the control well in high glucose. 
The results of the study overall suggest a downregulation of VEGF-R2 expression in ARPE-19 cells by 
SST 10-7 M in high glucose.  
Hyperglycemia results in a variety of metabolic imbalances and vascular changes in the retina prior 
to clinical diagnosis of DR and is established as a major risk factor for the development and 
progression of DR (Klein, Klein, Moss, & Cruickshanks, 1998). Since transport of glucose into the 
retina does not rely on insulin but occurs instead through the glucose transporter-1 (Glut-1) (Sone, 
Deo, & Kumagai, 2000), hyperglycaemia leads to high intracellular glucose levels, leading to the 
formation of free radicals (oxidative stress) and a state of intracellular ‘pseudohypoxia’ (Williamson, 
et al., 1993). 
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The formation of advanced glycation end products (AGEs) as a result of hyperglycemia are found to 
be increased in diabetic retina (Stitt, et al., 1997). These AGEs cause increased oxidative stress and 
subsequent cell death, leading to a gradual loss of retinal cells. For these reasons, high glucose 
conditions alone were applied to the cells in this study. 
VEGFRs are also upregulated in non-proliferative diabetic retinopathy (G. Smith, McLeod, Foreman, 
& Boulton, 1999). As previously discussed in Section 5.1, upregulation of VEGFR-2 in early preclinical 
DR was observed in streptozotocin-induced DM in rats (Hammes, et al., 1998) and the presence of 
VEGFR-2 correlated with the presence of leaky retinal vessels (Witmer, et al., 2002) in humans. This 
may suggest that the vascular expression of VEGFR-2 enables the effects of VEGF-A such as 
increased vascular permeability in areas with established DR (Schlingemann, et al., 1999). Induction 
by VEGF-A itself can upregulate VEGF-R2 expression, as was shown in the monkey retina in a monkey 
model of VEGF-induced retinopathy (Witmer, et al., 2002). Summarily, upregulation of VEGF-R2 is 
seen in the pathological changes caused by VEGF and can be induced by VEGF itself. This explains the 
rationale behind our immunofluorescence study as we sought to determine if SST had any effects on 
VEGF-R2 expression. In this regard, the results of our study are promising in the investigation of the 
relationship between SST and VEGF, through the expression of VEGF-R2 on the apical surface of the 
ARPE-19 cells. It is conceivable to hypothesize that a downregulation of VEGF-R2 expression by SST 
may result from a decrease in VEGF secretion. This hypothesis was investigated in Section 5.3.3.  
In studies done with SST analogues, octreotide was applied to mouse retinal explants in hypoxic 
conditions with analyses of VEGF secretion and VEGF-R2 expression (Mei, et al., 2011). Mei et al 
found that octreotide decreased VEGF secretion as well as inhibited the phosphorylation of VEGF-R2 
in the conditions studied, thus inhibiting the downstream effects of VEGF-R2 activation. The effects 
of octreotide were postulated to be due to actions on SSTR2, which is consistent with work done by 
Dal Monte et al (Dal Monte, et al., 2007) in a transgenic mouse model of hypoxia-induced 
neovascularization. Hypoxia increased the expression of VEGF and its receptors, VEGF-R1 and VEGF-
R2 and somatostatinergic function at SSTR2 reduced this increase. In the context of the results of the 
current study, this provides a hypothesis of the mechanism of VEGF-R2 downregulation by SST. This 
is further supported by the work of Klisovic et al (Sall, et al., 2004) demonstrating that action on 
SSTR2 by somatostatin and its analogue, octreotide, reduced downstream VEGF synthesis by 
inhibition of phosphorylation of IGF-1R in ARPE-19 cells. VEGF-R2 expression was not assessed. 
Klisovic and co-workers found SST 10-11 M to 10-9 M to be most effective for reduction of VEGF 
synthesis. This is in contrast to our study which found SST 10-7 M to be most effective in the 
downregulation of VEGF-R2, in the range of SST 10-8 M to 10-5 M investigated, keeping in mind that 
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the markers are different. While there are multiple studies done on the effect of SST on VEGF 
secretion, these studies are usually performed under different conditions to the current study, such 
as under hypoxic conditions and with no assessment or report of VEGF-R2 expression. As such, it can 
perhaps be hypothesized that this study has investigated the expression of VEGF-R2 as a “proxy” for 
the effects of SST on VEGF secretion. These results then led to the study discussed in the following 
section (5.3.3) to assess VEGF secretion directly. 
5.3.3 Quantification of VEGF secretion by ELISA 
Based on the results from the immunofluorescence studies, an ELISA assay was conducted as 
described above with SST 10-8 M to 10-5 M applied to the cells and incubated for 72 hours. The results 
of the ELISA assay (Figure 5.8) show that SST did not have a statistically significant effect on the 
amount of VEGF secreted in high glucose and normal glucose conditions. It was hypothesized that 
the effect of SST on VEGF secretion may occur prior to the change in the expression of VEGF-R2 (at 
72 hours), as reported in our results from Section 5.3.2. There were a number of studies that 
investigated the changes in VEGF secretion by retinal cells at shorter time points ranging from 4 
hours to 48 hours (Heimsath Jr, et al., 2006; Mugisho, et al., 2018; Sall, et al., 2004; S. X. Zhang, 
Wang, Gao, Parke, & Ma, 2006). The study was thus repeated at the 24hr time-point in high and 
normal glucose conditions (Figure 5.9). The treatments applied were SST 10-6 M and 10-7 M and 
release samples from SST 5% w/w in HPMC 6% w/w hydrogels at day 1 and day 10. Levels of VEGF 
secretion are higher in high glucose compared to normal glucose conditions at both 24 hours (Figure 
5.8) and 72 hours (Figure 5.9), although not significantly so. At both time points studied, there was 
no significant down-regulation of VEGF secretion by the treatments applied compared to controls in 
high and normal glucose conditions (Figures 5.8 and 5.9). Paradoxically, there was a significant 
increase in the amount of VEGF secreted in the wells treated with SST 10-7 M and release Day 1 
samples in high glucose conditions only (Figure 5.9). This may be attributed to the highly viscous 
nature of the release day 1 samples which may have an irritant effect on the cells when applied. This 
correlates to the results of the MTT assay in Section 5.3.1. No explanation can be offered for the 
significant increase in VEGF levels in the wells treated with SST 10-7 M at 24 hours, as this effect was 
not observed in the 72 hour study (Figure 5.8) and requires further investigation. 
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Figure 5.8: Results of ELISA assay of effect of somatostatin 10-8 M to 10-5 M in high glucose (25 
mmmol/L) (solid bars) and normal glucose (5 mmol/L) (dotted bars) conditions on VEGF secretion at 
72 hours. (n=3). Results are presented as mean + SD. (* indicates the concentrations that were 
significantly different to control wells). There were no significant differences between control and 
treatments in normal and high glucose conditions. 
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Figure 5.9: Results of ELISA assay of effect of somatostatin 10-6 M and 10-7 M and Release samples 
Day and Day 10 from SST 5% w/w in HPMC 6% w/w hydrogels in high glucose (25 mmmol/L) (solid 
bars) and normal glucose (5 mmol/L) (dotted bars) conditions on VEGF secretion at 24 hours. (n=3). 
Results are presented as mean + SD. (* indicates the concentrations that were significantly different 
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to control wells). A paradoxical significant increase in VEGF levels were seen in wells treated with SST 
10-7 M and Release Day 1 samples from SST 5% w/w in HPMC 6% w/w hydrogels. 
There are a number of studies in the literature that have been conducted under different conditions 
to this study and may provide some hypotheses for the results above. Rupenthal and Green 
(Mugisho, et al., 2018) subjected ARPE-19 cells to culture in HG conditions alone (15 mM glucose), a 
combination of pro-inflammatory cytokines 10 ng/mL TNF-α and 10 ng/mL IL-1β or a combination of 
high glucose, 10 ng/mL TNF-α and 10 ng/mL IL-1β. Levels of VEGF secretion, amongst other markers 
were assessed 24 hours post-treatment. The authors found that HG alone did not produce a 
significant increase in VEGF secretion compared to the group challenged with the combination of 
inflammatory cytokines and HG. This is consistent with the findings in our study, as the levels of 
VEGF between the control wells in high glucose and normal glucose conditions were not significantly 
different. The combination of inflammatory cytokines and HG significantly increased VEGF release (p 
< 0.0001) with VEGF concentrations being more than double its baseline level in the study by 
Rupenthal et al. This implies that high glucose alone, in the absence of other factors involved in the 
pathology of DR, may be insufficient to affect levels of VEGF release by the ARPE-19 cells. 
With regards to the VEGF levels determined by the ELISA assay, we are not the first to report no 
effect on VEGF secretion by somatostatin-14. Studies by Lawnicka and co-workers (Ławnicka, et al., 
2000) have been unable to demonstrate the inhibitory effects of somatostatin-14 or octreotide in 
concentrations of 10-14 to 10-6 M on VEGF secretion in vitro, in HeCa10 mouse endothelial cells. 
Although somatostatin and octreotide displayed antiproliferative activity in HeCa10 cells, they did 
not suppress VEGF levels in the culture supernatant. The authors concluded that the abrogation in 
VEGF secretion by somatostatin agonists may be primarily an in vivo effect, which may not be 
observed in certain cell types as in vitro experimental systems. Of the few studies that have assessed 
the impact of high glucose alone on VEGF secretion, Sone’s group (Sone, et al., 1996) reported that 
VEGF production in bovine cultured RPE cells was significantly elevated at 10 days, but not by 1 or 3 
day exposure to 16.5 mM glucose compared to a 5.5 mM glucose group. In the context of the 
current study, this may mean that in the absence of other cytokines, a longer duration of study is 
required to detect an increased level of VEGF secretion in high glucose conditions. 
According to another school of thought, it has been suggested that hyperglycemia might not be 
responsible for all clinical aspects of diabetic retinopathy, since there are numerous cases of this 
pathology without evident hyperglycemia (Chan, Cole, & Hanna, 1985; Harrower & Clarke, 1976), 
raising the question if hyperglycemia per se is necessary or sufficient for the establishment of the 
disease (Antonetti, et al., 2006; Barber, et al., 2001). Diabetic retinopathy also presents 
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characteristics of a low grade chronic inflammatory disease, characterized by increased production 
of cytokines (Carmo, Cunha-Vaz, Carvalho, & Lopes, 1999; Kowluru & Odenbach, 2004).  
In a study similar to this study, Senthilkumari (Senthilkumari, Sharmila, Chidambaranathan, & 
Vanniarajan, 2016) investigated VEGF-mRNA expression as well VEGF secretion by ARPE-19 cells in 
normal glucose (5 mM) as well as two different concentrations of high glucose (25 mM and 50 mM ) 
at 72 hours. In that work, although there was a significant upregulation of VEGF mRNA at 72 hours at 
both high glucose concentrations tested versus normal glucose, only the VEGF secretion (measured 
by ELISA) in 50 mM glucose was significantly different to normal glucose conditions. These results 
are consistent with the current findings of the VEGF secretion at 72 hours in 25 mM glucose.  
The assessment of VEGF mRNA was also performed by Wang and co-workers (Wang, et al., 2012), 
who reported the increased expression of VEGF mRNA and protein (assessed by Western Blot) at 48 
hours in ARPE-19 cells cultured in 30, 40 and 50 mM glucose compared to normal (5.5mM) glucose. 
The implications of the results of Wang’s study for this work suggest the use of a different technique 
in addition to ELISA for the quantification of VEGF secretion as well as a higher level of glucose for 
HG conditions.  
A study that used the same cell line and glucose concentrations as this study was performed by 
Miranda and Simó (Miranda, et al., 2011). However, the markers assessed did not include VEGF. The 
treatment investigated (fenofibrate) was applied for 72 hours (days 16, 17 and 18 of culture). It was 
found that high glucose alone and in combination with hypoxia triggered increased levels of stress 
markers and the induction of pro-apoptotic factors. Reactive oxygen species (ROS) were elevated 
and the integrity of tight junctions was disrupted in this study. This suggests that in further work, 
markers such as pro-apoptotic factors in addition to VEGF may be investigated. 
Summarising the studies discussed above in the context of this study, significant effects of 
somatostatin on VEGF secretion may have been detected at a longer duration of incubation in HG, 
higher glucose levels (30-50 mM), the addition of inflammatory cytokines and/or with use of 
additional techniques like Western Blot. There are several studies that have been conducted on 
various retinal cell types, retinal explants and animal models that have demonstrated a variety of 
beneficial effects in the retina resulting from somatostatin at different concentrations (Akopian, 
Johnson, Gabriel, Brecha, & Witkovsky, 2000; Arroba, et al., 2016; Baldysiak-Figiel, et al., 2004; 
Bigiani, et al., 2004; D. Cervia, et al., 2012; Cervia, Martini, et al., 2008; Cervia, et al., 2002; Dal 
Monte, et al., 2007; Kokona, et al., 2012; Kouvidi, Papadopoulou-Daifoti, & Thermos, 2006; Niki 
Mastrodimou, et al., 2006; N. Mastrodimou, et al., 2005; Wilson, et al., 2001). In these studies, a 
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variety of markers have been evaluated in response to somatostatin in different conditions, 
however, VEGF was chosen for this study as its role in the pathology of diabetic retinopathy is 
established. This hypothesis is supported by the anti-VEGF agents that are currently on the market. 
Future work with different retinal cell types, a series of higher glucose concentrations, inclusion of 
inflammatory cytokines and/or hypoxic conditions can be undertaken with analysis at more time-
points. A positive control using one of the commercial anti-VEGF agents would make for a good 
comparison with SST. 
5.4 Conclusion 
The most promising formulation candidate, SST 5% w/w in HPMC 6% w/w hydrogel was tested for 
safety and efficacy on ARPE-19 cells as well as somatostatin solutions at different concentrations. 
Release samples from day 1 and day 10 were picked as they represent the highest and lowest 
concentrations of SST released from the formulation. The immunofluorescence studies demonstrate 
that SST 10-7 M produced a significant downregulation of VEGF receptor 2 (VEGF-R2) levels in high 
glucose at 72 hours. The ELISA assay, however, did not show any significant effects on the amount of 
VEGF secreted from any of the treatments applied. This may be due to the conditions of the study in 
comparison to other work discussed in Section 5.3.3, including the glucose concentration for high 
glucose conditions, time-points assessed and the absence of other factors like inflammatory 
cytokines and hypoxia. Future work may focus on varying the conditions as mentioned above based 
on existing literature for further investigation. The addition of another technique (e.g. Western Blot) 
and inclusion of other markers (e.g. proapoptotic factors or stress kinases) should be explored. The 
inclusion of a commercial anti-VEGF agent for comparison would be ideal. Results of the MTT assay 
demonstrate that the concentrations of SST 10-7 M and 10-6 M, blank HPMC and release Day 10 
samples did not cause significant cytotoxicity. Supra-physiological concentrations of SST 
compounded by the viscosity due to HPMC in the Release Day I samples resulted in significant 
cytotoxicity in a static in vitro cell study. Therefore, further evaluation in an animal model would 
provide clarification to these results as it is more representative of an in vivo environment. 
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CHAPTER 6: GENERAL DISCUSSION AND CONCLUSION 
6.1 Summary of findings 
Diabetes poses one of the greatest challenges to current healthcare systems worldwide. According 
to the International Diabetes Federation, an estimated 415 million adults globally were living with 
diabetes in 2015, with this figure set to rise to 642 million by 2040, constituting some 10% of the 
global adult population aged between 20 and 79.  Diabetic retinopathy (DR) is a common 
complication of diabetes and can result in severe visual impairment. It is currently the leading cause 
of irreversible vision loss of people with diabetes (Dall, et al., 2014; Mohamed, Gillies, & Wong, 
2007). DR affects the small blood vessels of the retina of the eye in people with diabetes. The vessels 
swell and leak liquid into the retina, blurring the vision and sometimes leading to blindness (Wild, et 
al., 2004). Persistent hyperglycaemia can damage small blood vessels (microvasculature) in organs 
such as the eye, leading to DR (Cade, 2008). It is estimated that approximately 93 million people 
worldwide have DR, and that a third of the global diabetic population are expected to develop some 
form of retinopathy in their lifetime (R. Lee, Wong, & Sabanayagam, 2015).  
There are a number of treatments available for sight-threatening DR such as laser treatment 
(photocoagulation), intra-vitreal anti-VEGF drugs, intra-vitreal steroid injections, and vitrectomy. 
However, these treatments are associated with serious complications and are only used at the late 
stages of the disease to reduce the rate of disease progression.  
The postulated therapeutic effects of somatostatin (SST) in the retina have been described in 
Chapter 1, Section 1.4.4. A tremendous amount of work done by Simó and co-workers in the ocular 
formulation of SST has seen the investigation of SST eye drops in clinical trials (EUROCONDOR) 
(Simó-Servat, et al., 2018). This clinical trial revealed that SST was only useful in patients with pre-
existing retinal neurodysfunction and suggests screening to identify patients in whom 
neuroprotective treatment might be of benefit. Thus, the purpose of this thesis was to develop a 
modified-release formulation of SST for the treatment of diabetic retinopathy. 
The eye has a number of properties that make it well suited to targeted drug delivery strategies, 
including its relative accessibility for delivery, limited size which can reduce the amount of drug 
required, and inner barriers, which limit drug clearance (Hosoya, Tomi, & Tachikawa, 2011). 
However, unlike the anterior segment, topical delivery to the posterior segment is limited by pre-
corneal drainage, the lipoidal nature of the corneal epithelium, and systemic circulation absorption, 
which leads to low drug bioavailability – typically less than 5% (Gaudana, Ananthula, Parenky, & 
Mitra, 2010; Mishra, Bagui, Tamboli, & Mitra, 2011; Urtti, 2006). Therefore, subconjunctival 
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(between the conjunctiva and the sclera) or intravitreal injections are the most common routes of 
administration for drug delivery to the posterior segment of the eye (S. H. Kim, Lutz, Wang, & 
Robinson, 2007).  
In this work, two modified-release formulations of somatostatin were developed. Somatostatin 
microparticles were intended for intra-ocular administration, particularly the suprachoroidal or 
scleral route. Whereas, somatostatin in HPMC hydrogel formulation, the more promising candidate, 
may be administered topically as an ophthalmic gel. In the early stages of diabetic retinopathy with 
no discernible changes to vision, it would be difficult to persuade patients to an injectable 
formulation. However, the patient acceptance of a topical formulation that does not require 
frequent administration is likely to be higher. 
The first experimental chapter of this thesis (Chapter 2) investigates and characterises the properties 
of self-assembled somatostatin hydrogels. Somatostatin self-assembly in water and in the presence 
of electrolytes has been reported (W. van Grondelle, et al., 2007). Lanreotide, a somatosatin analog, 
exhibits similar self-assembly properties(Valery, et al., 2004) and has been marketed as a sustained-
release monthly subcutaneous injection (Somatuline Autogel®). The purpose of Chapter 2 was to 
determine if self-assembled somatostatin hydrogels had the potential to act as a depot for the 
sustained release of somatostatin monomers. The hydrogels were extensively characterised with 
regard to their rheological properties, morphology using transmission electron microscopy and 
release kinetics of the somatostatin monomers from the hydrogels. The rheological studies showed 
that somatostatin formed a gel with higher storage modulus (G’) at higher SST concentrations and in 
the presence of electrolytes (Figure 2.7). All the concentrations tested exhibited shear-thinning 
properties, with declining viscosity as shear rate increased. This is a favorable property for 
administration via intra-ocular injection. The frequency sweeps showed a trend to increase in moduli 
with increasing frequency. As high frequencies represent shorter timescales and low frequencies are 
representative of longer timescales, this indicates a lowering of the stiffness of the gel over longer 
timescales. This is beneficial as the administration of the gel will not become more difficult over a 
period of use or storage. However the G’ remained higher than G” at all frequencies indicating the 
SST hydrogel structure was not destroyed. This indicates that the SST hydrogels retain the properties 
of a gel over longer periods of time. Temperature sweeps showed a progressive decrease in G’ and 
G” with increasing temperature from 20 °C to 50 ° C characteristic of materials in the absence of 
thermogelation . Thixotropic behavior was observed in plots of shear rate against stress. The 
thixotropic feature is favourable, relevant in view of transforming an initially viscous hydrogel into a 
thin product, easy to deliver to the desired site. The moduli of the SST hydrogels are equal to, or 
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greater than, that of moduli reported for comparable hydrogel systems (Aggeli, et al., 1997; Caplan, 
et al., 2002; Collier, et al., 2001). 
In summary, the rheological studies showed that the somatostatin hydrogels were shear-thinning, 
did not exhibit thermogelation and exhibited a higher degree of structure with higher concentration 
and in the presence of electrolytes. This was correlated to morphological analysis. Transmission 
electron micrographs demonstrated the presence of nanofibrils that were narrower and denser in 
appearance in the presence of electrolytes. This corresponds to the higher G’ (storage modulus) of 
the SST hydrogels in electrolytes and at a higher concentration as discussed in Chapter 2.  
The release studies revealed that the hydrogels in the presence of electrolytes released a lower 
cumulative percentage of somatostatin monomers at 48 hours compared to those in water. The 
release kinetics of the somatostatin monomers were fitted to a hybrid model of release, indicating 
concurrent first-order (diffusion of adsorbed SST monomers) and zero-order (erosional release) 
mechanisms of release. The pattern of release appears to be a bimodal consistent with the 
hypothesis that different release mechanisms predominate at different times rather than the same 
mechanism remaining predominant. The observed rapid but incomplete initial release may proceed 
as a result of the more rapid release of material adsorbed onto the surface of the gel. As the release 
of adsorbed material is depleted, release then slows to a zero-order rate, perhaps related to the 
erosion of the gel matrix. The low percentage of monomer release (2.95% to 3.6%) at 48 hours in 
vitro revealed the low potential of these self-assembled hydrogels to follow the path of lanreotide. 
Although the initial release from SST 5% w/w in water hydrogels in SLF was high (cumulative release 
of 38%), the release stopped at 9 hours as a solid gel layer formed on top of the hydrogel. 
Electrolytes are ubiquitous in the physiological environment and therefore, would provide the ideal 
environment for self-assembly of somatostatin to occur. It is important to note, however, that in 
vitro release characteristics are likely to be very different to those observed in vivo and merely 
provide a means of comparison between the different samples tested. The limitations of this study 
were the short duration of the study (48 hours) and the method of peptide quantification. The 
duration of the study could have been extended further to determine further release of monomers 
had a more sensitive method of detection been used. For these reasons, HPLC was used for the 
quantification of somatostatin release in the following chapters. 
Maji et al (Maji, et al., 2008) have studied the potential of amyloids as a long-acting depot for 
peptides. Maji et al reported that certain peptides formed very stable fibrils, which released 
peptides so slowly that an effective concentration of the drug for action was not attained. While the 
amyloid fibrils formed are stable, there must be a thermodynamic equilibrium condition between 
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the fibrils and monomers. If the monomer release is insufficient for effective drug concentrations, 
then there is failure of the depot formulation. Although the same group (Anoop, et al., 2014) has 
demonstrated the reversibility of somatostatin fibril formation, that study was conducted at much 
lower concentrations of somatostatin (0.2% w/v) than in the current study and in the presence of 
heparin an aggregation inducer. The results from Chapter 2 show that self-assembled somatostatin 
hydrogels form very stable fibrils in the presence of electrolytes and once formed, release only a low 
percentage of somatostatin present in the hydrogel. This discovery then led to efforts to modulate 
the formation of the nanofibrils in an attempt to increase the cumulative percentage released which 
culminated in the work in Chapter 3. 
In Chapter 3, a hypothesis was explored regarding strategies to hinder somatostatin nanofibril 
formation. Somatostatin 5% w/w was entrapped in hydroxypropyl methylcellulose (HPMC) 3% w/w 
and 6% w/w hydrogels and aged for 7 days. The time required for relaxation of the HPMC 
entanglement networks was determined by rheological analysis. The SST in HPMC hydrogels were 
subjected to extensive rheological studies consisting of amplitude sweeps, frequency and flow 
sweeps as well as temperature sweeps. The frequency sweeps showed a progressive decline in the 
G’ (storage modulus) of the blank HPMC 3% w/w and 6% w/w gels and SST 5% w/w in HPMC 3% w/w 
and 6% w/w gels. This indicates that the gels are stiffer at longer timescales (low frequencies) and 
less at shorter timescales (higher frequencies). This means that the inclusion of SST in the HPMC gel 
does not alter this property of the HPMC gels. In contrast, the frequency sweeps of the SST 5% w/w 
aqueous solution showed an increase in G’ as the frequency increased, consistent with our data in 
Chapter 2. The flow sweeps indicated all samples tested were shear-thinning and will flow more 
easily with the application of shear. This is a desirable property should the formulation be 
administered as an injection or as a topical formulation. The temperature sweeps showed that the 
HPMC gels undergo thermogelation at 65°C, a characteristic property of HPMC matrices (Joshi, 
2011).This is not observed with the SST 5% w/w aqueous samples where there is a decline in G’ with 
increasing temperatures. This is consistent with materials that do not undergo thermogelation. 
There was a decrease in the G’ of the SST 5% in HPMC 3% w/w hydrogel initially as the gel is diluted 
with the addition of the SLF on top then significantly increases on Day 4 of release. This correlated 
with the end of the release of somatostatin monomers as detected by HPLC based on our release 
data. This may be attributed to formation of nanofibrils, resulting in an increase in the stiffness of 
the gel.  The same applies to the SST 5% w/w aqueous samples where the G’ is highest on Day 4 of 
release. For all blank HPMC samples, the G’ was lowest after 4 days of release. This can be attributed 
to the dilution of the HPMC hydrogels with the presence of SLF on top removed and replaced every 
24 hours. The SST 5% w/w in HPMC 6% w/w gels exhibited the same trend in the change in G’ as the 
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SST 5% w/w in HPMC 3% w/w gels but smaller in magnitude. The stiffer 6% w/w HPMC matrix would 
be more resistant to the diluting effects of the SLF and provide a stronger barrier to the interaction 
of the electrolytes in the SLF with the entrapped somatostatin. This may explain the longer duration 
of release (10 days and continuing) compared to 4 days for the SST 5% w/w in HPMC 3% w/w gels. 
FTIR characterization of SST 5% w/w in HPMC 3% w/w and 6% w/w was performed on Days 1 and 7 
of aging and for four days of release after exposure to SLF. These data showed that there is 
transition of SST structure from random conformations (1643 cm-1) to parallel and anti-parallel β-
sheets (1615 cm-1 and 1675 cm-1) upon exposure to SLF. These transitions are hindered in the HPMC 
hydrogels compared to SST 5% in water, which is consistent with the hypothesis that the 
entanglement network of HPMC acts a barrier to the interaction of the electrolytes in SLF with SST. 
The secondary derivative plot (Figure 3.8) demonstrates a higher degree of structure in the SST 
aqueous solutions in SLF compared to SST 5% w/w in HPMC 3% w/w and 6% w/w hydrogels. 
Transmission electron micrographs of SST 5% aqueous solutions at Day 7 of aging and Release day 4 
demonstrate increased density of nanofibrils after exposure to SLF (Figures 3.9 and 3.10).  In the 
TEM micrographs of SST 5% w/w in HPMC 6% w/w hydrogels (Figure 4.12), however, there are no 
visible SST nanofibrils at Release Day 4. The micrographs demonstrate a network similar to those of 
blank HPMC 6% w/w hydrogels (Figure 3.11). The challenge of performing microscopy on these 
samples was the viscosity of the HPMC hydrogels. The formvar-coated copper grids had a fragile 
mesh which was easily broken by the weight of the hydrogels, resulting in many grids that were 
unable to be imaged. With the limitations, however, the TEM images appear to support the 
hypothesis that SST nanofibril formation is delayed by the presence of HPMC when exposed to 
electrolytes.  
Release studies conducted on the SST 5% w/w in HPMC 3% w/w and HPMC 6% w/w hydrogels 
demonstrated an extended release of SST monomers from the SST/HPMC hydrogels compared to 
SST 5% w/w in water. The SST 5% w/w solution reached a 100% release at 6 hours. The SST 5% w/w 
in HPMC 3% w/w gels released a total of 45.6% incorporated SST at 96 hours and there was no 
further release (no detectable peaks by HPLC) whereas the SST 5% w/w in HPMC 6% w/w gels 
continued to release a total of 37.6% at 10 days when the experiment was stopped, however, the 
release had not concluded. The release kinetics of SST 5% w/w in HPMC 3% w/w and HPMC 6% w/w 
hydrogels were fitted to a hybrid model of release (Equation 3.1) with R2 values of 0.998 and 0.997 
respectively. The time taken for 90% of SST to be released from the core of the hydrogels for the SST 
5% w/w in HPMC 6% w/w hydrogels (35.3 hours) is almost double that of  SST 5% w/w in HPMC 3% 
w/w hydrogels (19.6 hours). The initial higher percentage of release from both samples is attributed 
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to diffusional release that is later supervened by erosional release. The higher stiffness of the HPMC 
6% w/w hydrogel leads to a longer duration of release of 10 days compared to 4 days for the HPMC 
3% w/w hydrogel. Mass spectrometry was performed to confirm the structural integrity of the 
somatostatin released from the SST 5% w/w in HPMC 6% w/w hydrogels. Therefore, SST 5% w/w in 
HPMC 6% w/w hydrogels are the most promising candidate in terms of SST delivery, with delayed 
SST nanofibril formation and extended duration of release in comparison to SST 5% w/w aqueous 
dispersions. 
Chapter 4 describes a second formulation approach to extend duration of SST release. Microparticles 
of somatostatin were synthesized by two different techniques. The use of surface acoustic waves 
(SAW) was attempted to encapsulate the model drug (FITC-DEAE-Dextran) in a triblock co-polymer 
of polycaprolactone-polyethylene glycol-polycaprolactone (PCL-PEG-PCL). The model drug was used 
in place of somatostatin to optimize parameters of the process prior to using somatostatin itself. 
Alvarez et al (Alvarez, et al., 2008) had demonstrated the encapsulation of bovine serum albumin 
(BSA) in polycaprolactone microparticles using the SAW technique. However, experiments with FITC-
DEAE-Dextran revealed low encapsulation efficiencies (0.03%) and a very low percentage of 
cumulative release (3%), which stopped after 7 days. Attempts were made with somatostatin but 
the experiment was unsuccessful due to the visible deposition of the peptide on the SAW device. 
This technique was limited to the use of the lower molecular weight triblock (PCL1k-PEG2k-PCL1k) as 
the set-up did not permit the use of two immiscible solvent systems. 
The production of somatostatin microparticles was then attempted using the traditional double 
emulsion method. PCL-PEG-PCL was selected as the polymer candidate in this work. It was 
hypothesized that the duration of release may be extended in comparison to PLGA due to the 
crystalline nature of PCL resulting in slower degradation. In this study, the method published by 
Vaishya et al (Vaishya, et al., 2015) to synthesize PCL-PEG-PCL microparticles encapsulating 
octreotide, a somatostatin analogue, was adapted. FITC-DEAE-Dextran was used as the model drug 
to optimize the parameters (drug and polymer concentration, polymer molecular weight and 
sonication time). The encapsulation efficiency of the model drug was relatively high (61.5%) with a 
polymer concentration of 2% w/w and drug concentration of 2.5% w/w. The same parameters were 
applied to the synthesis of somatostatin microparticles with this technique. The results from our 
study showed that the encapsulation efficiency of somatostatin was highly variable (ranging from 
19% to 43%). The release profiles of somatostatin from the microparticles were similarly variable in 
the cumulative percentage released (1.4% -4%) and duration of release (16-24 days). The 
microparticles were characterised morphologically using scanning electron microscopy. The images 
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showed spherical aggregates, resembling microspheres to a larger degree than the polydisperse 
irregularly-shaped products of the SAW technique. The microparticles were analysed for size and 
determined to average 32 µm, ranging from 10.9 µm to 50.4 µm. The release kinetics of 
somatostatin from the microparticles were fitted to a first-order decay to plateau model with good 
mean R2 value of 0.979. 
In comparison to the current results, Herrmann and Bodmeier (Herrmann & Bodmeier, 1998) had 
produced  somatostatin microparticles using different molecular weights of poly-lactic acid (PLA) and 
poly-(lactic/glycolic) acid (PLGA). Different methods like oil-in-water dispersion, oil-in-water co-
solvent and water-in oil-in water double emulsion were investigated. The authors reported good 
encapsulation efficiencies ranging from 64% to 85%. They performed a release study for 7 days, 
showing about 10%-25% somatostatin released in that duration. This indicates better results with 
PLA and PLGA in comparison to PCL-PEG-PCL. However, this remains too variable for clinical 
application. 
Vaishya et al used the PCL10k-PEG2k-PCL10k to encapsulate octreotide, an analogue of somatostatin. 
An encapsulation efficiency of 45% was achieved with this triblock polymer. The release studies 
demonstrated complete release of octreotide over 3 months. It is important to note that the 
microparticles were suspended in a polymeric thermosensitive gel of the same composition as the 
microparticles, which had the effect of further extending duration of release.  
As discussed in Chapter 4, the encapsulation of somatostatin in the polymer used was not successful 
due to the inability to shield the charges. This was due to the reported self-assembly properties in 
the presence of electrolytes. Another limitation in the technique used was the ultrasonication step. 
Variation in the position of the ultrasound probe despite best attempts at consistency and the small 
volumes tested led to considerable effects on the variable encapsulation efficiency.  
This work shows promise of somatostatin encapsulation in PCL-PEG-PCL triblock polymer with 
further optimization of parameters. Current results show a reasonable encapsulation efficiency of 
ca. 30% and a duration of release ranging from 16 to 24 days. Further work should focus on 
strategies to improve the amount of somatostatin encapsulated, for example, pH adjustment, co-
solvents, solid dispersion method and consistency of technique.  
In Chapter 5, the safety and efficacy of somatostatin solutions at different concentrations and 
released somatostatin from the SST 5% w/w in HPMC 6% w/w hydrogels were tested on 
immortalized human retinal pigment epithelium cells (ARPE-19). MTT cell viability assay was used to 
assess the safety of the Release day and Release Day 10 samples as well as SST 10-7 M and 10-6 M. 
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The results of the MTT assay demonstrated a significant negative effect on cell viability (ca. 65%) by 
the Release Day 1 samples compared to control in both high and normal glucose conditions. 
However, Release day 10 samples (ca. 11%), SST 10-6 M (ca. 14%), SST 10-7 M (ca. 17%) and blank 
HPMC (ca. 15%) did not result in a significant effect on cell viability. It is thus postulated that the 
combination of the viscosity of the Release Day 1 sample with the higher concentration of SST 
present at 24 hours may have additive effects on the viability of the cells. The MTT assay measures 
the viability of cells by the ability to reduce MTT, a yellow water-soluble tetrazolium dye, primarily 
by the mitochondrial dehydrogenases, to purple coloured formazan crystals. Somatostatin has anti-
proliferative properties via actions at SSTRs 2,3 and 4 and may decrease viability in a concentration-
dependent manner (Papadaki, et al., 2010). The concentrations of SST released in the first 24 hours 
from the SST 5% w/w in HPMC 6% w/w gels are in the order of 10-5 M, which resulted in the 
formation of a gel in the wells in our immunofluorescence studies. This is due to the propensity of 
SST to self-assemble in the presence of electrolytes, such as those found in the cell culture medium. 
A viscous, gel layer formed on the cells in a well could conceivably reduce their viability, explaining 
the results of our MTT assay. This is consistent with the finding that the Release Day 10 samples, 
which are both less viscous and have lower concentrations of SST (in the order of 10-8 M) that did 
not impact cell viability. 
The markers for assessment for efficacy were expression of vascular endothelial growth factor 
receptor-2 (VEGF-R2) and secretion of VEGF by the ARPE-19 cells. Immunofluorescence was used to 
assess the effect of SST on the expression of VEGF-R2 levels at SST concentrations from 10-8 M to 10-
5 M. The results of the first study showed that SST 10-7 M and 10-6 M produced significant 
downregulation of VEGF-R2 expression in high glucose (25 mM) conditions compared to normal 
glucose (5 mM) conditions. Based on this study, the experiment was repeated twice more with SST 
10-7 M and 10-6 M. The statistical analysis of the results in triplicate revealed that only SST 10-7 M 
resulted in a significant downregulation of VEGF-R2 expression in high glucose conditions. 
The quantitative analysis of VEGF secretion in the same conditions was performed by ELISA at two 
time points of 24 hours and 72 hours. These studies showed no significant difference in the amount 
of VEGF secreted between the SST concentrations tested (10-8 M to 10-5 M) and control wells in high 
glucose versus normal glucose conditions. Somatostatin released from SST 5% w/w in HPMC 6% w/w 
hydrogels on Release Day 1 and Release Day 10 was also applied to the cells and incubated for 24 
hours before the ELISA assay. The Release Day 1 samples paradoxically resulted in a significant 
increase in VEGF secretion in high glucose conditions. This is hypothesized to be due to the highly 
viscous nature of the Release Day 1 samples, which have a high amount of HPMC.   
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The results from Chapter 5 are equivocal and require clarification in future work. The current study 
shows that SST 10-7 M results in a significant downregulation of VEGF-R2 expression by the ARPE-19 
cells at 72 hours. The results from the ELISA assay, however, do not support that finding in terms of 
the effect on quantity of VEGF secreted. Both studies were performed at 24 hours and 72 hours. As 
highlighted in the literature, the experiments to quantify VEGF release may need to be repeated 
with analysis at shorter time points (e.g. 4 hours) more frequently but extending beyond 72 hours. In 
addition, comparison of results in the presence of inflammatory cytokines in the media versus in 
high glucose alone could be performed. The presence of inflammatory mediators would be more 
representative of the milieu in diabetic retinopathy. It is difficult to draw meaningful conclusions 
from one assay in one retinal cell line. However, this still adds to the existing body of work 
contributing to the search for treatments for diabetic retinopathy. As the stated end point could not 
be reached, the hypothesis in this instance is incorrect.  
 
In addition, it is postulated that somatostatin inhibits the post-receptor signalling events of peptide 
growth factors such as VEGF, which may account for the preliminary data of the downregulation of 
VEGF-R2 expression without significant effects on VEGF secretion. It is worth noting that although 
the VEGF secretion levels in high glucose conditions were higher, they were not significantly so. This 
supports the discussion that in vitro studies on a single cell line in only high glucose cannot replicate 
the complexity of biological systems. The decision was made not to proceed further with additional 
cell-based studies primarily because this is not the focus of the thesis and preliminary data on safety 
and effect on VEGF/VEGF-R2 had been obtained on ARPE-19 cells, which is the only cell line we had 
access to at the time of this research work.  
 
Future work will focus on the above as well as investigating the effect of SST on other retinal cell 
lines, such as the Müller cells. The Müller cells are macroglial cells that react to neuronal apoptosis 
by aberrant expression of glial fibrillary acidic protein (GFAP) in diabetes. Müller cells are involved in 
the modulation of blood flow, vascular permeability and cell survival in the retina. In addition, their 
processes surround all the blood vessels in the retina. It could be reasonably conceived that these 
cells are key players in the pathogenic events in the diabetic eye (Simo, et al., 2012). Studies on 
healthy animals to assess the biocompatibility of SST 5% in combination with HPMC 6% w/w can be 
conducted prior to efficacy tests on diseased animal models. This will be a more accurate 
assessment of potential irritant effects of the SST 5% w/w in HPMC 6% w/w hydrogels compared to 
the static conditions of cell studies. 
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6.2 Conclusion 
In conclusion, this work resulted in the development and characterization of two formulations of 
somatostatin for ocular delivery. The microparticle formulation has shown reasonable encapsulation 
and duration of release, however, further optimisation can be done to improve both parameters. 
The more promising candidate consists of somatostatin entrapped in a HPMC network and has 
demonstrated modified release of somatostatin over 10 days. This work has introduced HPMC as a 
suitable candidate for modifying the release rate of peptides. The FTIR data demonstrating a 
hindering of nanofibril self-assembly may provide a platform for the investigation of HPMC in the 
delivery of other self-assembling moieties.  The combination of SST with HPMC provides aqueous 
loading of the peptide with no denaturing conditions and 100% loading. The SST 5% w/w in HPMC 
6% w/w hydrogels are shear-thinning, which facilitates their application topically or as an injectable. 
The current work has also evidenced the downregulation of the VEGF receptor 2 (VEGF-R2) by 
somatostatin at a concentration of 10-7 M in high glucose (25 mM) conditions. At this concentration, 
there was no reduction in cell viability. Although further studies are warranted to investigate effects 
on other retinal cell lines and animal models with additional markers, the identification of a new 
polymeric carrier for the delivery of somatostatin adds to the current body of work in the search for 
a non-invasive treatment for diabetic retinopathy. 
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